Skip to main content

AJOMS Vol 3 Iss 2_Nov 2026_Final

Page 50

™

Nov 2026 AJOMS Volume 3 | Issue 2

Australasian Journal of

ORAL AND MAXILLOFACIAL SURGERY Official journal of the Australian and New Zealand Association of Oral and Maxillofacial Surgeons

Editor

and the Oceania Region

Professor A Goss editorajoms@anzaoms.org Deputy Editors Professor A Heggie AM A/Professor A Bobinskas

+61 2 8091 0535 ISSN: 2982-0065

ajoms@anzaoms.org

Level 13, 37 York Street, Sydney NSW 2000


Trusted Technology with Advanced Features

NEW

Excellent Handling

Superior Strength

Faster Procedure

Long-term Effectiveness

Enhanced membrane stability that is expected to offer a longer barrier function profile (6–10 weeks) with slower resorption compared to Geistlich Bio-Gide®*

For more details please contact your local Geistlich Product Specialist or call our customer service team on 1800 776 326. *Based on in-vitro degradation testing.


The Australasian Journal of Oral and

F O U N D AT I O N E D I T O R

EDITORIAL BOARD

Maxillofacial Surgery

Alastair Goss

is the official scientific

• Emeritus Professor of Oral and Maxillofacial Surgery, The University of Adelaide • Emeritus Consultant Surgeon, The Royal Adelaide Hospital

Business Manager Dieter Gebauer

journal of the Australian and New Zealand

Adelaide, SA, Australia

Association of Oral and Maxillofacial Surgeons.

Perth, WA, Australia

DEPUTY EDITORS Andrew Heggie, AM

Aim and Scope The Australasian Journal of Oral and Maxillofacial Surgery is the premier forum for the exchange of information for new and significant research in oral and maxillofacial surgery, promoting the surgical discipline in the Oceanic region. Oceania comprises 19 countries, spread over one-sixth of the globe, but with Australia and New Zealand being the dominant developed countries. The Journal comprises peer-reviewed scientific reports, reviews, case reports of rare and unusual conditions, and perspectives; all of value for continuing professional development. Information for prospective authors, including author guidelines, publication ethics, malpractice statements and patient consent forms are available for download from the Australian and New Zealand Association of Oral and Maxillofacial Surgeons homepage. All correspondence with the Editor is via editorajoms@anzaoms.org.

• Clinical Professor, Department of Paediatrics, The University of Melbourne • Senior Consultant Oral and Maxillofacial Surgeon, Royal Children’s Hospital of Melbourne Melbourne, VIC, Australia

Alexander Bobinskas • Unit Director, Oral and Maxillofacial Surgery, The Canberra Hospital • Associate Professor, School of Medicine, Australian National University Canberra, ACT, Australia

PRODUCTION MANAGEMENT Website, Distribution and Advertising Belinda Mellowes • Executive Officer, Australian and New Zealand Association of Oral and Maxillofacial Surgeons Sydney, NSW, Australia

AMPCo Production Editors Kate Steyn Laura Teruel

Advertising Information The Australasian Journal of Oral and Maxillofacial Surgery accepts paid advertisements from companies involved with the surgical discipline. For information on advertising guidelines and rates contact Ms Belinda Mellowes, Executive Officer, Australian and New Zealand Association of Oral and Maxillofacial Surgeons: eo@anzaoms.org Submit advertisements to ajoms@anzaoms.org

Disclaimer The Australasian Journal of Oral and Maxillofacial Surgery Editors and Editorial Board cannot be held responsible for error or consequence arising from the information contained in the Journal. The views and opinions expressed herein do not necessarily reflect those of the Australian and New Zealand Association of Oral and Maxillofacial Surgeons, AJOMS Editor or Editorial Board. Neither does publication of advertisements constitute any endorsement of the products advertised. © 2026 ANZAOMS

• Senior Consultant in Oral and Maxillofacial Surgery, Royal Perth Hospital • Clinical Associate Professor in Oral and Maxillofacial Surgery, The University of Western Australia

AMPCo Graphic Design Peter Humphries

A D M I N I S T R AT I O N Catherine Offler • Administrative Assistant to the Editor Adelaide, SA, Australia

Members Arun Chandu • Senior Consultant in Oral and Maxillofacial Surgery, Royal Dental Hospital of Melbourne • Clinical Associate Professor of Oral and Maxillofacial Surgery, The University of Melbourne Melbourne, VIC, Australia

Nigel Johnson • Consultant Oral and Maxillofacial Surgeon, Princess Alexandra Hospital • Associate Professor in Oral and Maxillofacial Surgery, The University of Queensland Brisbane, QLD, Australia

Paul Sambrook, AM • Director Oral and Maxillofacial Surgery, The Royal Adelaide Hospital • Senior Lecturer in Oral and Maxillofacial Surgery, The University of Adelaide Adelaide, SA, Australia

Darryl Tong • Professor of Oral and Maxillofacial Surgery, The University of Otago • Senior Consultant in Oral and Maxillofacial Surgery, Dunedin Public Hospital Dunedin, New Zealand

Andrew Watkins • Supervisor of Training, John Hunter Hospital • Senior Lecturer, Charles Sturt University Newcastle, NSW, Australia

Patrisha Bordbar • Consultant in Oral and Maxillofacial Surgery, The Royal Childrens Hospital of Melbourne • IAOMS Executive for the Oceanic Region Melbourne, VIC, Australia

Ex Officio Members Nathan Vujcich • President, Australian and New Zealand Association of Oral and Maxillofacial Surgeons • Consultant in Oral and Maxillofacial Surgery, Royal Perth and Perth Children’s Hospitals Perth, WA, Australia

Jasvir Singh • Immediate Past President, Australian and New Zealand Association of Oral and Maxillofacial Surgeons • Consultant in Oral and Maxillofacial Surgery Sydney, NSW, Australia

John Harrison • Regional Councillor for Oceania, International Association of Oral and Maxillofacial Surgeons Auckland, New Zealand

Jocelyn Shand • Clinical Associate Professor, Department of Paediatrics, The University of Melbourne • Chair, Australian and New Zealand Association of Oral and Maxillofacial Surgeons Research and Education Foundation • Head of Section of Oral and Maxillofacial Surgery, The Royal Children’s Hospital of Melbourne • Vice President Elect, International Association of Oral and Maxillofacial Surgeons Melbourne, VIC, Australia

AJOMS Volume 3 | Issue 2 · Nov 2026

| 53


Australasian Journal of Oral and Maxillofacial Surgery

CONTENTS 56

Nov 2026 Volume 3 | Issue 2

EDITORIAL — Evolving subspecialisation in oral and maxillofacial surgery Heggie A

58

SCIENTIFIC ARTICLE — Odontogenic infections requiring operative management at a single tertiary hospital: a comparison of rural versus metropolitan populations Young N, Gelzinnis S, Klasen C, Kruszelnicki L, Yarad C, Niddrie P, Manton-Hall G and Watkins A

63

REVIEW ARTICLE — A surgeons’ guide to the cost of hospital-based care of acute severe odontogenic infection: a systematic review of costs Richardson RJ, Jensen ED, Poirier B, Cheng A, Jamieson L and Sambrook P

75

REVIEW ARTICLE — Pharmacological pain management following third molar surgery: a scoping review Dang B, Jensen E and Musa A

85

SCIENTIFIC ARTICLE — Comparison of bone turnover markers in patients on denosumab undergoing complex dentoalveolar surgery Inderjeeth C, Inderjeeth D, Devlin J, Chang F and Gebauer D

91

SHORT COMMUNICATION — Muscle memory and functional adaptation in lingual frenotomy: implications for timing of intervention Gupta A, Sarkaria A, Kandasamy S, Nagpal T, Thapar A and Ganesan K

93

TECHNICAL INNOVATION — Three-dimensional-printed biomodels for post-traumatic orbital reconstruction: a low-cost, open access workflow Ruscoe Z, Sklavos A, Mian M and Carter M

100 SCIENTIFIC ARTICLE — The experiences of Australasian second-degree students pursuing oral and maxillofacial surgery specialisation Monk JHG, Wockner RS and Abu-Serriah M

106 SCIENTIFIC ARTICLE — Survey of oral and maxillofacial surgery trainees in Australia and New Zealand and comparison to United Kingdom trainees Karczub ASL, Ricciardo PV and Swarbrick WJ

110 CASE REPORT — Management of recurrent intraosseous dentinogenic ghost cell tumour: a case report Al Balushi L, Luo A, Bealing M, Connor N and Singh T

114 CORRECTION — The establishment of the Australian & New Zealand Association of Oral & Maxillofacial Surgeons Temporomandibular Joint Replacement Registry – Regulations and Registry Development Goss A, Burgess M, Moore L, Murdoch B, Mellowes B and Smith P

54 | AJOMS Volume 3 | Issue 2 · Nov 2026


THE DENTAL RADIOLOGY SPECIALIST Maxillo Facial Imaging (MFI) is Australia's leading dental radiology provider solely focusing on CBCT, OPG and Lat Ceph The highest quality imaging & workups Oral & Maxillofacial Radiologists State-of-the-art imaging technology

Exceptional patient care Convenient locations 24 hour turn around reporting service*

Assoc. Prof. Ronnie Ptasznik Senior Radiologist

Dr. Daniel Selim Oral & Maxillofacial Radiologist

Dr. Scott McNab Oral & Maxillofacial Radiologist

Dr. Tess Matias Oral & Maxillofacial Radiologist

Dr. Jake Samuels Oral & Maxillofacial Radiologist

Dr. Ivor Berman Radiologist

Dr. Alyssa Zhang Oral & Maxillofacial Radiologist

MFI operates at six locations and offers a streamlined teleradiology service for practices equipped with their own imaging technology FOR ENQUIRIES REGARDING REFERRALS AND MFI'S TELERADIOLOGY SERVICE, PLEASE VISIT OUR WEBSITE

mfiradiology.com.au Glen Iris

Canberra

(03) 9500 9811 (02) 6102 6204 Suite 5, Ground Floor: Suite 9, 12 Napier Close 431 Burke Road Glen Iris. Deakin ACT 2600 Vic 3146

MelbourneCBD (03) 9650 6266 Level 9, Suite 910 220 Collins Street Melbourne VIC 3000

Mornington

Wodonga

Southport

(03) 9500 9811 134 Tanti Avenue Mornington VIC 3931

(02) 6038 1616 Wodonga Specialist Centre 216 Beechworth Road Wodonga Vic 3690

(07)5609 7088 Griffith University Campus Level 3, Ian O'Connor Building (G40) Southport QLD 4215 *On request

MFI Radiology is a division of Curae Health Group - a leading company in the AJOMS AustralianVolume dental industry 3 | Issue 2 · Nov 2026 | 55


EDITORIAL

Evolving subspecialisation in oral and maxillofacial surgery From the medieval guilds to the present complexity of professional

guidelines to provide a body of evidence showing experience and

health practices, the natural aspiration of a group of individuals

training in a subspecialty area will become more important.

who have developed specific skills, is to receive recognition and the In 2012, the Board of Studies in OMS at the Royal Australasian

opportunity to collaborate with their colleagues.

College of Dental Surgeons endorsed credentialing of both head and As argued in a previous editorial, our specialty’s evolution in the

neck surgery and cleft and craniofacial surgery and provided some

practice of contemporary oral and maxillofacial surgery (OMS)

guidelines as to the necessary experience, to formally demonstrate

in Australasia is an interesting story of growth, innovation and

this status for third parties.

successful scope expansion albeit with fierce political opposition along the way from competing craft groups in the head and neck

Arguably, OMS can be considered to have a list of subspecialist areas that include oncological and reconstructive surgery, paediatric/cleft

1

region.

and craniofacial surgery, aesthetic surgery, orthognathic surgery, A major stride forward for OMS was being officially recognised as

traumatology and advanced temporomandibular joint (TMJ) surgery.

a principal surgical specialty by the Australian and New Zealand

It is quite reasonable to regard the practice of implantology and the

governments in the late 1990s, and this was followed in 2005 by

management of facial fractures as core training. But practitioners

accreditation of our training by the Australian and New Zealand

inevitably gravitate to their area of interest and, in the case of major

medical and dental councils. Dual degree training programs have

facial trauma in tertiary centres, not all may feel equipped to deal

equipped our surgeons with a superior understanding of many

with the most complex of cases and intra-unit triaging takes place.

aspects of maxillofacial surgery and have opened doors to additional It is now not unusual for specific surgical units to expect that

training that was unavailable in earlier times.

applicants should possess further training in the area within the Core training in our centres has enabled our trainees to be exposed

hospital unit they seek to join. The decision for a newly qualified oral

to a broad range of surgery, although, the experience and emphases

and maxillofacial surgeon to undertake further training does not imply

between the programs in some surgical areas varies. This has resulted

that they will necessarily pursue that subspecialty in the future. Any

in many young, qualified surgeons seeking further experience in

additional training can only augment experience for good practice

specific areas of surgery, usually immediately after training and before

whatever the scope of work chosen.

settling into a practice. This infers an understanding on their behalf that for some areas of practice to be conducted at a higher level,

Oral and maxillofacial surgeons have made significant inroads into

further training is required. Indeed, in a survey of trainees completed in

head and neck surgery in many units around Australasia. This has provided an excellent platform, when established, to train our next

2

2020, 84% wished to undertake post-Fellowship positions.

generation. With the advent of virtual surgical planning and the need Over the past two decades, the availability of formal, post-

for a high standard of functional jaw reconstruction, the unique skills

qualification Fellowships has increased since the first Fellowship was

of our practitioners are now better recognised with invitations to

established in paediatric OMS at the Royal Children’s Hospital of

participate in planning and surgery in major centres.

Melbourne in 2005, funded by the Stryker company. There are now eight Fellowships available in Australasia and many others in the

In the case of cleft and craniofacial surgery, which is my subspecialty,

United Kingdom and the United States of America, whose directors

involvement and acceptance of oral and maxillofacial surgeons in

have regarded Australian and New Zealand OMS applicants as well

the team has been more difficult and slower in evolution, as tertiary

trained and highly suitable for their posts.

paediatric hospital centres have been traditionally staffed by plastic surgeons who control the surgical appointments. At the Royal

Credentialing in hospital settings for specific aspects of surgery has 3-5

been under discussion for some years, and this is increasing.

This

Children’s Hospital in Melbourne, it was fortunate that the founding craniofacial surgeon was keen to involve OMS, as this was the

process, in smaller private hospitals, is usually under the control of

productive model he had experienced during his training in the USA.

the Medical Advisory Committees, often with only a few surgeons

The combination of skills and unit reputation has attracted large

who review applications. Unfortunately, at times, partisan opinions

numbers of overseas surgeons to gain further experience.

regarding the scope of OMS may prevent well-trained surgeons from gaining privileges. With the inevitable demands of providing

Over the last three decades, the role of the oral and maxillofacial

credentials for scope of practice by some public and private hospitals,

surgeon in these units has grown in our region and also in the USA, with respect to providing additional higher-level treatment for the

56 | AJOMS Volume 3 | Issue 2 · Nov 2026


skeletal deformities in cleft and craniofacial anomalies. In parallel

of our Editor in establishing a TMJR Registry will also bring a focus to

with this, paediatric OMS is emerging as a subspecialty, due to the

this discipline.

different nature and management of paediatric pathology, and management of the growing patient in facial trauma. Conditions such

Overall, OMS, underpinned by comprehensive undergraduate training,

as hypomobility of the mandible, ankyloses of the TMJ, the role of

experience of surgery in general, and advanced training, is also

distraction osteogenesis to resolve upper airway obstruction in infants

staking out subspecialist areas like other craft groups. Whether they

with micrognathia, and various orthognathic and reconstructive

overlap or not with other specialties is, in my view, irrelevant. What

options for syndromic facial deformity all contribute to the need for

is important is that appropriate training is obtained in high-standing

a paediatrics OMS specialty. Complex dentoalveolar surgery is also

units and it remains the desire and skill of each individual to forge

a major challenge, such as cleidocranial dysostosis and for patients

their pathway as they wish.

with syndromic craniosynostosis. With appropriate training and the right hospital “atmospherics” in the future, those who train in primary cleft and cranial vault surgery will hopefully be accepted to continue this surgery in their future careers. Andrew Heggie

As with other subspecialty areas, the limited number of units dictates

Deputy Editor, AJOMS

that not all trainees receive the same surgical education in some specific fields in hospitals in each region. This will be an ongoing difficulty for a smaller specialty but, for those surgical trainees focused on a particular area of interest, there is usually a resolve to find additional training at a later stage. When one traces the evolution of surgical specialties, there has been

Author contributions Heggie A: Conceptualisation, investigation, original draft, reviewing and editing.

an acceleration of subspecialisation as more knowledge and skill sets

Conflicts of interest

develop. With the establishment of each new, defined subspecialist

The author declares that they have no conflicts of interest.

area, it is understandable that there is a natural discomfort for some surgeons, who have practised across a full spectrum for years,

doi: 10.63717/2026.MS0087

perhaps feeling a sense of exclusion in some way. There will continue to be much debate about areas of surgery that should remain as “core” within the specialty, but this will need to be balanced against increasing hospital credentialing that will seek evidence of additional training. As an example, extended TMJ surgery (total joint replacement [TMJ replacement/arthroscopy]) has a specific category in a major Melbourne private hospital that must be accredited for practice in this field. Yet, across Australasia there are many surgeons who perform occasional TMJR procedures competently to the benefit of their patients, particularly in practices in more remote settings where travel for care is difficult. The hard work

References 1 Heggie AAC. Oral and maxillofacial surgery: What are our credentials? Ann Maxillofac Surg 2014: 4: 1-2. 2 Karczub SL, Ricciardo PV, Swarbrick WJ. Survey of oral and maxillofacial surgery trainees in Australia and New Zealand and comparison to international trainees. AJOMS 2026; 2: 106-109. 3 Sachdeva AK, Russell TR. Safe introduction of new procedures and emerging technologies in surgery: education, credentialing and privileging. Surg Clin North Am 2007; 87: 853-866. 4 Gurgacz SL, Smith JA, Truskett PG, et al. Credentialing of surgeons: a systematic review across a number of jurisdictions. ANZ J Surg 2012; 82: 492-498. 5 McElnay PJ, McGoldrick C, Beamish AJ, et al. Credentialing in surgical specialties: recommendations by the Association of Surgeons in Training (Editorial). Int J Surg 2016; 36: S10-13.

From the Editor-in-Chief: One of the joys of being the Editor-in-Chief is to present innovations and invited editorials to readers. I particularly commend Professor Andrew Heggie’s thought-provoking invited editorial to you. Editorship does however carry responsibilities to get it right. Unfortunately, in the May edition of AJOMS, I got it wrong. I draw your attention to my editorial statement below and the correction on page 114.

Statement from the Editor Following the publication of the paper “The

Subsequently I received acknowledgement from Mr Ben Baxter

establishment of the Australian & New Zealand Association of Oral &

(Managing Director, Lykka Smith) accepting my offer of correction in the

Maxillofacial Surgeons Temporomandibular Joint Replacement Registry

November 2026 issue.

– Regulations and Registry Development”, I received a letter from Device Technologies Australia on 25 May 2026 pointing out that there

As Editor of AJOMS and the corresponding author of the article I

were errors concerning OrthoTin’s listed devices in Table 4.

accept full responsibility for this error, unconditionally apologise for any unintended hurt and issue to all readers to disregard the Table 4

On review I agreed that there was an error and offered to issue a

published in the May 2026 issue and replace it with this corrected

correction in my reply dated 22 June 2026.

version. I draw readers attention to the website www.orthotin.com for full technical information. Professor Alastair Goss Editor, AJOMS

AJOMS Volume 3 | Issue 2 · Nov 2026

| 57


SCIENTIFIC ARTICLE

Odontogenic infections requiring operative management at a single tertiary hospital: a comparison of rural versus metropolitan populations Young N (BMedSci/MD, MTrau)1-3; Gelzinnis S (BMedSci, MD)3; Klasen C (BMedSci/MD)3; Kruszelnicki L (BMedSci, MD)3; Yarad C (BMedSci/MD, MTrau)3; Niddrie P4; Manton-Hall G (BMedSci)5; Watkins A (FRACDS (OMS), BDS, MBBS)3,6

Introduction

ABSTRACT

The incidence and severity of odontogenic infections is higher in ruraland remote-based patients compared with metropolitan populations in Australia.1 Rural Australians experience more frequent and severe infections due to poorer general oral health, delayed care seeking and barriers to accessing dental care.1,2 Rural general medical

Purpose: To compare the prevalence, access to care and clinical outcomes of patients with odontogenic infection requiring operative intervention across metropolitan and rural populations within a regional New South Wales network.

practitioners see a range of oral health issues, including infection,

Methods: A retrospective cohort study assessing all children

but can often only provide interim management (such as antibiotics

and adults who underwent surgical intervention for odontogenic

and analgesia) due to limited access to dental services, which delays

infection by the Oral and Maxillofacial Surgical Service in the

definitive treatment and increases the risk of complications and

Hunter New England Local Health District from January 2018

hospital admission.2,3

to June 2024. The primary outcome was hospital length of

In Australia, preventable hospital admissions for dental conditions place a significant burden on the healthcare system. Nationally, between 2018 and 2024 there were between 66,809 and 88,600 potentially avoidable admissions yearly from dental conditions. Over this same period, New South Wales (NSW) comprised 17,583 to 24,306 yearly admissions to the national total.1 Rates of hospitalisation are strongly linked to rurality. In 2022–2023, an increased rate of potentially preventable hospitalisations was associated with rurality, with 3.2 per 1000 in major cities, compared with 4.7 per 1000 in remote areas.1 Severe odontogenic infections requiring operative intervention are a routine cause of admission under oral and maxillofacial surgical teams. These infections are the result of common oral disease progression including neglected dental caries, and endodontic and periodontal infection that can be prevented with appropriate and timely primary dental care.4 Inpatient admission for operative intervention poses significant resource burden on the health system, with a previous study in South Australia demonstrating an average cost of over $12,000 per admission.5

stay (LOS). Secondary outcomes included intensive care unit (ICU) admission, ICU LOS, number of emergency department presentations before definitive care, postoperative followup attendance, rurality (Modified Monash Model, MMM), and distance from the tertiary centre. Results: A total of 397 operative episodes were included. Mean hospital LOS was 4.7 days (median, 4 days; interquartile range [IQR], 3–5 days). ICU admission occurred in 42 cases (10.6%), with a median ICU stay of 2.5 days (IQR, 1–4 days). Patients were predominantly male (62.2%), with a mean age of 38.5 years. Most patients resided in metropolitan (42.6%) or small rural town (37.3%) locations. Mean distance to the tertiary centre was 90.8 km and this increased with rurality. Distance was positively correlated with LOS (ρ = 0.179, P < 0.001), whereas MMM category showed only a small effect. Conclusions: Increasing distance from tertiary care was associated with greater disease severity and longer hospitalisation. Improving access to early dental care for geographically distant patients may reduce morbidity and resource utilisation.

School of Dentistry, Adelaide University, Adelaide, SA, Australia; 2 School of Medicine, Flinders University, Adelaide, SA, Australia; 3 Hunter New England Local Health District, NSW, Australia; 4 School of Health and Medicine, University of Newcastle, Newcastle, NSW, Australia; 5 School of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia; 6 School of Dentistry and Medicine, Charles Sturt University, Wagga Wagga, NSW, Australia.

1

Corresponding author: Nick Young

✉ n.young@adelaide.edu.au | doi: 10.63717/2026.MS0081

58 | AJOMS Volume 3 | Issue 2 · Nov 2026

Keywords: accessibility | length of stay | odontogenic infection | rural health | tertiary care


This study was conducted within the Hunter New England Local

Univariate analyses were undertaken to evaluate factors associated

Health District, which incorporates 25 local government areas over

with hospital length of stay, including rurality (MMM category),

a sixth of the surface area of NSW, and has a resident population of

distance from the tertiary centre, age and ICU admission with effect

one million.6 The tertiary Oral and Maxillofacial service for this district

sizes reported, where applicable.

is provided by the John Hunter Hospital, in Newcastle. All statistical tests were two-sided, with a P value < 0.05 considered This article aims to compare the prevalence, access to care and

statistically significant. Statistical analyses were conducted using R

clinical outcomes of patients with odontogenic infection requiring

Core Team.7

operative intervention across metropolitan and rural populations within a regional NSW network.

Results

Methods

A total of 397 operations for odontogenic infection were captured by

This retrospective cohort study was performed in accordance with

3–5 days) (Figure 1).

this review. Mean LOS was 4.7, with a median LOS of 4 days (IQR,

institutional ethics approval from the Hunter New England Human Research Ethics Committee (reference: AU202411-04). Informed consent was waived due to the retrospective nature of the study; however, patient confidentiality and data security were strictly maintained. The study was conducted using patient and operation records from John Hunter Hospital over a five-year period, from January 2018 to June 2024. Patients of all ages were included if they presented with odontogenic infection requiring operative intervention in theatres within the Oral and Maxillofacial Department. Patients with incomplete records were excluded. Figure 1. Length of stay distribution

Data collected included patient demographics of age, gender, distance to the tertiary centre and geographical classification (based on postcode), smoking status, use of intravenous drugs or cannabis,

Variable

and diabetes status. Clinical data collected included ICU length of

Age

stay (LOS), number of emergency department presentations before

Mean age (years)

38.5

operative intervention, type of operative intervention, length of

Mean length of stay (LOS) (days)

4.7

hospital stay, and follow-up outcomes.

Median LOS (interquartile range, days)

4 (3–5)

< 18 years

36 (9.1%)

18–25 years

57 (14.4%)

26–45 years

163 (41.1%)

46–65 years

104 (26.2%)

> 65 years

37 (9.3%)

Descriptive statistics were used to summarise patient demographics, clinical characteristics and outcomes. Continuous variables were assessed for normality and are presented as means with standard deviations or medians with interquartile ranges (IQR), as appropriate. Categorical variables are reported as counts and percentages.

Count (%)

Gender

Geographic rurality was classified using the Modified Monash Model

Female

150 (37.8%)

(MMM) based on patient postcode at presentation. Distance from the

Male

247 (62.2%)

tertiary centre was calculated using postcode-based straight-line

Diabetes

distance to John Hunter Hospital.

No

370 (96.9%)

Yes

12 (3.1%)

Comparisons between metropolitan and rural groups were performed using chi-square tests or Fisher’s exact tests for categorical variables, and independent samples t-tests or non-parametric equivalents (Mann–Whitney U or Kruskal–Wallis tests) for continuous variables, as appropriate. Associations between continuous variables (including distance

Substance use Smoker

181 (45.6%)

Vaper

8 (2.0%)

Cannabis use (Tetrahydrocannabinol)

32 (8.1%)

Intravenous drug use (unspecified drug)

10 (2.5%)

Follow-up No appointment

213 (53.7%)

assessed using Spearman rank correlation coefficients due to non-

Attended

124 (31.2%)

normal distributions.

Did not attend

60 (15.1%)

from the tertiary centre, age, ICU LOS, and total hospital LOS) were

Table 1. Patient demographics and characteristics

AJOMS Volume 3 | Issue 2 · Nov 2026

| 59


Demographic characteristics of the cohort are summarised

Description

n (%)

Mean distance (km)

with a mean age of 38.5 years. This male predominance

Modified Monash Model (MMM) category

aligns with previous literature, demonstrating a male

MMM 1

Metropolitan

169 (42.6%)

22.6

predominance in severe dental infections presenting to

MMM 2

Regional centre

30 (7.6%)

30.2

MMM 3

Large rural town

30 (7.6%)

207.7

MMM 4

Medium rural town

18 (4.5%)

223.0

MMM 5

Small rural town

148 (37.3%)

146.2

MMM 6–7

Remote/very remote

0

—

No fixed address

—

2 (0.5%)

—

in Table 1. The cohort was predominantly male (62.2%)

hospital.5,8 However, this finding contrasts to the national data that shows a consistently higher rate of potentially preventable hospitalisations for dental conditions among females.

1

Smoking was the most frequently recorded substance use (45.6%), followed by cannabis use (8.1%), intravenous drug use (2.5%) and vaping (2.0%). The prevalence of smoking

Table 2. Geographic distribution and distance to tertiary centre

was markedly higher than the NSW general population rate (11%), aligning with its role as an established risk factor for infection.9,10 Cannabis use was similar to the NSW prevalence (8.1% compared with 8.9%).11 Vaping was lower than the current prevalence statewide (7.6% of the NSW population has reported daily or occasional vaping in 2023); however, the prevalence of vaping has increased markedly over the study period (January 2018 to June 2024).9 Geographic distribution was concentrated to metropolitan areas (MMM 1) and small rural towns (MMM 5), together comprising nearly 80% of the cohort (Table 2). Focal clusters of patients were identified via postcode mapping, as demonstrated in Figure 2, around the major rural centres of Tamworth, Taree and Armidale. As shown in Table 2, mean distance to the tertiary centre increased markedly with increasing rurality, ranging from 22.6 km in metropolitan areas to over 200 km in medium rural towns (MMM 3 and MMM 4). Distance to the John Hunter Hospital was significantly associated with LOS (Spearman ρ = 0.179, P < 0.0005) (Figure 3). MMM category was significantly associated with LOS; however, had a small effect size (Kruskal-Wallis P = 0.12 with effect size of 0.024). ICU admission occurred in 42 episodes (10.6%) with details summarised in Table 3. The ICU median LOS was 2.5 days (IQR, 1–4 days) (Table 3). Of patients who required

Figure 2. Patient distribution by postcode

ICU admission, most cases were admitted due to delayed extubation (33/42). Other reasons for admission included preoperative intubation (6/42 intubated preoperatively for

No significant associations with LOS were observed for gender,

airway management), or airway monitoring (3/42). ICU admission

diabetes status, substance use variables, follow-up status or number

was strongly associated with LOS (Wilcoxon rank-sum, P < 0.001).

of emergency department presentations before admission.

In addition, ICU LOS was positively correlated with LOS (Spearman correlation, 0.347; P < 0.001) (Table 3).

ICU admission occurred in 42 of 397 episodes (10.6%), and these

Approximately half of the patients, 213 (53.7%), did not have

those managed outside of ICU (Wilcoxon rank-sum, P < 0.001).

a follow-up appointment scheduled. Of those with scheduled

Among ICU-admitted patients, the ICU LOS was positively correlated

appointments, 67.4% (124/184) attended, while 32.6% (60/184) did

with total hospital LOS (Spearman, ρ = 0.347; P < 0.001), consistent

not attend.

with greater severity and resource use within this subgroup (Table 3).

Increasing age demonstrated a modest but significant association

Rural patients were more likely to require ICU admission, by both

with LOS (Spearman correlation, 0.186; P < 0.001).

distance from the tertiary centre and MMM category (Wilcoxon,

60 | AJOMS Volume 3 | Issue 2 · Nov 2026

patients also had a significantly longer length of hospital stay than


substance use variables (including smoking, cannabis use, intravenous drug use and vaping) were not significantly associated with ICU admission in univariate analysis.

Discussion This study examined the relationship between degree of rurality, access to care and outcomes in patients requiring operative management of odontogenic infection at a single tertiary referral centre. The principal finding was that an increasing distance from the tertiary hospital was associated with greater disease severity, as reflected by longer hospital LOS and likelihood for ICU admission. In contrast, rurality (defined by the Each circle represents one or more patients. Darker circles indicate areas of higher patient density (overlapping patients), while lighter grey circles indicate areas of lower patient density. The blue line represents the correlelation between length of stay and distance to John Hunter Hospital. The shaded area represents the confidence interval.

Figure 3. Length of stay versus distance to John Hunter Hospital

P < 0.001; Fisher’s exact test with simulation, P = 0.003) (Table 3). These findings suggest that patients travelling longer distances or residing in rural locations may be more likely to require critical care on admission. The number of presentations to the emergency department before admission was significantly higher among ICU-admitted patients than patients who were not admitted to ICU (Wilcoxon, P = 0.010). Gender demonstrated a non-significant trend towards association with ICU admission (P = 0.090), whereas diabetes status, and

Modified Monash Model) demonstrated only a weak association with LOS and was not a strong predictor of ICU admission. These findings suggest that distance

to definitive care may be a more clinically relevant marker of accessrelated risk than categorical rurality measures within large regional health districts. The geographic distribution of cases highlights the reliance of rural and regional populations on a centralised oral and maxillofacial surgical service. Patients from small and medium rural towns often travelled > 150–200 km for definitive management. These distances are likely to contribute to delays in presentation and the progression of infection, resulting in longer hospital stay requirements. This is in keeping with previous literature demonstrating poorer health outcomes in rural patients.12-14

Variable

Value

ICU admission

42 (10.6%)

ICU length of stay (LOS) (median, interquartile range)

2.5 (1–4) days

In previous studies, remoteness is strongly associated with higher health service utilisation and outcomes. In previous literature, it has been found that patients in more remote MMM categories experience higher rates of emergency department visits and ICU admissions.14

Reason for ICU admission Delayed extubation

33/42 (78.6%)

Strategies that may improve the access of rural communities to

Preoperative intubation

6/42 (14.2%)

dental care and reduce the volume of preventable hospitalisations

Airway monitoring

3/42 (7.1%)

for odontogenic infection include utilising mobile dental clinics, teledentistry, strengthening community dental programs and

Associations Distance vs ICU admission

P < 0.001

Modified Monash Model category vs ICU admission

P = 0.003

Emergency department presentations vs ICU admission

P = 0.010

ICU LOS vs total LOS

ρ = 0.347, P < 0.001

workforce expansion (particularly rurally).15,16 This study has several limitations. As a retrospective single-centre study, it is subject to potential biases in data recording and selection. The data reflect only the most severe cases that reached the tertiary centre and underwent operative intervention; the study does not capture patients managed entirely in rural emergency departments or private dental practices, nor does it record cases managed outside of

Table 3. Intensive care unit (ICU) admission and severity indicators

an operating theatre setting such as patients who are managed with

AJOMS Volume 3 | Issue 2 · Nov 2026

| 61


intravenous antibiotics and delayed extraction under local anaesthetic

pathways for geographically distant patients may reduce morbidity

outside of theatre. The classification of rurality by postcode may

and health system burden associated with severe odontogenic

not capture individual access barriers, such as travel time within a

infection.

large postcode area. The review also did not capture the method of transportation from rural centre to the tertiary centre, which would be

Author contributions

valuable for assessing access, timeliness of care, safety in transport

Young N: Conceptualisation, methodology, formal analysis, investigation, data curation, writing – original draft, writing – reviewing and editing.

and system costs; we aim to prospectively collect these data in future reviews. Further, the presence of mental illness was not collected by this review and has been flagged as a key contributor to odontogenic 17,18

infection.

We aim to collect this information in future reviews.

Gelzinnis S: Methodology, formal analysis, data curation, writing – reviewing and editing.

Data on specific socio-economic indices or exact time from symptom

Klasen C: Investigation, data curation, writing – reviewing and editing.

onset to first presentation was not available. Finally, the absence of patients from MMM 6–7 categories limits the generalisability of our

Kruszelnicki L: Investigation, data curation, writing - reviewing and editing.

findings to remote and very remote communities.

Yarad C: Investigation, writing – reviewing and editing. Niddrie P: Investigation, writing – reviewing and editing.

Conclusions

Manton-Hall G: Investigation, writing – reviewing and editing.

In this tertiary-centre cohort of odontogenic infections requiring operative management, increasing geographic distance from the

Watkins A: Conceptualisation, methodology, writing – reviewing and editing, consultation.

treating hospital was associated with greater disease severity, as

Conflicts of interest

reflected by longer hospital LOSs. In contrast, rurality as defined by

The authors declare no conflicts of interest. Artificial intelligence tools were used for minor language refinement, limited to grammar and phrasing. No AI tools were used for data analysis, interpretation or generation of content. All text was reviewed, edited and approved by the authors, who take full responsibility for the final manuscript.

the Modified Monash Model was not a strong independent predictor of ICU admission or LOS, likely reflecting limitations of categorical rurality measures within large regional catchments. Distance to tertiary services may represent a more clinically relevant marker of risk than rurality classification alone. Strategies aimed at improving early access to dental care and streamlining referral

Data sharing The data underlying this article cannot be shared due to the limitations imposed by the ethics approval for the study.

References 1

Australian Institute of Health and Welfare. Oral health and dental care in Australia [Internet]. Canberra: AIHW, 2024. https://www.aihw.gov.au/reports/dentaloral-health/oral-health-and-dental-care-in-australia (accessed June 2025).

2

The Oral Health Monitoring Group. Healthy Mouths, Healthy Lives: Australia’s National Oral Health Plan 2015-2024. Adelaide: COAG Health Council. 2015. https://www.health.gov.au/sites/default/files/ documents/2022/04/healthy-mouths-healthy-livesaustralia-s-national-oral-health-plan-2015-2024.pdf

3

Barnett T, Hoang H, Stuart J, et al. The relationship of primary care providers to dental practitioners in rural and remote Australia. BMC Health Serv Res 2017; 17(1): 515.

4

Uluibau I, Jaunay T, Goss A. Severe odontogenic infections. Aust Dent J 2005; 50: S74-S81.

5

Han J, Liau I, Bayetto K, et al. The financial burden of acute odontogenic infections: the South Australian experience. Aust Dent J 2020; 65(1): 39-45.

6

NSW Health. Local health districts: Hunter New England. https://www.health.nsw.gov.au/lhd/Pages/hnelhd.aspx (accessed June 2025).

62 | AJOMS Volume 3 | Issue 2 · Nov 2026

7

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria: 2025. https://www.Rproject.org/.

13 Cote CL, Singh S, Yip AM, et al. Increased distance from the tertiary cardiac center is associated with worse 30day outcomes after cardiac operations. Annals Thoracic Surg 2015; 100(6): 2213-2218.

8

Kent S, Regan A, McDonald C, et al. Gender differences in patients with severe dental infections presenting to hospital. Br Dent J 2021: Published online ahead of print, February 24, 2021. Doi: 10.1038/s41415-020-2351-7.

14 Fu B, McGowan K, Sun JH, et al. Increasing frequency and severity of odontogenic infection requiring hospital admission and surgical management. Br J Oral Maxillo Surg 2020; 58(4): 409-415.

9

NSW Health. Smoking and vaping. HealthStats NSW. https://www.healthstats.nsw.gov.au/topic-overview/ Smoking (accessed Feb 2026).

15 Theriault H, Bridge G. Oral health equity for rural communities: where are we now and where can we go from here? Br Dent J 2023; 235(2): 99-102.

10 Furuholm J, Rautaporras N, Uittamo J, et al. Health status in patients hospitalised for severe odontogenic infections. Acta Odontol Scand 2021; 79(6): 436-442.

16 Anderson W, Ahmed H. A retrospective analysis of hospitalisation for diseases of the pulp and periapical tissues in NHS Grampian 2011-2015: geographic, socioeconomic and increased primary care availability effects. Br Dent J 2019; 226(12): 951-954.

11 NSW Health. Recent non-medical use of cannabis (previous 12 months). HealthStats NSW. https://www. healthstats.nsw.gov.au/indicator?name=-beh-drugcannabis-phs&location=NSW&view=Trend&measure=pr evalence&groups= (accessed Feb 2026). 12 Chondur R, Li SQ, Guthridge S, et al. Does relative remoteness affect chronic disease outcomes? Geographic variation in chronic disease mortality in Australia, 2002– 2006. Aust N Z J Public Health 2014; 38(2): 117-121.

17 Choi J, Price J, Ryder S, et al. Prevalence of dental disorders among people with mental illness: An umbrella review. Aust N Z J Psychiatry 2022; 56(8): 949-963. 18 Manninen S, Snäll J, Puolakkainen T, et al. Severe odontogenic infections in patients with mental disorders: the challenge of ineffective initial treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2025; 139(2): 139-145.


REVIEW ARTICLE

A surgeons’ guide to the cost of hospital-based care of acute severe odontogenic infection: a systematic review of costs Richardson RJ (BDS)1,2; Jensen ED (BDS, BScDent (Hons), DClin Dent (Paed))1,2; Poirier B (BAH, MSc, PhD)1; Cheng A (MBBS, BDS, FRACDS (OMS))2; Jamieson L (BDS, MComDent, PhD)1; Sambrook P (MDS, MBBS, FRACDS (OMS), FIBCOMS)2

Introduction

ABSTRACT

A severe odontogenic infection is a potentially life-threatening complication of dental disease. Diagnosis of severe odontogenic infection is made from a combination of clinical and radiographic findings. Clinical signs include dyspnoea, dysphagia, swelling of the floor of mouth, trismus, facial or neck swelling and systemic signs of infection, including malaise, fevers, tachycardia and pallor.1 Purulent

Severe odontogenic infection is a life-threatening complication of dental disease that requires acute management at a tertiary level facility. The aim of this systematic review was to synthesise the available literature of the direct cost of acute management of severe odontogenic infection at a tertiary level facility.

material from the odontogenic nidus accumulates in the fascial

The protocol for this review was formulated in concordance with

spaces of the head and neck, resulting in potential complications

the Professional Society for Health Economics and Outcomes

including airway compromise, cavernous sinus thrombosis, sepsis and

Research (ISPOR) Criteria for Cost and Cost Effectiveness

death.2 Inpatient management includes emergent surgical drainage

Review Outcomes (CiCERO) and Joanna Briggs Institute (JBI)

of purulent material, control of the often compromised airway,

recommendations. Twelve databases were searched using

removal of the dental source, administration of intravenous antibiotics

key words and index terms related to “cost” and “odontogenic

and fluid replacement therapy.3 The course of admission is often

infection”. Extracted data were presented narratively and

protracted, requiring intensive level care and often multiple general

quantitively synthesised. The quality was assessed using the

anaesthetic procedures.4,5

consensus-based checklist for cost-of-illness studies (COI).

An awareness by surgeons of the treatment costs involved in

The systematic search identified 1757 results, with 85 selected

managing odontogenic infections allows an understanding of its

for full-text review and 13 that met the final inclusion criteria.

impact on the local, state and national health budgets of which they

Overall, the quality of studies was low. The average cost of acute

operate in. In Australia, 88,600 hospitalisations for dental-related

management of odontogenic infection was $18,316.38 2024 Int$.

presentations could have been prevented by earlier treatment in 2023–24.6 Policies are formed in consultation with experts. Oral and

The direct cost of acute management of odontogenic infections

maxillofacial surgeons are seen as leaders in the community and

presents a significant burden on the healthcare system. Further

health system. This article aims to help inform oral and maxillofacial

cost descriptive studies using a standardised health economics

surgeons in the economic impact of largely preventable odontogenic

methodology is required for reliable cost estimates of the direct

infections.

cost of acute management of severe odontogenic infection.

Globally, the burden of dental disease is significant, with untreated dental disease in permanent teeth being the most prevalent condition

barrier to care.9,10 Progression to life-threatening severe odontogenic

in the 2021 global burden of disease.7 In 2017, 3.7 billion people

infection is potentially preventable with routine dental care (such as

globally were reported to have untreated dental conditions and

dental extraction and endodontics).4 Due to the prevalence of severe

27.5% of the global population had untreated caries in the adult

odontogenic infection and the high level of emergent care required,

dentition. Funding and delivery of oral healthcare varies between

management of severe odontogenic infection presents a significant

countries. Globally, oral health inequities exist between low-income

fiscal burden to the healthcare system. An estimated $164 million

and marginalised communities and high out-of-pocket costs are a

USD in 2006 was charged in hospitals for emergency department

8

School of Dentistry, Adelaide University, Adelaide, SA, Australia; 2 Oral and Maxillofacial Surgery Unit, Royal Adelaide Hospital, Adelaide University, Adelaide, SA, Australia.

1

Corresponding author: Ruby Richardson

✉ a1880895@adelaide.edu.au | doi: 10.63717/2026.MS0077

Keywords: cost | bill | dental infection | odontogenic infection | systematic review

AJOMS Volume 3 | Issue 2 · Nov 2026

| 63


(ED) management of individuals with a primary diagnosis of pulpal 11

and periapical disease.

An Australian-based study estimated a cost

care without admission (such as extractions or drainage under local anaesthetic) or admission with medical/intravenous antibiotic

of $765,000 for intensive care unit (ICU) management for the 292

therapy only. Indirect costs and intangible costs including social cost,

individuals admitted with severe odontogenic infection.12

preventive treatment and long-term rehabilitative treatment were also excluded from analysis.

Cost descriptive approaches, such as cost-of-illness (COI) studies, aim to assess the total burden of a disease including the direct, indirect or intangible costs from the perspective of a society, healthcare provider or the payer.13 Systematic reviews of cost and cost effectiveness synthesise the available cost literature, to inform healthcare providers and health decision makers in optimal resource allocation for maximal benefit.14,15 The objectives of this systematic review of cost are to synthesise the available data on the direct cost of acute management of severe odontogenic infection globally and to identify strengths and weaknesses in the included health economic studies.

Methods An initial search was made of the International Prospective Register

Data extraction Two reviewers (RR, EJ) independently screened the search results and potentially relevant sources were retrieved for full text reading. Disagreements were resolved with discussion and additional reviewer input, if required. One reviewer (RR) extracted the main characteristics of included studies in a predesigned form, including: (i) general information (authors, publication year, country, conflicts of interest); (ii) study characteristics (population size, inclusion and exclusion criteria); (iii) methodology (perspective, time horizon, currency, discounting, source of information); and (iv) variable analysis results. Google Translate was used to translate to English if required.

Assessment of methodological quality The quality of studies included was assessed using the consensus-

of Systematic Reviews (PROSPERO), MEDLINE, the Cochrane

based checklist for COI studies by Schnitzler and colleagues.17 The

Database of Systematic Reviews and Joanna Briggs Institute (JBI)

twelve-question tool focused on domains of study characteristics,

Systematic Reviews Register in June 2025, which revealed no

methodology and cost analysis, results and reporting. Each domain

comparable published or underway reviews. This systematic review

question was allocated an answer of yes/partial/no/not applicable/

was registered, publicly available with PROSPERO as of 30 June 2025

unclear. The checklist was designed to not require quantification

(registration: PROSPERO 1013510).

with scoring (yes=1, no=0) but instead to be used to indicate comprehensiveness of the study and reflect on quality or limitations.17

The methodology was formulated in concordance with JBI and the Professional Society for Health Economics and Outcomes Research (ISPOR) Criteria for Cost and Cost Effectiveness Review Outcomes (CiCERO) recommendations.14,15 The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines were adhered to.16

Search strategy A search strategy was adapted for keywords and index terms for

Cost synthesis Cost inflation and currency conversion were completed using the formulae in Table 1. Prices were inflated to account for variance in price values over time and reflect the cost as of 2024. As per recommendations in the World Health Organization (WHO) Guide to Cost Effectiveness Analysis, the World Bank Gross Domestic Product (GDP) deflator was used.18,19 If the base year was not stated, it was assumed to be the last year of data collection.

PubMed, Embase, Emcare, MEDLINE, CINAHL Ultimate, EBSCO Dental & Oral Sciences Source, EBSCO Host, Econlit and PROQUEST.

International dollars (Int$) are a hypothetical currency used in health

No study format, date or language restrictions were used. The

economics to reflect the differences in relative prices used to compare

reference lists of all included studies were hand-searched for

the costs of goods and services by location.20 Int$ are the equivalent

additional studies. Grey literature was searched from the International

of the USD value for the stated year21. To convert the real/adjusted

Health Technology Assessment database, ProQuest and open grey.

cost values into Int$, Purchasing Pay Parity (PPP) was used from the

Databases were searched for studies from database inception to July

World Bank.19 PPP is calculated using the International Comparison

2025. Eligibility criteria were formulated using Population (P), Intervention (I) and Outcome (O) (Comparator was not applicable).14 Inclusion criteria included cost studies (O) involving individuals without any restriction of age, gender, race or socioeconomic status (P) who were taken to acute general anaesthetic for surgical management (I) of a severe odontogenic infection at a tertiary level facility. Exclusion criteria included studies on the direct costs of nonodontogenic infection of the spaces of the head and neck (such as salivary gland, peritonsillar, secondary infection of fractures/hardware following trauma). Articles involving outpatient-based/ED-based

64 | AJOMS Volume 3 | Issue 2 · Nov 2026

Abbreviations: AUD = Australian dollar; GDP = gross domestic product; USD = United States dollar.

Table 1. Formulae for price adjustments and conversion to international dollars


setting, cost data was pooled for synthesis.12

Results Our search resulted in 1757 studies for screening, of which 856 were removed as duplicates (Figure 1). Of the 901 studies screened, 85 were taken for full-text reading and 13 were included for data synthesis.23-35

Study characteristics The study designs of included studies ranged from retrospective cohorts of primary data to retrospective analyses of secondary data (Table 2). Lee and colleagues included secondary data on a representative sample of individuals aged ≤ 21 years admitted with severe odontogenic infection in the United States Kids’ Inpatient Database.34 The remaining twelve studies were in the retrospective cohort format using primary data. The study by Gams and colleagues was based on three sites in Texas, United States (Table 2).26-38 The remaining eleven cohort studies were based on a single-site design.26-30,32,33,35-38 Most of the studies (69%, n = 9) were based in the United States (Table 1).27-31,3335,38

Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart

The remaining studies were

based in Japan, Australia, Canada and China.26,32,36,37 The studies

Program (ICP) by implementing the prices of items within a “common basket of goods” and the expenditure weights on these items in the

included were published between 2009 and 2024. Age criteria were included in the studies by Lee and

economy.22

colleagues (≤ 21 years), Oxner (≤ 18 years), and Christensen and

COI studies may be conducted from the societal, healthcare provider

age of individuals in the studies was 39.8 years (range 11.5–53.2

or payer perspective.23 The aim of this study was to quantify and

years). The mean length of admission reported in the studies ranged

compare the direct cost, from the healthcare provider (hospital)

between 1 to 7.1 days on the general ward and 2.2 to 3.1 days in ICU.

colleagues and Han and colleagues (≥ 18 years).30,32,34,36 The mean

perspective. The epidemiological approach to pricing may be

All studies used the healthcare provider perspective, prevalence

prevalence-based (over a specific time period) or incidence-based

design and a bottom-up approach in pricing (Table 3). The study

(the lifetime cost attributed to a disease). Pricing may be from a bottom-up (data from real cases) or top-down (disaggregated from a population with the illness) approach. In economic evaluations such over which the cost of the disease or the intervention is assessed.

A

descriptive statistical analysis was performed using IBM SPSS 30.0.0 25

software.

Study characteristics were presented in a tabulated form. In studies

study duration ranged between 3 and 14 years.33,34,36-38 The time horizon of pricing was short-term (length of admission) in all studies.

as cost-effectiveness analyses, the time horizon is the time period 24

population size ranged between 22 and 736 individuals.34,36 The

Quality assessment The quality was assessed using the checklist from Schnitzler and colleagues and is presented in Table 4.17

considered compatible regarding methodology, time horizon and

AJOMS Volume 3 | Issue 2 · Nov 2026

| 65


Reference

Country

Demographic results

Inclusion criteria/ exclusion criteria Design: Retrospective cohort, single-site

Adachi et al 200926

AfwerkeLynch et al 202027 Ahmad et al 201328

Japan

US

US

Inclusion: Individuals taken to GA for OI

Age (mean): 53.2 years (6–83 years)

Exclusion: Individuals with underlying medical conditions that require management

Gender: 65.8% male (n = 79)

Design: Retrospective cohort, single-site Inclusion: Admitted for I&D OI under GA under OMS team

Age (mean): 40 years ± 17

Exclusion: NS

Gender: 63% male

Design: Retrospective cohort, single-site

Age (mean): 43 years (1–85)

Inclusion: Admitted for I&D OI under GA under OMS team Exclusion: NS

Gender: 54.74% male (n = 179)

Outcome results

Cost variables

LOA: 7.05 ± 5.51 days (mean)

NS

LOA: 1 +/- 6.2 days (mean)

Positive correlation between receiving outside treatment and an increase in severity of infections, hospital stay, and cost

NS

NS

Design: Retrospective cohort, single-site Bhagania et al 201829

US

Inclusion: Admitted for I&D OI under GA with OMS within 24 hours of admission, with MC&S results Group I: patients treated with intravenous (IV) Clindamycin

Gender: 58.97% male (n = 46)

Group II: patients treated with IV Penicillin G and IV Metronidazole

LOA: 6.22 (mean) Group I: 5.87 Group II: 6.57

Design: Retrospective cohort, single-site Christensen et al 201330

US

Inclusion: Individuals aged 18 admitted for OI Exclusion: postoperative infections, non-OI, OMS service not consulted, the patient was not admitted, age <18 years, or incomplete chart

Design: Retrospective cohort, multi-site (3 hospitals, TX) Gams et al 201731

US

NS

NS

Australia

Inclusion: Admission and surgical treatment under GA for OI

Age (mean): 38.9 years

LOA: 5.46 days (average)

Exclusion: Infection not of odontogenic origin, treatment provided outside of OR, incomplete medical record

Gender: 55% male

45.2% patients required ICU

Inclusion: Emergency admission for I&D OI under GA under OMS team, in individuals 18 years Exclusion: post-operative infections, non-OI, where OMS not consulted, <18 years age, admitted during the 2011–2012 and 2012–2013 financial years (n = 140)

Multivariate analysis: after controlling for other variables increased LOA, increased length of ICU stay, additional OR uses, use of the ER and OR for the location of surgical treatment, and use of ampicillin or sulbactam with metronidazole for the antibiotic regimen were significantly associated with an increased total bill. Location of treatment, LOA, length of ICU stay, additional OR uses, and antibiotic regimen accounted for 90.2% of the variation in billed amount.

Average OR visits: 1.37

Design: Retrospective cohort, single-site Han et al 201932

NS

LOA: 4.7 ± 4.7 NS

Duration in ICU 51.6 ± 65.1 hours Mean time in OR 84.5 ± 45.2 (mins)

Multivariate analysis: Elevated OI severity score and ASA score of 3 or 4 were associated with increased hospitalisation charges. Multivariate analysis: After controlling for the other variables, age and variables relating to diagnosis, i.e. high-risk OI involving deep fascial spaces, and each 5-unit increase in admission WCC were significantly associated with an increased total cost. High-risk OI were associated with a 5.49x increase in the mean total cost. Each 10-year increase in age and 5-unit increase in admission WCC was associated with a 6% and 18% increase in mean cost respectively.

Table 2. Main characteristics of studies on the acute cost of management of severe odontogenic infection at a tertiary-level site (Continues on page 67)

66 | AJOMS Volume 3 | Issue 2 · Nov 2026


Reference

Country

Inclusion criteria/ exclusion criteria

Demographic results

Outcome results

Cost variables

LOA: 4.57 days Design: Retrospective cohort, single-site Jundt & Gutta 201233

Lee et al 202034

US

Inclusion: Inpatients treated for OI Exclusion: Individuals with admission stays 24 hours, incomplete medical records except for microbiologic data

Design: Retrospective cohort, representative sample from Kids’ Inpatient Database NS

Inclusion: 21 years, presenting primary admitting diagnosis of oral cellulitis or an oral abscess Exclusion: Records that did not provide the age at admission

Age (mean): 35.8 years

ICU LOA: 3.1 days

Gender: 50% male (n = 21)

187.25 days admission

12 patients with recreational drug, tobacco, or alcohol abuse

Age (mean): 11.45 years Gender: 59.2% male (n = 429)

9 (21%) had multiple operations 70% presented with an elevated temperature, 38% had elevated blood glucose levels

NS

58% reported preadmission treatment

NS

NS

LOA: 5.25 nights, group A 6.7 (2 – 47), group B 3.8 (2 – 9)

Mean billed cost for group A: $63,509.68, group B: $35,934.14

7 (4.86%) admitted to ICU

Subjects with a hospital bill of >$47,835.60 were 4.5 times more likely to have an infection OISS 5 (OR 4.57; 95% CI 1.79 to 11.68) (statistically significant (P = 0.01)).

Design: Retrospective cohort, single-site Neal et al 202235

Inclusion: All individuals admitted with OI from ED for >1 hospital day and received surgical treatment in the OR US

Exclusion: Individuals with infections of nonodontogenic origin Severity scores as per Flynn et al: Group A: severity score 5, Group B: severity score <5

Age (mean) 41.6 years Gender: 54.86% male (n = 79)

102 (70.83%) individuals presented with WCC >11,000

Design: Retrospective cohort, single-site Oxner 200936

Canada

Inclusion: Individuals who presented to the ED at SickKids Toronto with OI (ages 18 years)

NS

Exclusion: OI involving permanent teeth, mild cellulitis treated with extraction or treatment not at SickKids Qiu et al 201937

Design: Retrospective cohort, single-site China

Inclusion: Severe OI admitted under OMS team Exclusion: NS

Age (median): 62 years Gender: 65.8% male (n = 48)

LOA (mean): 36 hours (SD: 19, range: 7–73)

NS

NS

NS Cohorts separated by before and after introduction of SMART Act. Total charges related to OI in cohort 2 were $3.67 million, total charges in cohort 1 were $2.08 million.

Design: Retrospective cohort, single-site Salomon et al 201738

US

Inclusion: Individuals admitted via ED for nontraumatic OI Exclusion: Individuals presenting with non-odontogenic complaint, or related to a non-infectious odontogenic process

NS

NS

A 77% increase in total charges after passage of the SMART Act. Average charge per ED visit increased from $3,948 to $4,729 (increase, 20%).

Abbreviations: GA = general anaesthetic; OI = odontogenic infection; LOA = length of admission; NS = not stated; US = United States of America; I&D = incision and drainage; OM = oral and maxillofacial surgery; MC&S = microbial culture and sensitivity; ICU = intensive care unit; SD = standard deviation; CI = confidence interval; OISS = odontogenic infection severity score; WCC = white cell count; ASA = American Society of Anaesthetists Physical Activity Score; TX = Texas; ER = emergency room; OR = operating room.

Table 2. Main characteristics of studies on the acute cost of management of severe odontogenic infection at a tertiary-level site

67 | AJOMS Volume 3 | Issue 2 · Nov 2026


Reference

Time period

Sample size

Data source

Perspective

Adachi et al 2009

2005 – 2009

45

Primary data

Provider (bill)

Afwerke-Lynch et al 202027

2012 – 2016

70

Primary data

Provider

Ahmad et al 201328

2003 – 2010

327

Primary data

Provider (billed)

Bhagania et al 201829

2009 – 2014

78

Primary data

Provider (treatment cost)

Christensen et al 201330

1July 2001 – 30 June 2011

248

Primary data

Provider (bill), payer (funds recuperated)

Gams et al 201731

January 2010 – January 2015

298

Primary data

Provider (bill)

Han et al 2019

1 January 2006 – 31 December 2014

344

Primary data

Provider (bill)

Jundt & Gutta 201233

1 July 2005 – 1 July 2008

42

Primary data

Provider (bill), payer (funds recuperated)

Lee et al 202034

2000 – 2014

736

Secondary data

Provider (billed)

Neal et al 202235

1 January 2016 – 31 December 2020

144

Primary data

Provider (bill), payer (funds recuperated)

Oxner 200936

2005 – 2008

22 (68 total study population)

Primary data

Provider (bill)

Qiu et al 201937

June 2014 – May 2017

35 (73 total study population)

Primary data

Provider (treatment costs)

Salomon et al 201738

1 January 2011 – 31 December 2013

82 (1405 total study population)

Primary data

Provider (bill)

26

32

Table 3. Methodological characteristics of studies on cost of acute management of severe odontogenic infection at a tertiary facility

All included studies were in a retrospective format using a

admission and the minimum wage for the locality at the time.33

prevalence-based, bottom-up approach to pricing. All studies

Most of the studies (88.89%, n = 8/9) based in the United States and

presented cost using the provider perspective. The time horizon used

Australia had a mean price per individual exceed the GDP spending

was the length of admission for the individual, a justified horizon

per capita.19,27,28,30-35,38 Ahmad and colleagues and Gams and

as our review is focused on the direct cost of acute management

colleagues presented the price as both an itemised cost and the billed

of odontogenic infection. Most of the studies (61.5%, n = 8) did not

amount.28,31 In both studies, the billed price was higher ($28,841 and

include disaggregation of price components. Three studies conducted

$48,351) than the sum aggregate cost ($9,417 and $13,058).

a sensitivity analysis of variables in relation to cost.30-32

The method of payment was presented in studies by Afwerke-Lynch No studies converted the price value to international dollars or

and colleagues, Christensen and colleagues, Jundt and Gutta, and

discussed PPP. Two studies used a deflator on account of fluctuations

Lee and colleagues, all of which are United States based.27,30,33,34

32,38

in price during the study period.

Han and colleagues adjusted for

inflation using the Australian Institute of Health and Welfare public hospitals industry scope-specific health deflator.32,39 Salomon and colleagues calculated the adjusted cost of components to reflect a single point in time during the study.38

Cost characteristics Cost data were available from the admissions of 2468 individuals with severe odontogenic infection for acute surgical management. All studies were based in countries considered as upper-middle (China) or high-income (United States, Canada, Australia and

Payment methods included state-funded medical assistance, Medicaid, Medicare, private insurance, self-pay and emergency medical assistance. The recuperation of cost was presented in studies by Christensen and colleagues, Jundt and Gutta, and Neal and colleagues.30,33,35 All three studies reported losses by the provider of between $966,522 and $5,330,583 2024 Int$ or 42–91%. Itemised subcategories of price were presented in studies by Jundt and Gutta, Gams and colleagues and Neal and colleagues (Table 5).31,33,35 The cost of imaging in individuals admitted with severe odontogenic infections ranged from $2,673.64 to $5,553.34

Japan).

2024 Int$. The price of an ED visit was similar in the three studies

The mean direct cost of management of an odontogenic infection

to ICU per night was higher in the study by Salomon and colleagues

from the hospital perspective per patient was $18,316.38 (standard

($13,848.37 2024 Int$) compared with Gams and colleagues

26-29,31-33,35,36-38,40,41

deviation [SD], ± $15,859.68) 2024 Int$ (Table 4). The mean price per patient ranged between $253.49 and $48,531 2024 Int$. Jundt and Gutta included an assessment of the direct costs from a societal perspective ($15,367 2024 Int$) based on length of

68 | AJOMS Volume 3 | Issue 2 · Nov 2026

($2,379.86–$2,934.03 2024 Int$).31,33,38 The price of an admission

($3,597.13 2024 Int$).31,38


Adachi et al18

AfwerkeLynch et al19

Ahmad et al20

Bhagania et al 21

Christensen et al22

Gams et al23

Han et al24

Jundt & Gutta25

Lee et al26

Neal et al27

Oxner28

Qiu et al29

Saloman et al30

Study characteristics 1)

Is the research question clearly stated?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

2)

Is the study population described?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

3a) Is the chosen study perspective stated?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

3b) If so, is the perspective justified?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Methodology and cost analysis 4)

Is the epidemiological approach reported (prevalence/incidence)

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

No, prevalence

5)

Is the costing approach reported (top-down, bottomup)?

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

Bottom-up

6)

Is the data collection process reported (prospective/ retrospective)?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

(retrospective)

Are all components of resource use identified that are relevant to the condition/disease, population, intervention, study objectives, and study perspective?

No

No

No

No

Yes (partial) Yes (partial)

Yes (partial)

Yes (partial)

Yes (partial)

No

No

No

Yes

7b)

If not, is a justification provided for excluding relevant components of resource use?

No

No

No

No

N/A

N/A

N/A

N/A

N/A

No

No

No

N/A

8a)

Are all components of resource measured?

No

No

No

Yes

Yes

Yes

Yes

Yes

Yes

No

No

No

Yes

8b)

If not, is a justification provided for not measuring certain components of resource use?

No

No

No

N/A

N/A

N/A

N/A

N/A

N/A

No

No

No

N/A

9a)

Are all components of resource use valued in monetary terms?

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

Yes, partial

9b)

If not, is a justification provided for not valuing certain components of resource use?

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

7a)

Table 4. Quality assessment of cost of acute management of odontogenic studies using the consensus-based checklist for cost-of-illness studies

69 | AJOMS Volume 3 | Issue 2 · Nov 2026

(Continues on page 70)


Adachi et al18

AfwerkeLynch et al19

Ahmad et al20

Bhagania et al 21

Christensen et al22

Gams et al23

Han et al24

Jundt & Gutta25

Lee et al26

Neal et al27

Oxner28

Qiu et al29

Saloman et al30

10a) Is the chosen time horizon specified?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

10b) If so, is the chosen time horizon justified?

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

11a) Are future costs discounted?

No/NS

No/NS

No/NS

No/NS

No/NS

No/NS

Yes

No/NS

No/NS

No/NS

No/NS

No/NS

Yes

11b) If so, is a justification provided of the discount rate?

N/A

N/A

N/A

N/A

N/A

N/A

Yes

N/A

N/A

N/A

N/A

N/A

Yes

12a) Are all variables whose values are uncertain subjected to sensitivity analysis?

No

No

No

No

Yes

Yes

Yes

Yes

No

No

No

No

Yes

12b) If so, is a justification provided for which variables are subjected to sensitivity analysis?

N/A

N/A

N/A

N/A

Yes

Yes

Yes

Yes

N/A

N/A

N/A

N/A

Yes

12c) Are analyses done on relevant subgroups?

No

No

No

No

Yes

Yes

Yes

Yes

Yes

No

No

No

Yes

13) Are the study results presented transparently by cost category/ sector?

No

No

No

Yes

Yes

Yes

Yes

Yes

No

No

No

Partial

Yes

14) Do the authors discuss the generalisability of the study results?

No

No

No

No

Yes

Yes

Partial

Partial

Yes

Yes

No

Yes

Yes

15) Do the authors report important limitations?

No

No

No

No

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

16a) Do the authors report ethical issues?

No

No

No

No

No

No

No

No

No

No

No

No

No

16b) Do the authors report distributional issues?

No

No

No

No

No

No

No

No

No

No

No

No

No

17) Do the authors report any potential conflict of interest?

NS

No

No

No

No

No

No

No

No

No

NS

No

Yes

Results and reporting

Abbreviation: NS = not stated.

Table 4. Quality assessment of cost of acute management of odontogenic studies using the consensus-based checklist for cost-of-illness studies

70 | AJOMS Volume 3 | Issue 2 · Nov 2026


Study

Year calculated

Adachi et al 200918

2008

Afwerke-Lynch et al 202019

2016

Ahmad et al 201320

2010

Bhagania et al 201821

Average cost/ patient

Total cost

24,109.68

Currency Japanese Yen

Average cost/ patient Int$ 2024

Social cost

Social cost 2024 Int$

Cost recovered

Net loss 2024 Int $ (%)

GDP spending Healthcare 2022 Int$

253.49

5,387.27

USD

17,660.03

12,434.43

28,841.00

USD

28,841.00

12,434.43

2014

6,817.72

USD

6,817.72

12,434.43

Christensen et al 201322

2011

21,660.50

USD

21,660.50

Gams et al 201723

2015

48,351.00

USD

48,351.00

12,434.43

Han et al 201924

2014

12,228.00

5,649,249

AUD

8,860.87

7,072.17

Jundt & Gutta 201225

2008

17,842.43

749,382

USD

17,842.43

Lee et al 202026

2014

18,311.96

USD

23,783.52

Neal et al 202227

2020

47,835.60

USD

47,835.60

Oxner 200928

2008

2,003.00

CAD

1,757.02

6,991.10

Qiu et al 201929

2017

3,534.60

EUR

1,001.30

1,135.67

Salomon et al 201730

2013

18,920.00

USD

18,920.00

12,434.43

17,660.03 ± $21,667.06

5,422,838

6,888,326.52

5,750,000

Mean: 18,316.38

$1,528,869

10,800

15,367

$70,123

$5,330,583 (72%)

$966,522 (91%)

12,434.43

12,434.43 12,434.43

$4,023,468.70

$3,405,146 (42%)

12,434.43

SD 15,859.68

Median: 17,842.43 Table 5. Cost synthesis of cost of management of severe odontogenic infection from a healthcare perspective

71 | AJOMS Volume 3 | Issue 2 · Nov 2026


Jundt & Gutta 202125

Gams et al 201723

Salomon et al 210730

Subcategory

Average cost/ individual (USD)

Average cost/ individual 2024 Int$

Average cost/ individual (USD)

Average cost/ individual 2024 Int$

Average cost/ individual (USD)

Average cost/ individual 2024 Int$

Radiology

1,879

2,673.64

4,315.67

5,553.34

2,117

2,797.42

ED care

2,062

2,934.03

1,945.50

2,503.44

1,801

2,379.86

OR

6,368

9,061.07

8,789.00

11,309.56

12,448

16,448.91

Anaesthetic medications

1,069

1,521.09

1,293.00

1,663.81

Recovery

2,943

4,187.61

2,276.67

2,929.58

2,787.67

3,587.13

10,480

13,848.37

1,268.67

1,632.50

2,776

3,668.23

ICU admission Ward admission

2,080

2,959.65

Surgeons fee

1,345.5

1,914.52

Abbreviations: ED = emergency department; OR = operating room; ICU = intensive care unit.

Table 6. Cost aggregate of acute management of severe odontogenic infection at a tertiary level-site

Cost variables

The presented cost of acute management of severe odontogenic

Three studies completed multivariate analyses on variables and the 30-32

outcome of total hospitalisation costs (Table 1).

increased hospitalisation cost with greater infective severity on multivariate analysis.

estimate of the true cost. Inpatient medical management (without surgery) and outpatient level care, including emergency, were

Gams and colleagues and Han and colleagues both reported an 31,32

infection per individual of $18,316.38 2024 Int$ is a conservative

Neal and colleagues separated individuals

into cohorts based on Flynn severity scores.35,42 Individuals with a Flynn severity score of ≥ 5 had a statistically significant higher total hospital bill. Han and colleagues used institutional acute head and

considered outside the scope of this systematic review. A nationwide study based in the United States reported that 33.5% of individuals presenting to ED with odontogenic infection in 2018 were admitted.44 The cost of ED assessment of $1,801–$2,061 2024 Int$ is significant, where 2 million ED presentations in the United States in 2018 were related to a primary dental-related diagnosis.31,33,38,45 A

neck protocols to measure severity.32

societal perspective in pricing provides a broader assessment

Han and colleagues found that with each 5-unit increase of white

transport, accommodation, childcare) and indirect costs (such as job

of the cost, including the direct non-healthcare costs (such as

cell count on admission, the cost of hospitalisation significantly

absenteeism).46 Indirect costs not included add to the cumulative

increased.32 Patient comorbidity measured by American Society of

burden of odontogenic infection. A COI study based in Sweden on

Anaesthetists Physical Status Classification (ASA) and age were

individuals admitted with odontogenic infection found that 93% of the

32,35

found to significantly impact the total cost of management.

total cost was attributed to direct healthcare costs, with the indirect costs of odontogenic infection amounting to 1,122 Euros ($1,664

Christensen and colleagues reported that a 90.2% variation of the

2024 Int $).47

hospital bill was due to location of treatment, length of admission (LOA), length of ICU admission, additional operating room (OR) use,

The mean direct cost of acute management of severe odontogenic infection appeared highest in the United States studies. These

30

and antibiotic regimen.

findings are in line with GDP expenditure, with the United States

Discussion

having the highest healthcare spending per capita in the Organisation

This review found that only a few studies assessed the direct cost of

United States healthcare structure is largely privatised, where public

acute management of odontogenic infection (n = 13) in individuals

coverage via Medicare and Medicaid is only available to select

for Economic Co-operation and Development countries.48 The

treated under general anaesthesia. The mean cost per individual

populations, resulting in private prices driven by market power.49 This

of acute inpatient management of severe odontogenic infection

is displayed by the higher average price per patient admission in the

treated under general anaesthesia was $18,316.38 2024 Int$ (range

included United States studies of $25,137.80 USD (2024) compared

$253.49–$48,351). The proportion of spending on healthcare per

with the remaining countries included of $253.49 to $8,860.87 USD

capita (both private and public funding) is presented as a proportion

(2024). The cost of $6,817.72 to $48,351 for individuals based in the

19,43

of the GDP by the World Bank.

Most of the studies’ price per

person was higher than the average GDP spending per person on 27,28,30-35,38

healthcare for the studies’ location in 2022.

The direct cost

per individual in one study was 3.89 times higher than the average 31

spending per capita as a proportion of GDP on healthcare.

72 | AJOMS Volume 3 | Issue 2 · Nov 2026

United States is a significant financial burden to the individual, where 24 million (7.2%) people were uninsured in 2023.50 Individuals not in the position to cover co-payment or out-of-pocket costs present a burden to healthcare providers where 42–91% of bills were not recuperated. Structural variation in healthcare delivery and funding limits the ability to directly compare prices between countries.51 Local


clinical protocols in management will also affect the presented price as clinical variables vary, such as length of admission and intensive care requirement.52

Conclusion The results of this systematic review indicate a significant direct

Health economic studies aim to inform healthcare providers and decision makers for the allocation of scarce resources.13 High outof-pocket costs are a barrier globally to dental care, with the end result of this unmet need being life-threatening severe odontogenic infection.9 Progression to severe odontogenic infection is preventable with root canal treatment or extraction of the necrotic tooth. It is difficult to ascertain the potential cost-savings from a healthcare

cost burden of $18,316.38 2024 Int$ per individual for the acute management of severe odontogenic infection in the hospital setting. The cost of illness is likely significantly higher, as indirect costs and societal costs were not considered. The overall quality of the included studies was poor in terms of transparency in pricing. Further research using standardised health economic methodology will improve the validity and generalisability of results.

perspective in management of odontogenic infection as the cost of preventive care is often high and management of remaining illness 13

requires an ongoing cost.

Complete eradication of the disease

is unattainable.53 As presented by Han and colleagues, the cost of extraction ($181 AUD) is a small fraction of the mean cost of management of severe odontogenic infection per individual ($12,228

Author contributions Richardson RJ: Conceptualisation, methodology, formal analysis, data curation, writing – original draft. Jensen ED: Conceptualisation, methodology, data curation, writing – reviewing and editing.

resources for severe odontogenic infection following the introduction

Poirier B: Conceptualisation, methodology, data curation, writing – reviewing and editing.

of the ‘SMART Act’, which reduced public funding to dental care in

Cheng A: Methodology, visualisation, writing – reviewing and editing.

the United States.38 The authors reported a 77% increase in total cost

Jamieson L: Methodology, visualisation, writing – reviewing and editing.

AUD). Salomon and colleagues assessed utilisation of hospital

($1.6 million USD over 18 months) of management, indicating the cost impact of public funding for preventive dental care. Knowledge of the high costs involved allows surgeons to be involved in discussions regarding allocation of health resources and for advocacy of universal healthcare in oral health.

Sambrook P: Methodology, visualisation, writing – reviewing and editing.

Conflicts of interest The authors have no conflicts of interest to declare.

There are some limitations to our review. First, the included studies lacked transparency in sourcing of prices and were deemed to be

Funding

of low quality overall. All studies ascertained prices from hospital

The authors have no funding sources to declare.

billing. A limited number of studies included disaggregated prices of components of the bill. Further research in severe odontogenic

Data sharing

infections using structured health economic methodology is required

The data underlying this article are available for sharing upon reasonable request to the corresponding author.

to strengthen the validity of the presented cost result. Secondly, limitations of the methodology of this review include the use of PPP that may not be comparable to similar resources in healthcare. All

Acknowledgements

countries included were of similar economy (upper-middle or high-

Special thanks to the University of Adelaide medical librarians for their input in this article.

income), limiting the generalisability of the results to low and lowmiddle income countries.

References 1

Therapeutic Guidelines. Acute odontogenic infections [Internet]. Melbourne, Australia; 2025. Available from: https: //www.tg.org.au (accessed 12 May 2026).

2

Velhonoja J, Lääveri M, Soukka T, et al. Deep neck space infections: an upward trend and changing characteristics. Eur Arch Otorhinolaryngol 2020; 277: 863–872.

3

Shanti RM, Flynn TR. Odontogenic Infections. In: Miloro M, Ghali GE, Larsen PE, et al. (eds) Peterson’s Principles of Oral and Maxillofacial Surgery. Cham: Springer International Publishing, pp. 1193–1219. https://link.springer.com/book/10.1007/978-3-03091920-7?utm_medium=referral&utm_source=sn&utm_ content=RM&&utm_campaign=CONR_TBOOK_CON1_ GL_PBOK_035PL_CTB24-SURA

4

Uluibau I, Jaunay T, Goss A. Severe odontogenic infections. Aust Dent J 2005; 50: S74–S81.

5

6

for the Global Burden of Disease 2017 Study. J Dent Res 2020; 99: 362–373.

Fu B, McGowan K, Sun H, et al. Increasing Use of Intensive Care Unit for Odontogenic Infection Over One Decade: Incidence and Predictors. J Oral Maxillofac Surg 2018; 76: 2340–2347.

9

Australian Government, Australian Institute of Health and Welfare. Oral health and dental care in Australia, Costs. AIHW, 2026. https://www.aihw.gov.au/reports/dentaloral-health/oral-health-and-dental-care-in-australia/ contents/costs (accessed May 2026).

10 Proaño D, Huang H, Allin S, et al. Oral Health Care Out-ofPocket Costs and Financial Hardship: A Scoping Review. J Dent Res 2024; 103: 1197–1208.

7

Bernabe E, Marcenes W, Abdulkader RS, et al. Trends in the global, regional, and national burden of oral conditions from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet 2025; 405: 897–910.

8

Bernabe E, Marcenes W, Hernandez CR, et al. Global, Regional, and National Levels and Trends in Burden of Oral Conditions from 1990 to 2017: A Systematic Analysis

Ardakani MSZ, Bayati M. Global situation of oral health coverage toward universal health coverage: A scoping review. Prev Med Rep 2025; 58: 103227.

11 Nalliah RP, Allareddy V, Elangovan S, et al. Hospital Emergency Department Visits Attributed to Pulpal and Periapical Disease in the United States in 2006. J Endod 2011; 37: 6–9. 12 Fu B, McGowan K, Sun JH, et al. Increasing frequency and severity of odontogenic infection requiring hospital admission and surgical management. Br J Oral Maxillofac Surg 2020; 58: 409–415.

AJOMS Volume 3 | Issue 2 · Nov 2026

| 73


13 Byford S, Torgerson DJ, Raftery J. Economic note: Cost of illness studies. BMJ 2000; 320: 1335. 14 Mandrik OL, Severens JLH, Bardach A, et al. Critical Appraisal of Systematic Reviews With Costs and CostEffectiveness Outcomes: An ISPOR Good Practices Task Force Report. Value Health 2021; 24: 463–472. 15 Aromataris E, Lockwood C, Porritt K, et al. (eds). JBI Manual for Evidence Synthesis. JBI. 2024. 16 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 29: 372. 17 Schnitzler L, Roberts TE, Jackson LJ, et al. A consensusbased checklist for the critical appraisal of cost-of-illness (COI) studies. Int J Technol Assess Health Care 2023; 39: e34. 18 World Health Organization. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva: WHO, 2003.

28 Ahmad N, Abubaker AO, Laskin DM, et al. The financial burden of hospitalization associated with odontogenic infections. J Oral Maxillofac Surg 2013; 71: 656–658. 29 Bhagania M, Youseff W, Mehra P, et al. Treatment of odontogenic infections: An analysis of two antibiotic regimens. J Oral Biol Craniofacial Res 2018; 8: 78–81. 30 Christensen B, Han M, Dillon JK. The Cost of Odontogenic Infections: a Demographic, Financial, and Outcome Variable Analysis. J Oral Maxillofac Surg 2013; 71: e32–e33. https://www.joms.org/article/S02782391(13)00639-3/abstract

32 Han J, Liau I, Bayetto K, et al. The financial burden of acute odontogenic infections: the South Australian experience. Aust Dent J 2020; 65: 39–45.

45 Liang L, Wang TT, Lee CC, et al. Is Insurance Payor Associated With Hospital Admission of Emergency Department Adult Patients With Odontogenic Infections? J Oral Maxillofac Surg 2024; 82: 1576–1584.

20 Turner HC, Lauer JA, Tran BX, et al. Adjusting for Inflation and Currency Changes Within Health Economic Studies. Value Health 2019; 22: 1026–1032.

34 Lee KC, Wu BW, Park E, et al. What Is the Health Care Burden of Treating Pediatric Dental Infections on an Inpatient Basis? J Oral Maxillofac Surg 2020; 78: 343–349.

21 Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019.

35 Neal TW, Hammad Y, Carr BR, et al. The Cost of Surgically Treated Severe Odontogenic Infections: A Retrospective Study Using Severity Scores. J Oral Maxillofac Surg 2022; 80: 897–901.

22 Purdie E, Song I. Purchasing Power Parities – putting a global public good to work in socioeconomic analyses. The World Bank July 2022. https://datatopics.worldbank.org/ world-development-indicators/stories/purchasing-powerparities-putting-global-public-good-socioeconomicanalyses.html (accessed Sept 2025).

36 Oxner JE. Economics of management of facial cellulitis in a pediatric hospital. M.Sc. thesis, University of Toronto (Canada), https://www.proquest.com/ docview/305108061/abstract/C2DA62D9E35244B6PQ/1 (accessed July 2025).

23 Sittimart M, Rattanavipapong W, Mirelman AJ, et al. An overview of the perspectives used in health economic evaluations. Cost Eff Resour Alloc 2024; 22: 41.

37 Qiu Y, Li Y, Gao B, et al. Therapeutic efficacy of vacuum sealing drainage-assisted irrigation in patients with severe multiple-space infections in the oral, maxillofacial, and cervical regions. J Craniomaxillofac Surg 2019; 47: 837–841.

26 Adachi M, Kaneko N, Yamashita N, et al. Evaluation of the critical pathway for oral infections. Oral Ther Pharmacol 2009; 28: 82–87. 27 Afwerke-Lynch H, Sabino M, Christensen L, et al. Effect of Outside Provider Interventions on Severity and Management of Odontogenic Infections in a Hospital Setting. J Oral Maxillofac Surg 2020; 78: e70–e71.

43 Flynn TR, Shanti RM, Levi MH, et al. Severe Odontogenic Infections, Part 1: Prospective Report. J Oral Maxillofac Surg 2006; 64: 1093–1103. 44 Organisation for Economic Co-operation and Development. Health spending [Internet]. OECD, https:// www.oecd.org/en/data/indicators/health-spending.html (accessed Sept 2025).

33 Jundt JS, Gutta R. Characteristics and cost impact of severe odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 558–566.

25 IBM. SPSS Software, https://www.ibm.com/spss (2024, accessed Oct 2024).

42 The World Bank. World Development Indicators: The World by Income and Region. https://datatopics. worldbank.org/world-development-indicators/the-worldby-income-and-region.html (accessed Sept 2025).

31 Gams K, Shewale J, Demian N, et al. Characteristics, length of stay, and hospital bills associated with severe odontogenic infections in Houston, TX. J Am Dent Assoc 2017; 148: 221–229.

19 World Bank Group. World Bank Open Data, https://data. worldbank.org (accessed Sept 2025).

24 Kim DD, Wilkinson CL, Pope EF, et al. The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res 2017; 17: 615–623.

41 Health and Welfare Expenditure Data. Australian Institute of Health and Welfare, https://www.aihw.gov.au/ reports-data/health-welfare-overview/health-welfareexpenditure/data (2025, accessed Sept 2025).

38 Salomon D, Heidel RE, Kolokythas A, et al. Does Restriction of Public Health Care Dental Benefits Affect the Volume, Severity, or Cost of Dental-Related Hospital Visits? J Oral Maxillofac Surg 2017; 75: 467–474. 39 Australian Government, Australian Institute of Health and Welfare. Health & welfare expenditure: Data. AIHW, https://www.aihw.gov.au/reports-data/health-welfareoverview/health-welfare-expenditure/data (accessed Sept 2025). 40 Christensen B, Han M, Dillon JK. The cause of cost in the management of odontogenic infections 2: multivariate outcome analyses. J Oral Maxillofac Surg 2013; 71: 2068–2076.

ANZAOMS27 KEYNOTE SPEAKER Dr Stanley Y. C. Liu MD, DDS, FACS Alongside our keynote speaker, delegates will hear from a distinguished line-up of international experts, including Prof Alfred Lau, Dr Mark Green, Dr Bonnie Padwa, Dr Corey Resnick, A/Prof Patricia Stoor and Dr Phillipe Korn, delivering a truly global and engaging scientific program.

KEY DATES

46 Owens PL, Manski RJ, Weiss AJ. Emergency Department Visits Involving Dental Conditions, 2018. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US), http://www.ncbi.nlm.nih.gov/books/ NBK574495/ (accessed Sept 2025). 47 Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol 2014; 20: 327–337. 48 Hellgren C, Hellgren J, Malekzadeh BÖ. Deep neck space infections of odontogenic origin are costly and preventable. Acta Odontol Scand 2024; 83: 469–474. 49 Telesford I, Cotter L, Wager E, et al. How does health spending in the US compare to other countries? [Internet]. Peterson-KFF Health System Tracker, https:// www.healthsystemtracker.org/chart-collection/healthspending-u-s-compare-countries/ (accessed Sept 2025). 50 The Commonwealth Fund. International Health Care System Profiles: United States [Internet]. New York, United States of America; 2025. Available from: https://www. commonwealthfund.org/international-health-policycenter/countries/united-states (accessed Sept 2025). 51 Hale J, Hong N, Hopkins B, et al. Health Insurance Coverage Projections For The US Population And Sources Of Coverage, By Age, 2024–34. Health Aff (Millwood) 2024; 43: 922-932. 52 Jacobsen E, Boyers D, Avenell A. Challenges of Systematic Reviews of Economic Evaluations: A Review of Recent Reviews and an Obesity Case Study. Pharmacoeconomics 2020; 38: 259–267. 53 Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ 2010; 19: 350–364. 54 Koopmanschap MA. Cost-of-Illness Studies. Pharmacoeconomics 1998; 14: 143–148.

ANNUAL SCIENTIFIC MEETING

13-15 May 202 7 Cr own Per th, WES TERN AUS TR ALIA

RD EARLY BAITION REGs I16SNTovRember 2026! O p en

CALL FOR A B S Closing 7 TR ACT S D e c emb er

2 0 2 6!

www.anzaomsasm.com.au 74 | AJOMS Volume 3 | Issue 2 · Nov 2026


REVIEW ARTICLE

Pharmacological pain management following third molar surgery: a scoping review Dang B (BDS, MBBS)1; Jensen E (BDS, DClinDent (Paed))2; Musa A (BDS, BSc(Hons))2

Introduction

ABSTRACT

Third molar surgery is one of the most frequently performed procedures in oral and maxillofacial surgery.1,2 It can be performed for

This scoping review was conducted to systematically map the existing literature regarding the pharmacological management

a variety of reasons: periodontal disease, dental caries, peri-coronal

of acute post-operative pain following third molar surgery. This

disease, orthodontic crowding, before prosthetic rehabilitation, before

review provides an overview of pharmacological agents and

other surgeries, cyst or tumour formation.3 Surgical intervention can lead to tissue trauma, which for third molar surgery predictably manifests with temporary pain, oedema and trismus.4 Acute, post-

regimens that have been evaluated, describes the available evidence and identifies critical gaps to guide future research.

operative pain is a primary concern for individuals as it can affect

A scoping review of the literature was performed using a

overall quality of life and short-term ability to function.5

pre-established search strategy tailored for Ovid MEDLINE, Embase, CINAHL and Cochrane databases covering

Effective pain management is a cornerstone of post-operative care,

publications from inception up to August 2025. Studies were

particularly the use of pharmacological adjuncts. There are a wide

included if they involved individuals undergoing third molar

range of options available, such as non-steroidal anti-inflammatory

removal and examined pharmacological pain management

drugs (NSAIDs), paracetamol, corticosteroids, opioids and local

within an academic or hospital setting. Data regarding study

anaesthetics.6 Clinicians can also employ various strategies such as pre-emptive analgesia, multimodal regimens combining agents with different mechanisms of action and long-acting local anaesthetics.7

characteristics, analgesic interventions and outcomes were extracted from the included articles and synthesised narratively.

Pre-emptive analgesia is a strategy where a combination of drugs

Sixty-five studies were identified as meeting the inclusion

are given before surgery. The goal of pre-emptive analgesia is to

criteria. The data support the use of pre-operative medication.

block the initial inflammatory cascade and subsequent peripheral and

Non-steroidal anti-inflammatory drugs (NSAIDs) were the

central sensitisation that would amplify post-operative pain.8 Given

most frequently studied and most effective class of medication.

the abundance of available treatment options, there exists clinical

Corticosteroids were found to be an efficacious adjunct. Long-

variability in practice regarding optimal protocols for pharmacological

acting local anaesthetic delayed the requirement for rescue

analgesia. This is compounded by a desire to reduce inappropriate

analgesia.

opioid prescribing, requiring a clearer understanding of non-opioid alternatives to reduce iatrogenic harms such as opioid use disorder.9

The evidence supports a pre-emptive, multimodal analgesic

Dentists are among the leading prescribers of opioids, with a majority

model for pain management following third molar surgery.

10

of prescriptions following third molar surgery.

Prescription opioid

use during adolescence is a risk factor for future opioid misuse.11

A combination of an NSAID and a corticosteroid should be considered the first-line standard of care, reserving opioids for severe, refractory pain. This review highlights the need for

Current research within the area of pain management following third

future research aimed at optimising multimodal analgesia and

molar removal spans across decades and includes diverse study

standardising outcome measures to reduce heterogeneity among

designs, drug combinations, dosing schedules, clinical variability

studies.

in patient health, variability in the difficulty of the procedure and outcome measures. This heterogeneity makes it challenging for clinicians, researchers and policymakers to gain a comprehensive overview of the existing knowledge, identify evidence gaps and prioritise future research. Systematic reviews are considered the

1

highest level of evidence. However, systematic reviews require a narrow, focused research question and struggle with heterogeneity. A scoping review is warranted to systematically map the extent, range and nature of the research literature on this topic. Therefore,

Royal Adelaide Hospital, Adelaide, SA, Australia; 2 Adelaide University, Adelaide, SA, Australia.

Corresponding author: Benjamin Dang

✉ benjamindang@hotmail.com | doi: 10.63717/2026.MS0069

Keywords: pain relief | third molar | wisdom teeth | analgesia | pharmacology

AJOMS Volume 3 | Issue 2 · Nov 2026

| 75


Inclusion criteria

Exclusion criteria

Population

Studies including patients undergoing surgical removal of third molars

Studies including patients undergoing surgical removal of other teeth

Concept

Studies that examine the use of pharmacological pain management for analgesia

Studies which examine alternative/non-pharmacological therapies

Context

Hospital-based setting

Private practice

Academic practice setting International guidelines Table 1. Inclusion and exclusion criteria

this review aims to provide a comprehensive overview of the pharmacological interventions evaluated for pain management following third molar surgery and collate evidence on the types of pharmacological agents and regimens used in the current literature.

Methods

Results Study characteristics A total of 65 studies met the inclusion criteria (Figure 1, Table 2). Of the 65 articles included, there were 53 randomised controlled trials (RCTs), 6 systematic reviews/meta-analyses, 5 non-randomised trials, and 1 case series. Most studies were conducted in university clinic or

Research question This review sought to map the literature for individuals undergoing surgical removal of third molars (P), which examined the use of pharmacological pain management for analgesia (C) and were either

hospital settings. Sample sizes varied for each trial from 16 to 393 individuals and 3 to 17 studies for systematic review and metaanalyses.

performed in an academic or hospital-based setting (C).

Research protocol This scoping review was registered in Open Science Framework with DOI 10.17605/OSF. IO/E523A. A search of this registry revealed no similar studies. A pre-established search strategy involving key terms and their variants was used to identify studies for inclusion in this review. This search was tailored per design for the following databases: Ovid MEDLINE, Embase, CINAHL and Cochrane. These databases were searched from inception to August 2025. All articles identified through the search were uploaded to Covidence, and duplicates were removed.

Study selection Titles and abstracts of all identified articles were screened independently by two researchers (BD and EJ). Disagreements between the two researchers were resolved through discussion until a consensus was reached. Full texts of articles were then retrieved and screened according to inclusion and exclusion criteria. Inclusion and exclusion criteria are presented in Table 1.

Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart

76 | AJOMS Volume 3 | Issue 2 · Nov 2026


Study and design

Drug class

Drug

Route

Timing

Class

Acham 2013 (RCT)12

Corticosteroid

Methylprednisolone (40-80 mg)

Oral

Pre-emptive

Placebo

Alizargar 2021 (RCT)13

Local anaesthetic

Dexmedetomidine (0.15 mL) + lidocaine (15 µg)

Submucosal

Intra-operative

Local anaesthetic

Almeida 2020 (RCT)14

Local anaesthetic

Articaine 4%

Submucosal

Intra-operative

Altaweel 2022 (RCT)15

Corticosteroid

Methylprednisolone (125 mg) + hyaluronic acid (2 mL)

Intravenous

Aoki 2006 (RCT)16

NSAID

Meloxicam (10 mg)

Aragon-Martinez 2025 (Systematic review)17

NSAID

Asadi 2017 (Nonrandomised trial)18

Name

Route

Timing

Findings

Oral

Preemptive

Single dose methylprednisolone decreased post-operative analgesia use

Lidocaine

Submucosal

Intraoperative

Addition of dexmedetomidine increased anaesthetic effect and reduced pain scores

Local anaesthetic

Mepivacaine 2%

Submucosal

Intraoperative

Both articaine and mepivacaine were effective and safe

Intra-operative

Placebo

Hyaluronic acid (125 mg)

Submucosal

Intraoperative

Methylprednisolone and hyaluronic acid performed better than each individually

Oral

Pre-emptive

Placebo, paracetamol

Ascorbic acid

Oral

Preemptive

Patients premedicated with meloxicam had reduced postoperative pain

Parecoxib (10/20/40 mg)

Oral

Post-operative

Placebo

Oral

Postoperative

Parecoxib high potency postoperative analgesia

NSAID, paracetamol

Ibuprofen (400 mg) paracetamol (600 mg), caffeine (15 mg)

Oral

Pre-emptive

Placebo

Oral

Preemptive

Combination of all three conferred better pain relief than placebo

Assari 2024 (Systematic review)19

Opioid

Tramadol (50-100 mg)

Submucosal

Intra-operative

Avelar 2012 (RCT)20

NSAID

Nimesulide (100 mg)

Oral

Post-operative

NSAID

Meloxicam (7.5 mg)

Oral

Postoperative

Nimesulide reduced pain medication requirement and swelling. Meloxicam reduced trismus

Bagade 2021 (RCT)21

Opioid, local anaesthetic

Buprenorphine with 2% lignocaine

Submucosal

Intra-operative

Local anaesthetic

2% Lignocaine

Submucosal

Intraoperative

Addition of buprenorphine prolonged anaesthesia and reduced rescue analgesia

Bailey 1993 (Nonrandomised trial)22

NSAID

Diclofenac (50 mg three times daily)

Oral

Post-operative

NSAID

Aspirin (600 mg three times daily)

Oral

Postoperative

Diclofenac greater pain relief and reduced trismus

Barath 2015 (RCT)23

Local anaesthetic

2% mepivacaine

Submucosal

Intra-operative

Local anaesthetic

2% lidocaine

Submucosal

Intraoperative

No difference for post-operative pain

Barbalho 2017 (RCT)24

NSAID, corticosteroid

Nimesulide (100 mg), dexamethasone (8 mg)

Oral

Pre-emptive

Placebo, corticosteroid

Dexamethasone (8 mg), placebo

Oral

Preemptive

Nimesulide and dexamethasone reduced pain intensity and rescue medication use

Bassyoni 2024 (RCT)25

NSAID

Celecoxib (100 mg twice daily)

Oral

Post-operative

NSAID

Diclofenac (50 mg three times daily)/ ibuprofen (400 mg four times daily)

Oral

Postoperative

Ibuprofen least effective pain control

Bauer 2013 (RCT)26

NSAID, corticosteroid

Ibuprofen (600 mg), dexamethasone (8 mg)

Oral

Pre-emptive

NSAID

Ibuprofen (600 mg)

Oral

Preemptive

Less analgesic use with ibuprofen and dexamethasone

Injection of tramadol extends the anaesthetic effect and reduces postoperative rescue analgesia

Table 2. Summary of all 65 included articles and findings

77 | AJOMS Volume 3 | Issue 2 · Nov 2026

(Continues on page 78)


Study and design

Drug class

Boccalari 2024 (RCT)27

Drug

Route

Timing

Class

Name

Route

Timing

Findings

Hyaluronic acid (0.1%), hydrogen peroxide (1.8%)

Intra-socket

Intra-operative

Placebo

Chlorhexidine (0.2%)

Submucosal

Intraoperative

Decreased pain with hyaluronic acid and hydrogen peroxide

Broome 1999 (RCT)28

NSAID, opioid

Diclofenac (75 mg), tramadol (100 mg)

Intravenous

Intra-operative

Placebo, NSAID

Diclofenac (75 mg), placebo

Intravenous

Intraoperative

Additional of tramadol had no improvement in analgesic effect

Budharapu 2015 (RCT)29

Local anaesthetic

0.5% Ropivacaine

Submucosal

Intra-operative

Local anaesthetic

2% lignocaine

Submucosal

Intraoperative

Onset and duration better for ropivacaine

Calvo 2007 (RCT)30

NSAID

Meloxicam 15 mg

Oral

Post-operative

NSAID

Meloxicam 7.5 mg

Oral

Postoperative

If there is osteotomy required, meloxicam 15 mg is recommended

Campbell 1998 (RCT)31

NSAID; Opioid; Local anaesthetic

0.5% bupivacaine, tenoxicam (20 mg), alfentanil (2 mg)

Intravenous

Pre-emptive

NSAID, local anaesthetic, opioid

0.5% bupivacaine, tenoxicam (20 mg), alfentanil (2 mg)

Intravenous

Postoperative

No difference in effect

Chang 2001 (RCT)32

NSAID

Rofecoxib (50 mg)

Oral

Post-operative

Paracetamol, opioid

Paracetamol (600 mg), codeine (60 mg)

Oral

Postoperative

Greater analgesia with rofecoxib

Chang 2004 (RCT)33

NSAID

Rofecoxib (50 mg)

Oral

Post-operative

Paracetamol, opioid

Paracetamol (650 mg), oxycodone (10 mg)

Oral

Postoperative

Rofecoxib pain relief as effective with longer duration

Dexmedetomidine (1 µgkg-1)

Intra-nasal

Pre-emptive

Placebo

Saline (0.9%)

Intra-nasal

Preemptive

Dexmedetomidine had better sedation and less post-op pain relief

2% mepivacaine

Submucosal

Intraoperative

4% articaine provided longer period of peri-operative analgesia

Oral

Preemptive

Etoricoxib reduced pain and rescue medication use

Cheung 2011 (RCT)34 Colombini 2006 (RCT)35

Local anaesthetic

4% articaine

Submucosal

Intra-operative

Local anaesthetic

Costa 2015 (RCT)36

NSAID

Etoricoxib (120 mg)

Oral

Pre-emptive

Placebo

Crincoli 2015 (RCT)37

Local anaesthetic

0.75% Ropivacaine

Submucosal

Intra-operative

Local anaesthetic

3% mepivacaine

Submucosal

Intraoperative

Ropivacaine prolonged numbness but better analgesic activity intraoperatively

Cristalli 2017 (RCT)38

Paracetamol, opioid

Paracetamol (500 mg), codeine (30 mg)

Oral

Post-operative

Placebo

Starch

Oral

Postoperative

Paracetamol + codeine better pain relief

DaCosta Arauio 2012 (RCT)39

NSAID

Nimesulide (100 mg)

Oral

Pre-emptive

Opioid

Tramadol (100 mg)

Oral

Preemptive

Similar pre-emptive effect and no change in rescue analgesia

deCarvalho 2022 (RCT)40

Paracetamol, opioid

Paracetamol (500 mg), codeine (30 mg)

Oral

Post-operative

Opioid

Oxycodone (10 mg)

Oral

Postoperative

Codeine group had less rescue analgesia and pain scores

Deo 2016 (RCT)41

Corticosteroid

Dexamethasone (8 mg)

Submucosal

Intra-operative

Placebo

Saline

Submucosal

Intraoperative

Submucosal dexamethasone reduced swelling and improved quality of life

DeSousa Santos 2012 (RCT)42

Opioid, corticosteroid

Tramadol (50 mg), dexamethasone (4 mg)

Oral

Pre-emptive

NSAID, opioid

Tramadol (50 mg), diclofenac (50 mg)

Oral

Preemptive

Tramadol and dexamethasone had better pain intensity, trismus and swelling

Diniz 2024 (RCT)43

Gabapentinoid, corticosteroid

Pregabalin (150 mg), dexamethasone (8 mg)

Oral

Pre-emptive

Placebo, corticosteroid

Placebo, dexamethasone (8 mg)

Oral

Preemptive

Pregabalin group better analgesia than placebo group

Table 2. Summary of all 65 included articles and findings

78 | AJOMS Volume 3 | Issue 2 · Nov 2026

(Continues on page 79)


Study and design

Drug class

Drug

Route

Timing

Class

Name

Route

Timing

Findings

Fernandez-Martin 2024 (RCT)44

Corticosteroid

Dexamethasone (8 mg)

Submucosal

Pre-emptive

Corticosteroid

Methylprednisolone (40 mg)

Submucosal

Preemptive

Dexamethasone controlled trismus better and pain than methylprednisolone

Forbes 1991 (RCT)45

NSAID

Ibuprofen (200 mg), caffeine

Oral

Post-operative

NSAID

Ibuprofen (200 mg)

Oral

Postoperative

Combination better than ibuprofen for onset and duration

Fricke 1993 (RCT)46

NSAID

Ibuprofen (400 mg)

Oral

Post-operative

NSAID

Naproxen (440 mg)

Oral

Postoperative

Naproxen better short-term pain relief and both drugs well tolerated

Fricke Jr 2004 (RCT)47

Paracetamol, opioid

Tramadol (75 mg), paracetamol (650 mg)

Oral

Post-operative

Opioid

Tramadol (100 mg)

Oral

Postoperative

Combination of tramadol and paracetamol superior to tramadol

Gonzalez-Morelos 2022 (Systematic review)48

Corticosteroid

Methylprednisolone

Oral

Pre-emptive

NSAID

Oral

Preemptive

Methylprednisolone better for trismus and swelling. No differences in pain control

Gregorio 2008 (RCT) 49

Local anaesthetic

0.5% bupivacaine

Submucosal

Intra-operative

Local anaesthetic

Submucosal

Intraoperative

Articaine had shorter onset time but shorter soft tissue anaesthesia time

Gunarajah 2015 (RCT)50

Opioid, corticosteroid

Dexamethasone (4 mg), tramadol (50 mg)

Submucosal

Pre-emptive

Placebo

Submucosal

Preemptive

Dexamethasone and tramadol significantly better pain control

Hadhimane 2016 (Non-randomised trial)51

NMDA-receptor antagonist

Ketamine (0.5 mg/kg)

Submucosal

Pre-emptive

Placebo

Saline

Submucosal

Preemptive

Ketamine group had lowered pain scores

Joshi 2004 (RCT)52

Paracetamol, opioid

Paracetamol (1000 mg) and codeine (60 mg)

Oral

Pre-emptive

NSAID

Ibuprofen (600 mg)/ diclofenac (100 mg)

Oral

Preemptive

No significant differences between groups

Kleinert 2008 (RCT)53

Opioid

Tapentadol (50-100 mg)

Oral

Post-operative

Opioid, NSAID

Morphine, ibuprofen

Oral

Postoperative

Tapentadol effectively reduced dental pain

Korn 2004 (RCT)54

Paracetamol, opioid

Oxycodone (5 mg), paracetamol (325 mg)

Oral

Post-operative

NSAID

Rofecoxib (50 mg)

Oral

Postoperative

Rofecoxib better analgesic effect and duration compared with oxycodone

LaRosa 2024 (RCT)55

NSAID

Etoricoxib (120 mg)

Oral

Pre-emptive and postoperative

NSAID

Etoricoxib (120 mg)

Oral

Postoperative

Pre-emptive and post-operative had better pain control and reduced oedema

Latifi 2023 (RCT)56

Gabapentinoid

Pregabalin (75 mg)

Oral

Post-operative

NSAID

Ibuprofen (400 mg)

Oral

Postoperative

Pregabalin reduced analgesic consumption and lowered pain

LaTorre 2021 (Systematic review)57

NSAID

Etoricoxib

Oral

Post-operative

NSAID

Ibuprofen (400 mg)

Oral

Postoperative

Etoricoxib better analgesic activity compared with ibuprofen

LaTorre 2021 (Systematic review)58

NSAID

Ibuprofen

Oral

Post-operative

NSAID, paracetamol

Paracetamol, meclofenamate, aceclofenac, bromfenac, and aspirin

Oral

Postoperative

Ibuprofen more effective than all other drugs

Lau 2009 (RCT)59

NSAID

Ibuprofen (400 mg)

Oral

Pre-emptive

NSAID

Ibuprofen (400 mg)

Oral

Postoperative

Ibuprofen effective both pre and post-operative

Liashek Jr 1987 (RCT)60

Paracetamol, opioid

Paracetamol (650 mg) and propoxyphene (100 mg)

Oral

Pre-emptive

Paracetamol

Paracetamol (650 mg)

Oral

Preemptive

Paracetamol + propoxyphene better than placebo

4% articaine

Table 2. Summary of all 65 included articles and findings

79 | AJOMS Volume 3 | Issue 2 · Nov 2026

(Continues on page 80)


Study and design

Drug class

Drug

Route

Timing

Class

Name

Route

Timing

Findings

Lim 2017 (RCT)

Corticosteroid

Methylprednisolone (40 mg)

Submucosal

Intra-operative

Corticosteroid

Dexamethasone (4 mg)

Submucosal

Intraoperative

Methylprednisolone group had less pain and less swelling

Lopez-Cedrun 2018 (RCT)62

NSAID, opioid

Celecoxib (112 mg) + tramadol (88 mg)

Oral

Post-operative

Opioid

Tramadol (100 mg)

Oral

Postoperative

Combined celecoxib and tramadol superior to tramadol

Lyngstad 2010 (RCT)63

NSAID, paracetamol, opioid

Paracetamol (1000 mg), ibuprofen (400 mg), codeine (60 mg)

Oral

Post-operative

Placebo

Oral

Postoperative

Paracetamol and ibuprofen superior to codeine

Malmstrom 1999 (RCT)64

NSAID

Celecoxib (200 mg), rofecoxib (50 mg)

Oral

Post-operative

Placebo/ NSAID

Ibuprofen (400 mg) + placebo group

Oral

Postoperative

Rofecoxib superior to celecoxib and comparable to ibuprofen

Mico-Llorens 2006 (Non-randomised trial)65

Corticosteroid

Methylprednisolone (40 mg)

Intramuscular

Post-operative

Placebo

No intervention

Mishra 2013 (Nonrandomised trial)66

NSAID/opioid

Tramadol (100 mg)/ ketorolac (20 mg)

Oral

Pre-emptive

NSAID/opioid

Tramadol (100 mg)/ ketorolac (20 mg)

Oral

Postoperative

Tramadol equally effective as ketorolac

Nitrous oxide (50% for 20 minutes)

Inhalation

Pre-emptive

Nitrous oxide (50% for 20 minutes)

Inhalation

Postoperative

Pre-emptive nitrous oxide had no effect

61

Ong 2004 (RCT)67

Methylprednisolone reduced pain and swelling

Ong 2004 (RCT)68

NSAID

Ketorolac (30 mg)

Intravenous

Pre-emptive

NSAID

Ketorolac (30 mg)

Intravenous

Postoperative

Pre-emptive administration decreased pain scores

Quesada-Bravo 2021 (RCT)69

Local anaesthetic/ corticosteroid

0.5% Bupivacaine + dexamethasone (8 mg)

Submucosal

Intra-operative

Local anaesthetic

4% articaine

Submucosal

Intraoperative

Bupivacaine reduced analgesic usage

Reid 2019 (Case Series)70

Opioid

Oxycodone

Oral

Post-operative

NSAID/ paracetamol

Paracetamol/ ibuprofen

Oral

Postoperative

Paracetamol/ibuprofen comparative pain control to opioids

Rood 2002 (RCT)71

Local anaesthetic

0.75% Bupivacaine

Submucosal

Intra-operative

Local anaesthetic

2% Lignocaine

Submucosal

Intraoperative

Bupivacaine had longer duration and better pain scores

Chlorhexidine (0.2%), povidone-iodine (0.5%), hydrogen peroxide (1.5%)

Intra-socket

Intra-operative

Placebo

Saline (0.9%)

Intra-socket

Intraoperative

Reduction in pain and swelling with chlorhexidine and hydrogen peroxide solutions compared with povidoneiodine solution.

Shahraki 2025 (RCT)72

Shibl 2021 (Systematic review 4 studies)73

Corticosteroid

Dexamethasone (8 mg)

Oral

Pre-emptive

Suleiman 2022 (RCT)74

NSAID

Ketoprofen (100 mg)

Oral

Pre-emptive

Corticosteroid

Dexamethasone (8 mg)

Oral

Preemptive

Decreased pain and swelling dexamethasone group

Tuffin 1990 (RCT)75

Local anaesthetic

0.75% Bupivacaine

Intra-socket

Intra-operative

Placebo

Irrigation

Intra-socket

Intraoperative

Bupivacaine irrigation reduced pain

Alveolar iodine packing

Intra-socket

Intra-operative

Placebo

Irrigation

Intra-socket

Intraoperative

Iodine packing reduced pain

Tuk 2019 (RCT)76

Dexamethasone reduced pain in all 3 studies

Abbreviations: NSAID = non-steroidal anti-inflammatory drugs; RCT = randomised control trial.

Table 2. Summary of all 65 included articles and findings

80 | AJOMS Volume 3 | Issue 2 · Nov 2026


Figure 2. Timeline of included studies

Country or region

Number of studies Abbreviations: COX = cyclo-oxygenase; NSAID = non-steroidal anti-inflammatory drugs.

Brazil

12

United States of America

11

United Kingdom

7

India

5

Italy

4

Mexico

4

The findings of this scoping review support the data for pre-emptive,

Spain

4

multimodal anti-inflammatory regimens. Pre-emptive analgesia

Hong Kong

2

for NSAIDs and corticosteroids that target the early inflammatory

Iran

2

cascade, before the activation of nociceptive pathways demonstrated

Malaysia

2

the greatest efficacy as demonstrated in Figure 3.55,59,68 In a cross-

Saudi Arabia

2

over RCT, pre-emptive ketorolac produced significantly lowered pain

Singapore

2

intensity, a longer time to first rescue analgesia and a decreased

Austria

1

amount of total post-operative analgesia when compared with post-

Egypt

1

Japan

1

Nepal

1

Netherlands

1

Nigeria

1

Norway

1

Taiwan

1

Germany

1 Table 3. Country or region of origin

Figure 3. Mechanism of action of non-steroidal antiinflammatory drugs and corticosteroids

operative ketorolac.68 Several other studies support pre-emptive NSAIDs, with improved pain control, intensity and rescue medication usage.16,24,36,52,55 Pre-emptive corticosteroids demonstrated excellent utility in managing pain but also reducing swelling and trismus, when given one hour before surgery.12,48,73,74 Submucosal corticosteroids also improved outcomes.44 Submucosal administration typically occurs intra-operatively; however, the drug exerts its effect before activation of the inflammatory cascade. NSAIDs showed superiority in analgesic property over placebo and either equivalence or increased efficacy when compared to opioidbased regimens.16,32,54,66 Specifically, selective COX-2 inhibitors

Discussion

(celecoxib, etoricoxib, rofecoxib) and traditional NSAIDs (ibuprofen, ketorolac) demonstrated high efficacy.25,33,57,64 However, rofecoxib was withdrawn from the Australian drug market in October 2004 for

This scoping review successfully mapped the extensive and

concerns regarding an increased risk of cardiovascular events.77

varied body of literature on pharmacological interventions for pain management following third molar surgery. The 65 included studies,

Dexamethasone was found to be superior to methylprednisolone

published over nearly four decades, reveal a clear evolution in

in direct comparison.44,48 Long-acting local anaesthetics, such as

analgesic strategies and highlight both areas of clinical consensus

ropivacaine and bupivacaine, when combined with adjuncts such

and significant evidence gaps (Figure 2). Multiple countries were

as dexamethasone or dexmedetomidine were found to be highly

involved, highlighting the international interest in establishing

effective for delaying the onset of post-operative pain and reducing

optimum analgesic methods (Table 3).

rescue analgesic use.29,34,36,37,49,62,69

AJOMS Volume 3 | Issue 2 · Nov 2026

| 81


author). The review does not provide gender-specific analyses, so

Analgesia

Recommendation

Local anaesthetic

0.5% bupivacaine

Pre-emptive analgesia

Dexamethasone + NSAID

Post-operative analgesia

Paracetamol + NSAID + opioid

no reliable inferences can be drawn about sex-related differences

Abbreviations: NSAID = non-steroidal anti-inflammatory drugs.

Table 4. Recommendations for analgesia based on the findings of this scoping review

in analgesic efficacy. Moreover, the studies originate from diverse geographic and ethnic populations, and without accounting for these demographic differences, the pooled evidence may be misleading, as genetic and cultural factors can influence pain perception and drug metabolism. While the scoping review has qualitative synthesis that complements the quantitative rigor of a metaanalysis—providing detailed clinical outcomes, mechanisms of action and an exploration of conflicting results—the article lacks a formal quality appraisal of

Amidst rising concerns of an opioid epidemic, with recognition of

the included literature and does not present a quantitative synthesis

increased harms such as opioid use disorder and death, there needs

of the data.81

78

to be a push for rationalisation of opioid prescription.

In a 2018

study, dentists in Australia accounted for 8.6 opioid prescriptions per 1000 population, with relatively high dispensing rates compared with English dentists by population.79 As first-line agents compared with placebo, opioids exhibit superior pain relief.19,38,50,60 Tapentadol and tramadol exhibit significant analgesic efficacy when compared with traditional opioids such as morphine.28,53 When used in multimodal analgesia, opioids exert a significant effect when compared with monotherapy.42,47,50,62 Using opioids within a multimodal approach can decrease total opioid burden, minimising associated harms.80 Recommendations provided by the authors of this study based on the findings of this scoping review are provided in Table 4. One strength of this study is the breadth, by mapping the literature from 1987 to 2025, providing a comprehensive review of the current landscape for analgesia following third molar surgery. This article also includes multiple other studies, the majority of which are RCTs, many of which are either double- or triple-blinded, which are high-level evidence.36,69 This article also includes systematic reviews, which provide a higher level of synthesised evidence, strengthening the overall conclusion. The use of a split-mouth design by several studies decreased inter-individual variability by allowing each individual to be their own control. Finally, most studies included as part of this article used validated pain scales and objective secondary outcomes such as rescue analgesic consumption to allow for quantitative comparison. The review acknowledges several critical limitations that restrict the

Conclusion Pre-emptive, multimodal analgesia for third molar surgery with a combination of an NSAID, corticosteroid and long-acting local anaesthetic demonstrates the highest efficacy. This should be given at least one hour before the procedure. This will reduce the use of rescue analgesia and pain intensity. The evidence supports the use of 8 mg dexamethasone and ibuprofen. This approach would target prostaglandin synthesis and the broader inflammatory pathway, improving outcomes not only related to pain but also swelling and trismus, which can be distressing to individuals.82 Non-opioid analgesics should be first-line agents for post-operative pain if not medically contraindicated. If pain intensity were to increase or remain refractory, atypical and typical opioids should be used. This would rationalise opioid prescribing and minimise adverse events and harm.70,83 This approach aligns with approved approaches such as the World Health Organization analgesic ladder, where targeting the cascade before nociceptive activation can reduce transition to higher steps of the analgesic ladder.84 Enhanced recovery after surgery (ERAS) protocols also recommend multimodal analgesia.85 Professional associations should develop and strongly advocate for evidence-based guidelines that establish a non-opioid multimodal regimen as the standard of care for third molar surgery. Given the significant heterogeneity encountered across all studies, there is a need for consensus on core outcome sets for third molar surgery to allow for more powerful and reliable analysis in future.

interpretability of its findings. Firstly, the included studies display extensive heterogeneity in key methodological features—drug choice, dosage and timing of administration (preemptive, intraoperative, postoperative)—as well as in outcome measures and assessment time points, making direct comparisons difficult. Sample size variation is also pronounced, ranging from very small to very large cohorts; the smaller studies are likely underpowered to detect statistically significant differences, while non-randomised trials and case series introduce greater susceptibility to confounding and bias compared with RCTs. The third molars removed were not standardised across all included papers, as bony impacted third molars can contribute significantly more pain and swelling than completely erupted third molars. The operative protocol for wisdom tooth removal was not standardised across the articles; variations in surgical technique and flap design can contribute to different outcomes. Some studies featured multiple operators, which may have affected study outcomes (additional information, available on request to the corresponding

82 | AJOMS Volume 3 | Issue 2 · Nov 2026

Author contributions Dang B: Conceptualisation, investigation, writing of initial and final script. Jensen E: Methodology, investigation, review of final script. Musa A: Consultation, review of final script.

Conflicts of interest The authors have no conflicts of interest to declare.

Funding The authors have no funding sources to declare.

Data sharing The data underlying this article are available for sharing upon reasonable request to the corresponding author.


References 1

Fonseca RJ. Oral and maxillofacial surgery. Third edition. ed. St. Louis, Missouri: Elsevier. 2018.

2

Ricciardo P, Bobinskas A, Vujcich N, et al. Survey of Australasian oral and maxillofacial surgeons 2011— scope and workforce issues. Int J Oral Maxillofac Surg 2015; 44(12): 1569-1573.

3

Hupp JR, Tucker MR, Ellis E. Contemporary Oral and Maxillofacial Surgery E-Book. Elsevier: Mosby; 2018.

4

Lopes da Silva BC, Machado GF, Primo Miranda EF, et al. Envelope or triangular flap for surgical removal of third molars? A systematic review and meta-analysis. Int J Oral Maxillofac Surg 2020; 49(8): 1073-1086.

5

Andersson L, Kahnberg KE, Pogrel MA. Oral and Maxillofacial Surgery. Wiley; 2012.

6

Therapeutic Guidelines: Oral and Dental [website]. Melbourne, Australia: Therapeutic Guidelines Limited; 2023. https://www.tg.org.au.

7

Xuan C, Yan W, Wang D, et al. Efficacy of preemptive analgesia treatments for the management of postoperative pain: a network meta-analysis. Br J Anaesthesia 2022; 129(6): 946-958.

8

Dahl JB, Møiniche S. Pre-emptive analgesia. Br Med Bull 2004; 71: 13-27.

9

Moffat AK, Apajee J, Le Blanc VT, et al. Reducing opioid use for chronic non-cancer pain in primary care using an evidence-based, theory-informed, multistrategic, multistakeholder approach: a single-arm time series with segmented regression. BMJ Qual Saf 2023; 32(11): 623-631.

10 Baker JA, Avorn J, Levin R, et al. Opioid prescribing after surgical extraction of teeth in Medicaid patients, 20002010. JAMA 2016; 315(15): 1653-1654. 11 Miech R, Johnston L, O’Malley PM, et al. Prescription opioids in adolescence and future opioid misuse. Pediatrics 2015; 136(5): e1169-1177. 12 Acham S, Klampfl A, Truschnegg A, et al. Beneficial effect of methylprednisolone after mandibular third molar surgery: a randomized, double-blind, placebocontrolled split-mouth trial. Clin Oral Investig 2013; 17(7): 1693-1700. 13 Alizargar J, Etemadi Sh M, Kaviani N, et al. Injection of lidocaine alone versus lidocaine plus dexmedetomidine in impacted third molar extraction surgery, a doubleblind randomized control trial for postoperative pain evaluation. Pain Res Manag 2021; 2021: 6623792. 14 de Almeida PC, Raldi FV, Sato FRL, et al. Volume and effectiveness assessment of articain 4% versus mepivacaine 2% used in third molar surgery: Randomized, double-blind, split-mouth controlled clinical trial. Med Oral Patol Oral Cir Bucal 2020; 25(6): e762-e768. 15 Altaweel AA, Gaber AEH, Alnaffar MZ, et al. Methylprednisolone and Hyaluronic acid versus each agent alone to control complication of impacted wisdom removal. Evid Based Complement Alternat Med 2022; 2022: 1563513. 16 Aoki T, Yamaguchi H, Naito H, et al. Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg 2006; 35(7): 613-617. 17 Aragon-Martinez OH, Gomez-Sanchez E, BolognaMolina R, et al. Author’s Reply to the Comment on “Pain control and adverse effects of parecoxib after wisdom teeth surgery: a quantitative systematic review”. Oral Maxillofac Surg 2025; 29(1): 143. 18 Asadi HK, Jamalpour MR, Saeedi A. Clinical trial of combination of acetaminophen, ibuprofen and caffeine on pain relief and analgesic use after impacted lower third molar surgery. Shiraz E Medical Journal 2017; 18(7): e13092. 19 Assari AS, Algharbi EMA, Abuhabsha AM, et al. Efficacy of submucosal administration of tramadol on acute pain following third molar surgery: a systematic review and meta-analysis. Front Oral Health 2024; 5: 1360298.

20 Avelar RL, Primo BT, Vogt BF, et al. Effect of partially selective cyclooxygenase-2 inhibitor in the removal of third molars. J Craniofac Surg 2012; 23(2): e108-e112. 21 Bagade SP, Joshi SS, Punamiya S, et al. To evaluate the efficacy of buprenorphine and 2% lignocaine with adrenaline as postoperative analgesia following mandibular third molar surgery: a comparative study. Ann Maxillofac Surg 2021; 11(2): 236-240. 22 Bailey BMW, Zaki G, Rotman H, et al. A double-blind comparative study of soluble aspirin and diclofenac dispersible in the control of postextraction pain after removal of impacted third molars. Int J Oral Maxillofac Surg 1993; 22(4): 238-241. 23 Barath S, Triveni VSS, Naga Sai Sujai GV, et al. Efficacy of 2% mepivacaine and 2% lignocaine in the surgical extraction of mesioangular angulated bilaterally impacted third molars: A double-blind, randomized, clinical trial. J Pharm Bioallied Sci 2015; 7(6 Supplement 2): S600-S606. 24 Barbalho JC, Vasconcellos RJH, de Morais HH, et al. Effects of co-administered dexamethasone and nimesulide on pain, swelling, and trismus following third molar surgery: a randomized, triple-blind, controlled clinical trial. Int J Oral Maxillofac Surg 2017; 46(2): 236-242. 25 Bassyoni L. Comparative Effect of celecoxib, diclofenac, and ibuprofen in controlling postoperative pain, edema, and trismus after third molar extraction: a doubleblinded randomized controlled trial. Cureus 2024; 16(2): e53687. 26 Bauer HC, Duarte FL, Horliana ACRT, et al. Assessment of preemptive analgesia with ibuprofen coadministered or not with dexamethasone in third molar surgery: A randomized double-blind controlled clinical trial. Oral Maxillofac Surg 2013; 17(3): 165-171. 27 Boccalari E, Khijmatgar S, Occhipinti C, et al. Effect of hydrogen peroxide and hyaluronic acid in mouth rinse after third molar extraction: a triple-blind parallel randomized controlled clinical trial. Eur Rev Med Pharmacol Sci 2024; 28(13): 3946-3957.

120 mg on inflammatory events following removal of unerupted mandibular third molars. Int J Oral Maxillofac Surg 2015; 44(9): 1166-1174. 37 Crincoli V, Favia G, Limongelli L, et al. The effectiveness of ropivacaine and mepivacaine in the postoperative pain after third lower molar surgery. Int J Med Sci 2015; 12(11): 862-866. 38 Cristalli MP, LaMonaca G, De Angelis C, et al. Efficacy of preoperative administration of paracetamol-codeine on pain following impacted mandibular third molar surgery: A randomized, split-mouth, placebo-controlled, double-blind clinical trial. Pain Res Manag 2017; 2017: 9246352. 39 Da Costa Araujo FA, De Santana Santos T, De Morais HHA, et al. Comparative analysis of preemptive analgesic effect of tramadol chlorhydrate and nimesulide following third molar surgery. J Craniomaxillofac Surg 2012; 40(8): e346-e349. 40 de Carvalho MF, de Matos Silveira G, de Carvalho PAR, et al. Analgesia and side effects of codeine phosphate associated with paracetamol versus oxycodone after the extraction of mandibular third molars: a randomized double-blind clinical trial using the split-mouth model. J Maxillofac Oral Surg 2022; 21(3): 1038-1043. 41 Deo SP. Effect of submucosal injection of dexamethasone on post-operative sequelae of third molar surgery. JNMA J Nepal Med Assoc 2011; 51(2): 72-78. 42 de Sousa Santos JA, da Silva LC, de Santana Santos T, et al. Comparative study of tramadol combined with dexamethasone and diclofenac sodium in third-molar surgery. J Craniomaxillofac Surg 2012; 40(8): 694-700. 43 Diniz JA, Dourado ACAG, Barbirato DDS, et al. Evaluation of the effects of pregabalin and dexamethasone coadministration on preemptive multimodal analgesia and anxiety in third molar surgeries: a triple-blind randomized clinical trial. Clin Oral Investig 2024; 28(6): 304.

28 Broome IJ, Robb HM, Raj N, et al. The use of tramadol following day-case oral surgery. Anaesthesia 1999; 54(3): 289-292.

44 Fernandez-Martin U, Lisbona-Gonzalez MJ, VallecilloRivas M, et al. Effect of preoperative administration of dexamethasone vs. methylprednisolone in surgical extraction of impacted lower third molars: randomized controlled clinical trial. J Clin Med 2024; 13(16): 4614.

29 Budharapu A, Sinha R, Uppada UK, et al. Ropivacaine: A new local anaesthetic agent in maxillofacial surgery. Br J Oral Maxillofac Surg 2015; 53(5): 451-454.

45 Forbes JA, Beaver WT, Jones KF, et al. Effect of caffeine on ibuprofen analgesia in postoperative oral surgery pain. Clin Pharmacol Ther 1991; 49(6): 674-684.

30 Calvo AM, Sakai VT, Giglio FPM, et al. Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study. Int J Oral Maxillofac Surg 2007; 36(1): 26-31.

46 Fricke JR, Halladay SC, Francisco CA. Efficacy and safety of naproxen sodium and ibuprofen for pain relief after oral surgery. Curr Ther Res Clin Exper 1993; 54(6): 619-627.

31 Campbell WI, Kendrick RW, Fee JPH. Balanced preemptive analgesia: Does it work? A double-blind, controlled study in bilaterally symmetrical oral surgery. Br J Anaesth 1998; 81(5): 727-730. 32 Chang DJ, Fricke Jr JR, Bird SR, et al. Rofecoxib versus codeine/acetaminophen in postoperative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 2001; 23(9): 1446-1455. 33 Chang DJ, Desjardins PJ, Bird SR, et al. Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Curr Med Res Opin 2004; 20(6): 939-949. 34 Cheung CW, Ng KFJ, Liu J, et al. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth 2011; 107(3): 430-437. 35 Colombini BL, Modena KCS, Calvo AM, et al. Articaine and mepivacaine efficacy in postoperative analgesia for lower third molar removal: a double-blind, randomized, crossover study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102(2): 169-174. 36 Costa FWG, Soares ECS, Esses DFS, et al. A splitmouth, randomized, triple-blind, placebo-controlled study to analyze the pre-emptive effect of etoricoxib

47 Fricke Jr JR, Hewitt DJ, Jordan DM, et al. A doubleblind placebo-controlled comparison of tramadol/ acetaminophen and tramadol in patients with postoperative dental pain. Pain 2004; 109(3): 250-257. 48 Gonzalez-Morelos M, Franco-de la Torre L, FrancoGonzalez DL, et al. Efficacy of methylprednisolone compared to other drugs for pain, swelling, and trismus control after third molar surgery: a meta-analysis. Healthcare (Basel) 2022; 10(6): 1028. 49 Gregorio LV, Giglio FP, Sakai VT, et al. A comparison of the clinical anesthetic efficacy of 4% articaine and 0.5% bupivacaine (both with 1: 200,000 epinephrine) for lower third molar removal. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106(1): 19-28. 50 Gunarajah DR, Royan SJ. Efficacy of pre-operative oral tramadol combined with submucosal dexamethasone versus placebo in mandibular third molar surgery: A double blind randomized controlled trial. Int J Oral Maxillofac Surg 2015; 1: e218. 51 Hadhimane A, Shankariah M, Neswi KV. Pre-emptive analgesia with ketamine for relief of postoperative pain after surgical removal of impacted mandibular third molars. J Maxillofac Oral Surg 2016; 15(2): 156-163. 52 Joshi A, Parara E, Macfarlane TV. A double-blind randomised controlled clinical trial of the effect of preoperative ibuprofen, diclofenac paracetamol with codeine and placebo tablets for relief of postoperative

AJOMS Volume 3 | Issue 2 · Nov 2026

| 83


pain after removal of impacted third molars. Br J Oral Maxillofac Surg 2004; 42(4): 299-306.

controlled, multicentre, Phase II trial. Drugs R D 2018; 18(2): 137-148.

53 Kleinert R, Lange C, Steup A, et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth Analg 2008; 107(6): 2048-2055.

63 Lyngstad G, Skjelbred P, Skoglund LA. The duration of analgesic drugs is the major determinant for numbers needed to treat (NNT) calculations. J Oral Maxillofac Surg 2013; 71: e37-e8.

54 Korn S, Vassil TC, Kotey PNA, et al. Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: A randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model. Clin Ther 2004; 26(5): 769-778. 55 La Rosa GRM, Consoli M, Abiad RS, et al. Comparing pre- and postoperative etoricoxib administration versus only postoperative on third molar extraction sequelae and oral health quality of life: a prospective quasiexperimental study. Clin Oral Investig 2024; 28(4): 218. 56 Latifi F, Choobsaz P, Yousefi-Koma AA, et al. Comparison of the analgesic effects of single-dose 75 mg oral pregabalin versus single-dose 400 mg oral ibuprofen after impacted third mandibular molar surgery: A randomized, double-blind, split-mouth clinical trial. Dent Med Probl 2023; 60(4): 619-625. 57 La Torre LFD, Franco-Gonzalez DL, Brennan-Bourdon LM, et al. Analgesic efficacy of etoricoxib following third molar surgery: a meta-analysis. Behav Neurol 2021: 9536054. 58 la Torre LF, Figueroa-Fernandez NP, Franco-Gonzalez DL, et al. A meta-analysis of the analgesic efficacy of single-doses of ibuprofen compared with traditional non-opioid analgesics following third molar surgery. Pharmaceuticals (Basel) 2021; 14(4): 360. 59 Lau SL, Chow RLK, Yeung RWK, et al. Pre-emptive ibuprofen arginate in third molar surgery: A doubleblind randomized controlled crossover clinical trial. Aust Dent J 2009; 54(4): 355-360. 60 Liashek Jr P, Desjardins PJ, Triplett RG. Effect of pretreatment with acetaminophen-propoxyphene for oral surgery pain. J Oral Maxillofac Surg 1987; 45(2): 99-103. 61 Lim D, Ngeow WC. Analgesic effect of submucosal dexamethasone and methylprednisolone in third molar surgery. Int J Oral Maxillofac Surg 2017; 46(Supplement 1): 278. 62 Lopez-Cedrun J, Videla S, Burgueno M, et al. Co-crystal of tramadol-celecoxib in patients with moderate to severe acute post-surgical oral pain: a dose-finding, randomised, double-blind, placebo- and active-

64 Malmstrom K, Daniels S, Kotey P, et al. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator- controlled clinical trial. Clin Ther 1999; 21(10): 1653-1663.

systematic review. Br Dent J 2021 Jul 8. Online ahead of print. 74 Suleiman IK, James O, Olasoji HO. Effect of dexamethasone, ketoprofen and cold compress on postoperative sequelae in mandibular third molar surgery: A randomized clinical trial. Advances Oral Maxillofac Surg 2021; 5: 100211. 75 Tuffin JR, Cunliffe DR, Begg R, et al. Does bupivacaine irrigation of third molar sockets reduce postoperative pain? A double blind controlled trial. Br J Oral Maxillofac Surg 1990; 28(2): 96-98.

65 Mico-Llorens JM, Satorres-Nieto M, Gargallo-Albiol J, et al. Efficacy of methylprednisolone in controlling complications after impacted lower third molar surgical extraction. Eur J Clin Pharmacol 2006; 62(9): 693-698.

76 Tuk JG, Lindeboom JA, Sana F, et al. Alveolar iodine tampon packing reduces postoperative morbidity after third molar surgery. J Oral Maxillofac Surg 2019; 77(12): 2401-2411.

66 Mishra H, Khan FA. A double-blind, placebo controlled randomised comparison of pre and post operative administration of tramadol for dental extraction pain. J Internat Med Sci Acad 2013; 26(2): 97-99

77 Barozzi N, Tett SE. What happened to the prescribing of other COX-2 inhibitors, paracetamol and nonsteroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? Pharmacoepidemiol Drug Saf 2007; 16(11): 1184-1191.

67 Ong KS, Seymour RA, Tan JM. A prospective randomized crossover study of the preemptive analgesic effect of nitrous oxide in oral surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98(6): 637-642. 68 Ong KS, Seymour RA, Chen FG, et al. Preoperative ketorolac has a preemptive effect for postoperative third molar surgical pain. Int J Oral Maxillofac Surg. 2004;33(8):771-6. 69 Quesada-Bravo FJ, Garcia-Carricondo AR, Espin-Galvez F, et al. Comparative study between the combination of dexamethasone and bupivacaine for third molar surgery postoperative pain: A triple-blind, randomized clinical trial. J Clin Med 2021; 10(21): 5081. 70 Reid D, Mir S, Brecher E, et al. A comparison of opioids and non-opioids in management of post-operative pain following third molar extraction. Int J Oral Maxillofac Surg 2019; 48(Supplement 1): 67. 71 Rood JP, Coulthard P, Snowdon AT, et al. Safety and efficacy of levoburpivacaine for postoperative pain relief after the surgical removal of impacted third molars: A comparison with lignocaine and adrenaline. Br J Oral Maxillofac Surg 2002; 40(6): 491-496. 72 Shahraki M, Khazaei AH, Hakimi S, et al. Effect of chlorhexidine, povidone-iodine, and hydrogen peroxide irrigation on pain and swelling after mandibular third molar surgery: randomized controlled trial. Int J Oral Maxillofac Surg 2025; 54(7): 677-683. 73 Shibl M, Ali K, Burns L. Effectiveness of pre-operative oral corticosteroids in reducing pain, trismus and oedema following lower third molar extractions: a

78 The Lancet Regional Health – Americas. Opioid crisis: addiction, overprescription, and insufficient primary prevention. Lancet Reg Health Am 2023; 23: 100557. 79 Teoh L, Hollingworth S, Marino R, et al. Dental opioid prescribing rates after the up-scheduling of codeine in Australia. Sci Rep 2020; 10(1): 8463. 80 Ramirez MF, Kamdar BB, Cata JP. Optimizing Perioperative use of opioids: a multimodal approach. Curr Anesthesiol Rep 2020; 10(4): 404-415. 81 Huang J, Gan Y, Xu H, et al. Acute pain management following mandibular third molar exodontia: a bibliometric analysis of randomized controlled trials. Int Dent J 2025; 75(2): 939-948. 82 Slade GD, Foy SP, Shugars DA, et al. The impact of third molar symptoms, pain, and swelling on oral healthrelated quality of life. J Oral Maxillofac Surg 2004; 62(9): 1118-1124. 83 Davies LEM, Koerkamp EAJ-G, Koster ES et al. Patients’ perspectives about the role of primary healthcare providers in long-term opioid therapy: a qualitative study in Dutch primary care. Br J Gen Prac 2024; 74(744): e475-e481. 84 Anekar AA, Hendrix JM, Cascella M. WHO Analgesic Ladder. StatPearls. Treasure Island (FL), StatPearls Publishing LLC.; 2026. 85 Kaye AD, Urman RD, Rappaport Y, et al. Multimodal analgesia as an essential part of enhanced recovery protocols in the ambulatory settings. J Anaesthesiol Clin Pharmacol 2019; 35(Suppl 1): s40-s45.

ANZAOMS 2027 A new era of DePuy Synthes Humanly Moved Proud Platinum Sponsors | Perth

84 | AJOMS Volume 3 | Issue 2 · Nov 2026


SCIENTIFIC ARTICLE

Comparison of bone turnover markers in patients on denosumab undergoing complex dentoalveolar surgery Inderjeeth C (MBCHB, MPH, FRACP)1,2,3; Inderjeeth D (DipCom)2; Devlin J (MBBS, DMD)1; Chang F (BDSc, MBCHB, FRACDS)1; Gebauer D (BDSc, MBBS, FRACDS / M Clin Res)1

Introduction

ABSTRACT

Bisphosphonates and the monoclonal antibody denosumab are antiresorptive medications used for osteoporosis, Paget’s disease and metastatic bone malignancies. A known complication is medicationrelated osteonecrosis of the jaws (MRONJ), a term that has replaced bisphosphonate-related osteonecrosis of the jaws (BRONJ). Denosumab is increasingly used, with bone turnover markers typically returning to baseline levels nine months post-dose.1 According to the 2022 American Association of Oral and Maxillofacial Surgeons (AAOMS) position paper, a diagnosis of MRONJ requires the fulfillment of three criteria: a history of current or previous treatment with antiresorptive or antiangiogenic agents; the presence of exposed bone or bone that can be probed via an intraoral or extraoral fistula in the maxillofacial region for more than eight weeks; and the absence of a history of radiation therapy to the jaws or obvious metastatic disease of the jaw.2,3

Purpose: Antiresorptive medications increase the risk of medication-related osteonecrosis of the jaw following extractions. Bone turnover markers (BTMs) assess bone metabolism. We evaluated the correlations between BTMs and impact of time since last dose in patients requiring dentoalveolar surgery. Methods: Statistically powered; prospective cohort of 56 patients on denosumab referred for dentoalveolar surgery. Serum C-terminal telopeptide (CTX), serum N-terminal propeptide of type I procollagen (P1NP), and urinary N-terminal telopeptide (NTX) were measured at three timepoints: initial presentation (initial), time of surgery (>6 months after last dose), and before resuming denosumab (>3 months post-surgery). Spearman correlation and linear regression analysis were performed to determine the relationships between BTMs.

MRONJ incidence varies, reported as 1 per 10,000–100,000 patientyears for bisphosphonates in osteoporosis, and 5.2 per 10,000 patient-years for denosumab.4–9 Risk increases with intravenous use, treatment duration and dental extraction.2,10–12 Antiresorptives slow bone turnover, measurable via levels of BTMs such as serum C-terminal telopeptide (CTX), N-terminal telopeptide (NTX, serum/urine), and N-terminal propeptide of type I procollagen (P1NP).13,14 The International Osteoporosis Foundation and International Federation of Clinical Chemistry recommend P1NP (formation) and serum CTX (resorption) for the monitoring of bone turnover.15 NTX (serum/urine) is considered to be a marker of bone resorption. Serum CTX is often used to assess MRONJ risk, despite systematic reviews questioning its predictive capacity.16 Australian guidelines suggest measuring the fasted morning serum CTX level before invasive dental procedures.12 CTX levels ≥150 pg/mL indicate low risk, 70–150 pg/mL indicates moderate risk, and <70 pg/mL indicates high risk.12,17,18 Delaying procedures to increase the time since last dose aims to reduce risk, especially with denosumab, where BTMs normalise around nine months post-dose.2,19

Results: There were strong positive correlations between the BTMs: 0.846 (CTX and P1NP), 0.837 (CTX and NTX) and 0.799 (P1NP and NTX). Linear regression models found that NTX and P1NP were good predictors of CTX levels. Days off medication significantly impacted the CTX levels (P <0.001). Conclusions: BTMs are strongly correlated, and NTX and P1NP can be used to predict CTX levels in patients on denosumab. Duration off medication significantly affects BTM levels. These findings provide valuable insights for managing patients on antiresorptive therapy who require invasive dental procedures and highlight the importance of monitoring BTMs to assess bone metabolism and surgical timing. Additionally, according to the 2022 AAOMS position paper, there should be caution taken when suspending denosumab in osteoporosis patients. Several studies have demonstrated a rebound increase in bone resorption following the discontinuation of denosumab, resulting in an increased risk of multilevel vertebral fractures.2,3,8

1 University of Western Australia, Crawley, WA, Australia; 2 Sir Charles Gairdner Osborne Park Health Care Group, Nedlands, WA, Australia; 3 Curtin University, Bentley, WA, Australia.

Corresponding author: Dieter Gebauer

✉ gebauerd@specialistomfs.com | doi: 10.63717/2026.MS0082

Keywords: bone turnover markers | C-terminal telopeptide (CTX) | denosumab | medication-related osteonecrosis of the jaws (MRONJ) | osteoporosis

AJOMS Volume 3 | Issue 2 · Nov 2026

| 85


Different BTM usage across specialties (dental: serum CTX; medical:

determine correlations between BTMs and the effects of time off

serum CTX, P1NP, or urine NTX) complicates patient management.

medication and age.

The correlation between BTMs after last dosing and before the next dose is poorly characterised, limiting their interchangeable

The main variables analysed were serum CTX, serum P1NP and

use. Previous work compared CTX and urine NTX for fracture risk

urinary NTX. Temporal variables included time since last dose of

20

assessment.

denosumab and time intervals between assessment timepoints.

This study aims to evaluate and compare P1NP,

CTX and NTX in patients on antiresorptive therapy to determine interchangeability and improve interspecialty communication and

Levels of each BTM (CTX, P1NP and NTX) were compared at each

result interpretation.

timepoint, and values analysed to determine if any correlation exists.

Methods

population not on antiresorptive therapy to determine if BTMs

BTM levels were compared with reference ranges for the normal returned to expected baseline levels.

This prospective, single-centre cohort study was conducted in a single-operator oral and maxillofacial surgeon private practice. The primary objective was to evaluate the correlation between CTX, NTX and P1NP in patients requiring dentoalveolar surgery. The secondary objectives were to describe longitudinal changes in each marker following the last dose of denosumab, to evaluate whether BTMs could be used interchangeably, including whether P1NP and NTX could predict CTX and to determine a safe threshold for surgery.

This study was approved by the University of Western Australia Human Research Ethics Committee (ROAP 2019/RA/4/20/4828).

Results Participants were referred by dental surgeons to a maxillofacial surgeon as they were at high risk of complications, including MRONJ, due to their denosumab exposure. The study enrolled 56 participants (48 females [85.7%], 8 males [14.3%]) with a mean age of 75.5

Inclusion criteria were patients currently being treated with denosumab for osteoporosis, including patients who have received a bisphosphonate before taking denosumab; and patients requiring

years (range: 53–92 years; interquartile range: 71–82 years). Four participants (7.1%) had MRONJ during the study period. The MRONJ

dentoalveolar surgery.

cohort was notably older (mean age: 84.0 years) compared with the

Patients receiving denosumab for indications other than osteoporosis,

of females, likely due to the high proportion of females in the study.

such as malignancy or Paget’s disease, were excluded from the study.

No patient developed multilevel vertebral fractures.

Sample size calculation was based on a one-sample correlation

The median time since last medication dose was 145.5 days (range:

power analysis using an expected correlation coefficient of 0.71

6–515 days) at initial assessment (hereafter, Initial), 210.0 days

20

(range: 101–634 days) at pre-operative assessment (hereafter,

non-MRONJ group (mean age: 74.9 years) and consisted exclusively

between CTX and NTX (derived from Chubb and colleagues).

A

minimum sample size of 50 participants was determined to achieve

Pre-op), and 311.0 days (range: 122–753 days) at post-operative

90% power at a significance level of 0.05. The study enrolled 56

assessment (hereafter, Post-op). The mean interval between Initial

participants to account for potential attrition.

and Pre-op was 82.4 days (median: 75 days, range: 7–262 days), whereas the mean interval between Pre-op and Post-op was 101

Subjects were recruited from the private rooms of a single oral and

days (median: 99.5 days, range: 21–230 days).

maxillofacial specialist. All patients that meet the inclusion criteria were provided with a participant information form and invited to

A mixed-effects model showed a significant increase in CTX

participate. Details of the study were provided to the participants

level from Initial to Pre-Op to Post-Op (P = 0.001). There was no

and informed consent was obtained. The decision to participate

significant difference between the MRONJ and non-MRONJ groups

was voluntary. All data collected were entered into a Microsoft Excel

(P = 0.702). The Mann-Whitney U tests revealed small effect sizes

spreadsheet and kept on a password-protected computer.

at all timepoints (Cliff’s Delta: Initial = 0.202, Pre-Op = 0.199, PostOp = 0.250) with no statistically significant differences (all P > 0.05).

BTM measurements (serum CTX and P1NP, and urinary NTX) were obtained at three predetermined timepoints: the initial assessment

P1NP levels showed a significant increase from Initial to Pre-Op to

at first consultation, a pre-operative assessment targeted for at least

Post-Op (P < 0.001). There was no significant difference between

six months after the last denosumab dose, and a post-operative

the MRONJ and non-MRONJ groups (P = 0.951). The Mann-

assessment performed before denosumab resumption at about three

Whitney U tests showed negligible to small effect sizes (Cliff’s

months following surgery. Samples were obtained as fasted morning

Delta: Initial = -0.194, Pre-Op = -0.125, Post-Op = -0.125) with no

blood and urine to reduce diurnal and feeding-related variability in

statistically significant differences (all P > 0.05).

CTX and NTX.

NTX levels had a significant increase from Initial to Pre-Op to Post-

At enrolment in the trial, patients were asked to fill out a history

Op (P < 0.001). There was no significant difference between the

regarding their antiresorptive use. This included the dose, route

MRONJ and non-MRONJ groups (P = 0.951). There was a marginally

of administration and duration of denosumab treatment, and any

significant interaction between time (Post-Op) and MRONJ status

previous exposure to bisphosphonates. Data were analysed to

(P = 0.077). The Mann-Whitney U tests revealed small effect sizes for Initial and Pre-Op (Cliff’s Delta: Initial = 0.317, Pre-Op = -0.370) with

86 | AJOMS Volume 3 | Issue 2 · Nov 2026


differences between all timepoints. Data were analysed to determine correlations between BTMs and the effects of time off medication and age. Age did not affect BTM changes over timepoints. All three BTMs demonstrated significant progressive increases across study timepoints (P < 0.001) (Figure 1, Table 1). Mean CTX levels increased from 126.46 pg/mL (standard deviation [SD] = 159.54 pg/mL) at Initial to 332.74 pg/mL (SD = 288.24 pg/mL) at Pre-op, and further to 588.39 pg/mL (SD = 409.53 pg/mL) at Post-op. Similar patterns were observed for P1NP (22.92 µg/L → 32.33 µg/L → 59.94 µg/L) and NTX (22.61 nmol/L → 35.00 nmol/L → 52.79 nmol/L).

Figure 1. Bone turnover marker change over time

Marker variability, assessed through standard deviation analysis, showed progressive increase across timepoints. CTX demonstrated the most pronounced

Timepoint

Marker

n

Mean

Standard deviation

Median

Interquartile range

Initial

CTX (pg/mL)

56

126.46

159.54

61.50

37.25–152.75

P1NP (µg/L)

53

22.92

16.99

21.00

13.00–25.00

NTX (nmol/L)

44

22.61

14.06

22.00

10.00–28.50

→ 18.19 nmol/L → 26.02 nmol/L). The

CTX (pg/mL)

43

332.74

288.24

271.00

122.00–392.50

distribution patterns, evaluated through

P1NP (µg/L)

40

32.33

22.75

26.00

18.25–36.50

NTX (nmol/L)

36

35.00

18.19

29.00

24.50–44.25

CTX (pg/mL)

36

588.39

409.53

409.00

264.75–973.00

value dispersion observed at each

P1NP (µg/L)

35

59.94

34.65

52.00

32.00–81.50

timepoint. This pattern suggests enhanced

NTX (nmol/L)

33

52.79

26.02

48.00

29.00–68.00

synchronisation of bone turnover

Preoperation

Postoperation

Abbreviations: CTX = C-terminal telopeptide; NTX = N-terminal telopeptide; P1NP = N-terminal propeptide of type I procollagen.

Table 1. Bone turnover marker levels across study timepoints

variability expansion (SD: 159.54 pg/mL → 288.24 pg/mL → 409.53 pg/mL), followed by P1NP (SD: 16.99 µg/L → 22.75 µg/L → 34.65 µg/L) and NTX (SD: 14.06 nmol/L

scatter plot analysis, revealed increasingly linear relationships between markers at subsequent timepoints, with broader

processes as the time since last dose progressed, despite increased individual variability in marker levels. Spearman’s rank correlation analysis was

Bone turnover marker

Spearman correlation (r)

CTX

0.683

P1NP NTX

P

Strength of correlation

performed to examine the relationship

< 0.001

Strong

between BTMs and time since last dose of

0.622

< 0.001

Moderate

0.514

< 0.001

Moderate

Abbreviations: CTX = C-terminal telopeptide; NTX = N-terminal telopeptide; P1NP = N-terminal propeptide of type I procollagen.

Table 2. Spearman correlation results for bone turnover markers versus time (days since last denosumab dose)

antiresorptive medication, due to nonparametric data distribution. All three markers demonstrated significant positive correlations with duration since last dose (Table 2). CTX showed the strongest correlation with last dose duration (ρ = 0.683, P < 0.001), followed by P1NP with a moderate correlation (ρ = 0.622,

no statistically significant differences (P > 0.05). Post-Op comparison was not possible due to insufficient data in the MRONJ group. Post-hoc Tukey Honestly Significant Difference tests showed significant differences between Initial and Post-Op, and between PreOp and Post-Op for all markers. P1NP additionally showed significant

P < 0.001) and NTX also with a moderate correlation (ρ = 0.514, P < 0.001). The analysis of relationships between BTMs was conducted using Spearman’s rank correlation coefficient following verification of non-normal distribution through Shapiro-Wilk testing (all markers

AJOMS Volume 3 | Issue 2 · Nov 2026

| 87


whether P1NP and NTX levels could predict CTX values. Analysis

Timepoint

Marker pair

n

ρ

Initial

CTX–P1NP

53

0.65

< 0.001

CTX–NTX

44

0.48

0.001

P1NP–NTX

43

0.45

0.003

CTX = 4.7793(P1NP) + 7.0262(NTX) – 94.8597. The combined model

CTX–P1NP

40

0.85

< 0.001

explained 78.68% of CTX variability (R² = 0.7868), with the root

CTX–NTX

36

0.70

< 0.001

P1NP–NTX

36

0.69

< 0.001

CTX–P1NP

35

0.82

< 0.001

CTX–NTX

33

0.89

< 0.001

P1NP–NTX

33

0.88

< 0.001

Pre-operation

Post-operation

P

was restricted to observations within 410 days since last dose to optimise model performance and exclude temporal outliers, CTX was predicted by P1NP and NTX using the equation

mean square error being 167.55 and cross-validation R² of 0.7339 (± 0.0971), suggesting reasonable stability despite limited long-term follow-up. Model development was limited by sample size and incomplete longterm follow-up data, particularly in later timepoints. However, crossvalidation results suggest reasonable model stability for predicting

Abbreviations: CTX = C-terminal telopeptide; NTX = N-terminal telopeptide; P1NP = N-terminal propeptide of type I procollagen.

CTX levels within 410 days since last dose.

Table 3. Spearman correlation coefficients between bone turnover markers

Discussion The AAOMS position paper was unable to reach a consensus

Metric

Value

regarding a recommendation on a structured treatment interruption when using antiresorptive agents (ie, drug holiday). The panel

Model coefficients P1NP

4.7793

NTX

7.0262

Intercept

-94.8597

was evenly split between offering drug holidays to patients on a case-by-case basis using prior recommendations versus those who never recommend drug holidays, believing that the risks of potential deleterious effects of suspending antiresorptive therapy were too high. MRONJ is still encountered regularly in specialist oral

Model performance R2 Score

0.7868 (78.68% variance explained)

Root mean square error

167.5519

Cross-validation R2

0.7339 (±0.0971)

Abbreviations: CTX = C-terminal telopeptide; NTX = N-terminal telopeptide; P1NP = N-terminal propeptide of type I procollagen.

Table 4. Linear regression model summary for CTX versus P1NP and NTX

and maxillofacial clinical practice. For those patients who develop MRONJ, it can be detrimental to their osteoporosis management as, in some instances, their denosumab treatment needs to be ceased to manage their MRONJ; thus exposing the patient to the rebound risk of osteoporosis. BTMs may have potential in identifying individual patient risk of development of MRONJ by balancing timing of dentoalveolar surgery and risk of rebound resorption due to prolonged periods of time since last denosumab dose.

P < 0.05). The correlation strength between markers demonstrated progressive enhancement across the study timepoints, with notably stronger associations between BTMs emerging in later phases since last dose (Table 3). At Initial, moderate to strong correlations were observed between CTX and P1NP (ρ = 0.65, n = 53, P < 0.001), whereas correlations between CTX–NTX (ρ = 0.48, n = 44, P = 0.001) and P1NP–NTX (ρ = 0.45, n = 43, P = 0.003) demonstrated moderate strength. At Pre-op, there were substantially strengthened correlations, with CTX– P1NP showing very strong association (ρ = 0.85, n = 40, P < 0.001), and both CTX–NTX (ρ = 0.70, n = 36, P < 0.001) and P1NP–NTX (ρ = 0.69, n = 36, P < 0.001) demonstrating strong relationships. The post-operative period exhibited the strongest correlations, with very strong associations between all markers: CTX–P1NP (ρ = 0.82, n = 35, P < 0.001), CTX–NTX (ρ = 0.89, n = 33, P < 0.001), and P1NP–NTX (ρ = 0.88, n = 33, P < 0.001). Linear regression modelling was performed to evaluate the predictive relationship between BTMs (Table 4). CTX is the preferred marker in dental and maxillofacial practice. Furthermore, CTX was chosen as the dependent variable as it had the highest correlation and covariance with the other two BTMs. We tested

88 | AJOMS Volume 3 | Issue 2 · Nov 2026

This prospective, cohort study investigated the patterns and correlations between the BTMs CTX, P1NP and NTX in patients on antiresorptive therapy requiring dentoalveolar surgery. The findings demonstrate several key insights regarding BTM behaviour during antiresorptive medication and their potential utility in clinical decisionmaking. Data were analysed to determine correlations between BTMs and the effects of time off medication and age. Age did not affect BTM changes over timepoints. All three BTMs showed significant progressive increases across the study timepoints (P < 0.001), with mean CTX levels rising from initial assessment to pre-operatively, and further post-operatively (Figure 1, Table 1). Similar progressive increases were observed for P1NP and NTX levels. This pattern aligns with the expected biological response to denosumab as its antiresorptive effect diminishes and bone turnover resumes. The further increase in BTMs post-operatively likely reflects increased local bone remodelling in response to surgical intervention. CTX exhibited the strongest temporal association, indicating that it may be the most sensitive marker for monitoring recovery of bone resorption activity after denosumab. The hierarchical pattern of correlations (CTX > P1NP > NTX) suggests varying rates of recovery


among different bone turnover processes following last denosumab

particularly relevant in healthcare systems where different specialties

dose. This finding has implications for marker selection when

routinely measure different markers. However, the model’s utility

monitoring patients on denosumab undergoing dentoalveolar surgery.

should be validated in larger, diverse populations before widespread clinical implementation.

A notable finding was the strengthening of correlations between BTMs as time since last dose progressed. While initial correlations

The lack of clear BTM distinctions between MRONJ and non-MRONJ

were moderate (ρ = 0.45–0.65), they strengthened substantially by

groups reinforces current understanding that MRONJ risk assessment

the pre-operative period (ρ = 0.69–0.85) and became very strong

should incorporate multiple clinical factors rather than relying solely

post-operatively (ρ = 0.82–0.89). This progressive enhancement of

on BTM values. The marginally significant NTX findings warrant

correlations suggests increasing synchronisation of bone turnover

further investigation in larger cohorts to determine their potential role

processes as the antiresorptive effects wane. We note that this could

in risk stratification.

also be due to scale sensitivity as the small numbers in the earlier timepoints are more susceptible to variability.

Several methodological constraints warrant consideration when interpreting the results of this study. Primary among these was the

The developed linear regression model demonstrated that P1NP and

variability in data collection timing across the three assessment

NTX together could explain 78.68% of CTX variability (R² = 0.7868),

points (Initial, Pre-Op and Post-Op). Although the protocol targeted

with reasonable cross-validation stability (R² = 0.7339 ± 0.0971).

specific intervals (initial assessment, six months after last dose for

This robust predictive relationship suggests potential clinical utility in

Pre-Op, and three months post-surgery for Post-Op), actual collection

situations where measuring all three markers is not feasible or cost-

times showed considerable variation. This variability was attributed

effective.

to multiple factors including referral timing, patient availability, and COVID-19 pandemic-related disruptions to healthcare services.

In this selective, high risk, referral cohort, 7.1% (4/56 patients) had existing MRONJ on referral. However, comparison of BTM profiles

Data completeness presented another significant limitation,

between MRONJ and non-MRONJ groups revealed no statistically

particularly regarding NTX measurements at the post-operative

significant differences in baseline levels or overall trends for CTX

timepoint. The progressive decrease in available data points across

(P = 0.702) and P1NP (P = 0.951). Although not conclusive due to

timepoints may have impacted the robustness of our longitudinal

sample size of the MRONJ group, this finding suggests limited utility

analyses, especially for the MRONJ subgroup comparisons.

of these markers in isolation for predicting MRONJ risk for this sample size.

The study’s statistical power to assess differences between patients with and without MRONJ was constrained by the marked disparity

Interestingly, NTX demonstrated a marginally significant interaction

between MRONJ (n = 4) and non-MRONJ (n = 52) group sizes.

with MRONJ status (P = 0.077), suggesting a potentially distinct

However, this comparison was not the premise of this study. Although

temporal pattern between groups. Although this observation requires

the overall sample size (n = 56) met the pre-study power calculation

validation in larger studies, it hints at the possibility that the rate

requirements for correlation analysis (based on the expected

of change in NTX levels, rather than absolute values, might offer

correlation coefficient of 0.71), the small sample size and missing data

additional insights into MRONJ risk assessment.

limited our ability to draw definitive conclusions about BTM patterns in MRONJ development.

The small effect sizes observed in the Mann-Whitney U test results further underscore the challenge of distinguishing between MRONJ

The observational study design imposed inherent limitations on

and non-MRONJ patients based solely on these BTMs. However, it

causal inference. Several potentially confounding variables could not

is crucial to interpret these results cautiously due to the significant

be fully controlled, including duration of prior denosumab treatment,

limitations of our study.

historical bisphosphonate exposure, variation in surgical procedures, individual factors influencing bone metabolism, and variability in time

We were not able to establish a safe threshold for the BTMs due

intervals between BTM measurements. Although the study achieved

to the wide variability in individual patient profiles, suggesting that

its primary aim of analysing BTM correlations, the high-risk cohort,

there may not be a specific threshold relevant to all patients due to

single-centre design and predominantly female cohort (85.7%) may

interpatient variability and comorbid characteristics.

limit the generalisability of findings to broader populations and

The strong correlations observed between BTMs, particularly in later phases since last dose, suggest that clinicians might reasonably rely on any of these three markers to monitor bone turnover recovery.

different clinical settings. However, the strength of this study is the consistency in patient cohort, single clinical team and use of a single laboratory for all biochemical assessments.

However, the significant interpatient variability in marker levels and

Most notably, the relatively small sample size of 56 patients was a

recovery rates, evidenced by increasing standard deviations across

significant limitation. Although this cohort size limits the ability to

timepoints, underscores the importance of individualised assessment

perform more granular subgroup analyses, the prospective nature of

rather than rigid threshold-based decision-making.

the study and the high correlation coefficients obtained provide strong

The predictive model developed for CTX estimation using P1NP and NTX values offers a potential tool for cross-specialty communication,

preliminary evidence for the interchangeability of BTMs in this clinical context.

AJOMS Volume 3 | Issue 2 · Nov 2026

| 89


Conclusion

Author contributions

This prospective cohort study demonstrates that CTX is the best predictor of bone turnover recovery of the three markers in this study. However, all three BTMs recover as time increases since the last denosumab dose with strong correlations between CTX, P1NP and NTX, suggesting all three have value in assessing bone turnover recovery in clinical practice. The predictive model developed accounts for 78.68% of CTX variability using P1NP and NTX measurements, suggesting potential clinical utility in cross-specialty communication and monitoring. The marginally significant temporal interaction between NTX and MRONJ status (P = 0.077) warrants further investigation, particularly regarding the potential utility of BTM rate-of-change in risk assessment. Future research directions should include larger multicentre studies with standardised assessment intervals and balanced outcome groups to validate these findings and explore BTM dynamics. This study highlights the need for larger, multi-centre studies with standardised assessment intervals and balanced MRONJ outcome groups to validate our findings and further explore the utility of BTMs in MRONJ risk assessment.

Inderjeeth C: Conceptualisation, methodology, formal analysis, investigation, data curation, visualisation, writing (original draft), writing (revision/editing), consultation. Inderjeeth D: Formal analysis, data curation, writing (original draft), writing (revision/editing). Devlin J: Conceptualisation, methodology, investigation, data curation. Chang F: Writing (revision/editing), consultation. Gebauer D: Conceptualisation, methodology, formal analysis, investigation, data curation, visualisation, writing (original draft), writing (revision/editing), consultation.

Conflicts of interest The authors have no conflicts of interest to declare relevant to this research and no artificial intelligence was used in the writing of this paper.

Funding This study was funded by the Sir Charles Gairdner Osborne Park Research Foundation (2021/22 Charlies Foundation for Research Midrange Grant Funding Program). The authors thank the clinical staff involved in patient coordination and sample collection.

Data sharing

Although BTM monitoring provides valuable information about bone metabolism recovery since last denosumab dose, clinical decision-

The data underlying this article cannot be shared because of limitations imposed by the ethics approval for the study.

making should incorporate comprehensive risk assessment rather than relying solely on marker levels. These findings contribute to the growing body of evidence supporting individualised approaches to managing patients requiring dentoalveolar surgery during antiresorptive therapy.

References 1

Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol 2015; 11: 461-470.

2

Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons’ Position Paper on medication-related osteonecrosis of the jaws 2022 Update. J Oral Maxillofac Surg 2022; 80: 920-943.

3

Yarom N, Shapiro CL, Peterson DE, et al. Medicationrelated osteonecrosis of the jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37: 22702290.

4

Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010; 68: 243-253.

5

Goss AN. Osteonecrosis of the jaw and denosumab. Aust Prescr 2022; 45: 208-209.

6

Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws. A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab 2012; 30: 171-182.

7

Eiken PA, Prieto-Alhambra D, Eastell R, Abrahamsen B. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users. Osteoporos Int 2017; 28: 2921-2928.

90 | AJOMS Volume 3 | Issue 2 · Nov 2026

8

Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017; 5: 513-523.

15 Vasikaran S, Cooper C, Eastell R, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011; 49: 1271-1274.

9

Watts NB, Grbic JT, Binkley N, et al. Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years. J Clin Endocrinol Metab 2019; 104: 2443-2452.

16 Dal Prá KJ, Lemos CAA, Okamoto R, et al. Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. Int J Oral Maxillofac Surg 2017; 46: 151-156.

10 Dodson TB. The frequency of medication-related osteonecrosis of the jaw and its associated risk factors. Oral Maxillofac Surg Clin North Am 2015; 27: 509-516. 11 Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65: 415-423.

17 Awad ME, Sun C, Jernigan J, Elsalanty M. Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: systematic review and meta-analysis. J Am Dent Assoc 2019; 150: 664-675.e8.

12 Wright C. Therapeutic Guidelines: Oral and Dental [Book review]. Version 2. Australian Prescriber 2012; 35: 182-182.

18 Marx RE, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007; 65: 2397-2410.

13 Szulc P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem 2012; 45: 907-919.

19 Narayanan P. Denosumab: a comprehensive review. South Asian J Cancer 2013; 2: 272-277.

14 Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 2012; 32: 105-112.

20 Chubb SAP, Mandelt C, Vasikaran S. Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis. Clin Biochem 2016; 49: 529-533.


S H O R T C O M M U N I C AT I O N

Muscle memory and functional adaptation in lingual frenotomy: implications for timing of intervention Gupta A (BDS, MFDS, RCPSG, PgCertDental Ed, MOralSurg, F(OS) RCPS Glasg)1; Sarkaria A (BSc(Hons), BDS (Hons), MFDS, RCS Eng)1; Kandasamy S2; Nagpal T (BDS, PGDip, PGCertDentalEd, MFDS, RCS Ed, MOralSurg, F(OS) RCS Ed, FHEA)3; Thapar A (FRCS, FEBVS, PhD, PGCE, FHEA)1; Ganesan K (BDS, MDS(OMFS), MFDS, RCS Eng, FFD RCSI (Oral Surg Oral Med))1

Lingual frenotomy is a well-established treatment for infant feeding concerns associated with ankyloglossia. Current National Institute for Health and Care Excellence (NICE) guidance focuses primarily on breastfeeding outcomes and provides limited direction for cases where significant ankyloglossia does not impair feeding in early infancy.1 Increasingly, clinicians encounter older children and adults presenting with mechanical and social difficulties attributable to longstanding ankyloglossia. Research shows that this cohort undergoes frenotomy to improve speech.2 Sixty percent of adult participants in a study reported that they regretted that a frenotomy was not carried out at a younger age to resolve the reported issues.3

ABSTRACT Lingual frenotomy is well recognised for its role in correcting breastfeeding difficulties in severe ankyloglossia. However, little research is available for the long-term implications of ankyloglossia, and the reduced post-operative benefits occasionally seen when frenotomy is performed in adolescence or adulthood. This communication highlights the concept of muscle memory as a potential explanation for the differences seen after frenotomy between infants and adolescents. Prolonged restriction may reinforce neuromuscular patterns

A clinical consensus statement released by a panel of experts agrees that there is a lack of studies and no randomised controlled trials in older children to determine if frenotomies lead to definitive improvement in mechanical and social issues reported.4

that limit adaptation after release, even when the anatomical restriction is corrected. Understanding this mechanism may improve patient decision-making regarding the timing of intervention and support the use of adjunctive therapy in older patients.

Our recurring observation is that a frenotomy performed in adolescence or adulthood yields a less substantial functional

any functional concerns. In comparison, adolescents had limitations

improvement than when performed in infants.

to tongue muscle motility following surgery (Table 1) and reported

A small cohort study was conducted that compared tongue motility when a frenotomy was completed for severe ankyloglossia in infants

difficulties in maintaining oral hygiene and controlling pain postoperatively (Table 2).

(n = 17) aged between 0 to 1 years of age and in adolescents (n = 12) aged between 10 to 17 years of age.5 The data show that infants had greater vertical and horizontal tongue motility in childhood without

Frenotomy in infants

Frenotomy in adolescents

Vertical tongue motility (recorded as a percentage from a tongue resting position)

76

59

Horizontal tongue motility (recorded as a percentage from a tongue resting position)

6

4

Table 1. Results of authors’ study. Outcomes related to vertical and horizontal tongue motility following lingual frenotomy are presented. Values recorded are median values using nonparametric (Mann-Whitney U) test

Frenotomy in infants (n = 17)

Frenotomy in adolescents (n = 12)

Improved feeding

5

x

Treated reflux issues

2

x

Improved weight gain

1

x

Painful to do tongue motility exercises post-release

x

6

Difficulty maintaining oral hygiene

x

3

Limited improvement in tongue motility post-release

x

2

Table 2. Self-reported outcomes following frenotomy

Department of Oral Surgery, Southend Hospital, Essex, United Kingdom; 2 UCL Medical School, London, United Kingdom; 3 Department of Oral and Maxillofacial Surgery, Luton and Dunstable Hospital, Luton, United Kingdom.

1

Corresponding author: Ashana Gupta

✉ info.drgupta@gmail.com | doi: 10.63717/2026.MS0066

Keywords: ankyloglossia | lingual frenotomy | muscle memory | oral function | myofunctional therapy

AJOMS Volume 3 | Issue 2 · Nov 2026

| 91


The age-related difference in outcomes of lingual frenotomy could

Author contributions

be attributed to tongue muscle memory whereby adolescents have

Gupta A: Conception and design of study/review/case series and methodology design, methodology and investigation, analysis and interpretation of data collected and data curation, drafting of article and/or critical revision and editing, final approval and guarantor of manuscript.

reduced neuroplasticity compared with infants.6 Furthermore, lingual muscle activity is highly coordinated in infants to support sucking patterns necessary for feeding, reflecting rapid and specialised neuromuscular development in early life.7 There is anatomical evidence that muscles have memory and the memory for skeletal muscles has an average of eighty years. In severe ankyloglossia where previously there was no anterior muscle use, the superior longitudinal tongue muscle fibres undergo atrophy, and will require more time and exercise to rehabilitate.8 Therefore, there is a suggestion that lingual frenotomy in older children has poorer outcomes, but research is limited in this cohort.9 These insights highlight the growing importance of adjunctive myofunctional therapy in adolescents undergoing lingual frenotomy. Although infants rarely require structured therapy post-frenotomy, adolescents and adults may benefit from targeted exercises to re-establish elevated tongue posture and strengthen previously underused anterior muscle fibres.10 Systematic reviews increasingly support the role of adjunctive myofunctional exercise in enhancing outcomes.2

Sarkaria A: Conception and design of study/review/case series and methodology design, methodology and investigation, drafting of article and/or critical revision and editing. Kandasamy S: Conception and design of study/review/case series and methodology design, methodology and investigation, drafting of article and/or critical revision and editing. Nagpal T: Conception and design of study/review/case series and methodology design, analysis and interpretation of data collected and data curation, drafting of article and/or critical revision and editing. Thapar A: Methodology and investigation, analysis and interpretation of data collected and data curation, drafting of article and/or critical revision and editing. Ganesan K: Conception and design of study/review/case series and methodology design, methodology and investigation, analysis and interpretation of data collected and data curation, drafting of article and/or critical revision and editing, final approval and guarantor of manuscript.

Conflicts of interest

If muscle memory does play a significant role in limiting postoperative benefit, intervention in early years could, in selected cases, offer improved long-term functional outcomes. The 2005 NICE guidelines in the United Kingdom require review and consideration of ankyloglossia in the absence of infant feeding concerns.

The authors have no conflicts of interest to declare. Artificial intelligence (AI) software was used to assist with grammatical checks and improvement of manuscript structure. The AI tool (ChatGPT) was not used to generate original scientific data, perform data analysis, interpret results, formulate conclusions, or determine the scientific content of the manuscript. All content generated with AI assistance was critically reviewed, edited, verified for accuracy, and curated by the authors. The authors take full responsibility for the final content of the manuscript.

Funding The authors have no funding sources to declare.

Data sharing The data underlying this article are available for sharing upon reasonable request to the corresponding author.

References 1

National Institute for Health and Care Excellence. Division of ankyloglossia (tongue-tie) for breastfeeding. HealthTech guidance HTG95. London: NICE; 2005.

4

Messner AH, Walsh J, Rosenfeld RM, et al. Clinical consensus statement: ankyloglossia in children. Otolaryngol Head Neck Surg 2020; 162: 597-611.

2

Lichnowska A, Kozakiewicz M. The effectiveness of frenotomy on speech in adults. Applied Sciences 2021; 11(6): 2727.

5

Beltre, Mendez. Child Development. StarPearls. Treasure Island (FL): 2023.

6

Cullins MJ, Wenninger JM, Cullen JS, et al. Tongue force training induces plasticity of the lingual motor cortex in young adult and aged rats. Front Neurosci 2019; 13: 1355.

3

Lalakea ML, Messner AH. Ankyloglossia: the adolescent and adult perspective. Otolaryngol Head Neck Surg 2003; 128: 746-752.

7

92 | AJOMS Volume 3 | Issue 2 · Nov 2026

Capilouto GJ, Cunningham T, Frederick E, et al. Comparison of tongue muscle characteristics of preterm

and full-term infants during nutritive and nonnutritive sucking. Infant Behav Dev 2014; 37(3), 435-445. 8

Eli C. Muscle memory: there is such a thing. J Aging Sci 2016; 4(2).

9

Hall D, Renfrew MJ. Tongue tie: common problem or old wives’ tale? Arch Dis Child 2005; 90(12): 1211-1215.

10 González Garrido MDP, Garcia-Munoz C, RodríguezHuguet M, et al. Effectiveness of myofunctional therapy in ankyloglossia: a systematic review. Int J Environ Res Public Health 2022; 19: 12347.


T E C H N I C A L I N N O VAT I O N

Three-dimensional-printed biomodels for post-traumatic orbital reconstruction: a low-cost, open access workflow Ruscoe Z (BBiomed, MD)1; Sklavos A (BDS, MD, MPhil)1,2; Mian M (BDS, BScDent, MD, MPH)3; Carter M (MBBS, BDS, FRACDS (OMS))1, 3

Introduction

ABSTRACT

The use of three-dimensional (3D) printed anatomical biomodels is becoming common practice in contemporary oral and maxillofacial surgery. In post-traumatic orbital reconstruction, it has been suggested that biomodels should be adopted as the standard of care where intraoperative imaging is not available.1 Current 3D technologies allow surgeons to print custom-made orbital reconstruction plates, or alternatively use anatomical biomodels to adapt a stock plate to span the traumatic defect.2 The benefits of using this technology include reduced operative time and a reduction in soft tissue trauma from multiple passes and adaptations of the orbital plate.2

In post-traumatic orbital reconstruction, anatomical biomodels have been recommended as the standard of care. Threedimensional (3D) printed anatomical models of the fractured orbit, or a mirrored image of the contralateral orbit can be used to facilitate preoperative shaping of orbital reconstruction plates. This technology allows for a faster operation, less soft tissue trauma and aids the surgeon in visualising the defect. A major downside of this technology is the additional cost. At a single centre with no in-house 3D printing available, we trialled a workflow for a low-cost anatomical biomodel for preoperative shaping of an orbital plate. Four patients with orbital floor and

A barrier to the use of this technology is the cost. In Australia, there are several companies that manufacture 3D anatomical biomodels for orbital reconstruction. The cost per model ranges from $2500 to $5000. A custom orbital reconstruction plate attracts additional cost. Although most of the cost is absorbed by private health insurers or the public hospital departments, there has been recent scrutiny over the use of 3D-printed models and the ongoing funding of their use, which has been subjected to a prostheses list review.3 High-volume operating units may overcome the costs associated with outsourcing 3D printing where in-house services are available.4,5 Whereas smaller units are left to outsource, and incur the cost set by the various biomedical companies.4,5 This may preclude the use of anatomical biomodels in settings where they would prove beneficial,

medial wall fractures, and one with a concurrent zygoma fracture had reconstruction surgery with a pre-bent orbital plate that had been bent using a 3D-printed biomodel. The entire workflow was completed on open access software. The orbital plates were bent on the anatomical model preoperatively and re-sterilised. The overall cost to set up the workflow was $330, which included the cost of the 3D printer. The preformed plates each cost $500. Time to manufacture and sterilise each plate was 48–72 hours. This equates to a cost saving per patient of about $12,500 for an equivalent anatomical model if outsourced to an external company. In this technical innovation article, we describe the workflow that can be used in hospitals with no in-house 3D printing available for printing anatomical biomodels for teaching and operative planning.

particularly in post-traumatic orbital reconstruction where the efficiency of the surgery and reliability of the anatomical adaptation

wide variation in the cost, time required and quality of 3D-printed

of the plate can be improved with 3D-printed models.1

biomodels currently in use.3 These factors are important to consider before investing in a 3D printer. In this technical innovation article,

At present, there is scope for printing anatomical biomodels on low-

we describe a workflow for manufacturing 3D-printed anatomical

cost 3D printers in accordance with patient-matched medical devices

biomodels, using open access software and a low-cost 3D printer for

(PMMDs) continuing to be exempt from the Australian Register

use in post-traumatic orbital reconstruction.

of Therapeutic Goods (ARTG) inclusion until 1 July 2029, at which time this process will require formal approval from ARTG.6 There is

Oral and Maxillofacial Surgery Unit, Western Health, Melbourne, VIC, Australia; 2 University of Melbourne. Faculty Medicine, Dentistry and Health Science, VIC, Australia; 3 Oral and Maxillofacial Surgery Unit, Barwon Health, Geelong, VIC, Australia.

1

Corresponding author: Mustafa Mian

✉ mustafa.kahil.mian@gmail.com | doi: 10.63717/2026.MS0068

Keywords: 3D printing | anatomical biomodels | maxillofacial trauma | orbital reconstruction

AJOMS Volume 3 | Issue 2 · Nov 2026

| 93


DICOM = digital imaging and communications in medicine.

Figure 1. Workflow overview with time and cost estimation

Workflow overview

2.

The process of creating 3D-printed biomodels for post-traumatic

3.

Acquire data in high resolution (maximum of 1.0 mm slices, with 0.6 mm preferred). To protect the privacy of patients, the DICOM data must be anonymised before importing into the segmentation software.

orbital reconstruction is illustrated in Figure 1, with approximate time lengths and costs per step. The process begins with DICOM (digital imaging and communications in medicine) data, a standard file format

Segmentation (for mirrored contralateral orbits)

for medical imaging, obtained from computed tomography (CT)

1.

scans of the patient’s orbit. Segmentation follows, where specialised software is used to isolate the region of interest (eg, the orbital bone/ fracture) from surrounding tissues and create a 3D model.7 This

(Figure 2). 2.

design) modelling transforms the model, using mirroring techniques

toolbar) and choosing files to add. 3.

Select deidentified patient data by double clicking in the patient DICOM database.

to transform the unaffected side, to add structural supports, and to imprint patient data onto the model. The resulting 3D model is then

Import DICOM data by dragging the file onto the 3D Slicer window or by clicking onto the import data icon (top left icon on

is done through automated techniques such as thresholding, and then manually editing for fine-tuning. Next, CAD (computer-aided

Open 3D Slicer software (Version 3.6.2, open-source, free)

4.

Select the type of imaging (bone window versus soft tissue

sliced into thin layers using slicing software, which generates a .gcode

window, etc.) to be displayed and drag into the display windows

file that the 3D printer can interpret. This file includes structural

(four quadrants on right-hand side: top left = axial; bottom left =

integrity supports that will be removed after printing. Finally, the

coronal; bottom right = sagittal; top right = 3D model [to be used

biomodel is printed using appropriate materials. After printing, any

later]). Avoid using the 3D model until segmentation is complete

support structures are carefully removed to reveal the final, patient-

as it will significantly slow down processing.

specific orbital model ready for surgical planning. This workflow, from

5.

Enter the segment editor from the main drop-down menu. Select

DICOM data to the final 3D-printed model, enables the creation of

source volume to the corresponding image to be segmented.

accurate, patient-specific biomodels for improved surgical outcomes

Add a new segment (name and alter colour accordingly to user

in orbital reconstruction.

preference). Adjust images to points of interest by using the

The steps of our workflow are as follows:

sliding bar at the top of each image window. 6.

Use the threshold tool to set an appropriate level of thresholding. Click and hold onto an area of interest (in this case the

1.

Obtain DICOM data.

2.

Segmentation of the DICOM data to generate 3D .stl file.

3.

Augmentation of the model to add structural support and

side of screen via arrows or typing a threshold range. Click

patient information.

‘Apply’.

4.

Modelling and preparation for printing.

5.

Print anatomical model using 3D printer.

6.

Cutting of preformed orbital plate and shaping on anatomical

orbital bone) and drag in and out to alter the threshold range accordingly. Threshold range can also be adjusted on the left

7.

optic canal) by adding additional separate segments for each. Name and colour accordingly. In the images for this workflow, the contralateral (unaffected) orbit was selected. Use the paint

biomodel. 7.

Sterilisation of plate.

8.

Utilisation of pre-bent plate in surgery.

The first seven steps of the above workflow are described in more detail below.

Obtaining DICOM data 1.

Imaging test results (CT scan) acquired from medical imaging archives or directly from imaging machine (higher quality).

94 | AJOMS Volume 3 | Issue 2 · Nov 2026

Mark two landmarks (infraorbital foreman and optic nerve/

tool and select a paint brush diameter accordingly. If errors are made, use the ‘erase’ tool, which works the same as the paintbrush. This step is useful when performed before cropping to desired interest to ensure all points of interest are included. 8.

Crop to the desired area of interest using the ‘scissors’ tool. Ensure the correct segment is selected, that is, select the ‘orbit’ segment. Select ‘erase inside’ option. Cutting can be performed by manually drawing or using pre-selected shapes such as ‘rectangle’. When cutting, ensure points of interest (infraorbital


Figure 2. 3D Slicer software showing the segmentation process for orbital reconstruction using a mirrored version of the contralateral (unaffected) orbit

Figure 3. Segmentation on 3D Slicer showing the orbital floor defect outlined on the model

AJOMS Volume 3 | Issue 2 · Nov 2026

| 95


9.

foreman and optic nerve/optic canal) remain in the object and

of optic canal would remain with the orbit model. .obj files are

are not erased.

compatible in Microsoft Word documents. .stl files will be used

Manually check segmentation by scrolling through imaging

for importation into the Blender software for 3D modelling.

slices to check for missing components. Where segmentation complete this before using the view 3D function as this will

Additional step for segmentation with virtually reconstructed orbit (Figure 3)

significantly slow down processing. Once manual checking of

1.

is missing, manually add using the paint tool. It is useful to

segmentation is complete, the view 3D function can be used. 10.

View the 3D model in the top right window by selecting ‘Show

instead of the contralateral unaffected orbit. 2.

3D’. Select the drop-down arrow on the ‘Show 3D model’ tab and select ‘Surface smoothing’. Alter the ‘smoothing factor’ accordingly. Generally, a factor of 0.5 to 1.0 works well for this

3.

Use the paintbrush tool on each slide of the DICOM data to create a virtual reconstruction of the orbit above the defect. This can be done by following the natural contour of the orbit and by

Save the 3D Slicer data. Click the gift icon to save as a ‘Medical Reality Bundle’ (.mrb) file, which will save your data into one file. Remove the infraorbital foreman segment before exporting so

visualising the unaffected side while doing so, as a guide. 4.

click the ‘remove’ button (red subtraction symbol). Export the 3D model by selecting the drop-down menu next to the green arrow (‘Export to files’). Save as an .stl file format. ‘Merge into single file’ will combine all segments together. For example, if you have added two separate segments of an

Modelling 1.

Open Blender software (Version 4.2.3, open-source, free) (Figure 4).

2.

Remove the cube and two light sources by clicking on them, pressing ‘x’ on the keyboard and selecting ‘delete’.

affected orbit (fracture) and another segment for the unaffected side, this function would merge these two segments into a

Ensure when exporting files (as in Segmentation - step 12) that the box for merging all segments together is selected.

the model has a clean unfilled foramen. Select the segment then 12.

Create a segment and name accordingly (eg, reconstructed fracture).

context. 11.

Follow steps 1 to 11 as above, segmenting the fractured orbit

3.

Import the .stl orbit file (either unaffected orbit to mirror, or

single file. If you do not select this, it will export the separate

fracture orbit). This can be done by dragging the file onto the

segments as two separate files. The decision is user dependent

Blender screen or using the file tab → import → .stl. If the scale

and depends on post-processing goals. For this workflow,

is not altered, you may not be able to visualise the object at first.

‘merge into single file’ was selected, so that the small portion

Zoom out/rotate the screen and locate the object. If the origin is

Figure 4. Blender software used for modelling, creation of patient identifier and added walls for reinforcement

96 | AJOMS Volume 3 | Issue 2 · Nov 2026


Figure 5. Slicing process on Creality Print

4.

not set to the centre, then right click the object → set origin →

Copy the cube and change the copied cube’s position to offset

geometry to origin.

by 2.5 mm to create the three walled structure. Use the Boolean

To mirror the orbit (in the case of using the contralateral/

difference modifier to subtract the copied cube from the original cube, to get a remaining three-walled structure. Alternatively, a

unaffected orbit for the model), right click the object and select

single rectangle floor can be added to support the model.

mirror → x-global. 5.

Subtract unwanted parts of the model using Boolean modifiers

9.

the three walls. Clicking on the axis diagram allows you to view

(for better visualisation, shaping titanium mesh and to reduce

the objects directly from the selected axis. The ‘toggle X-ray’ tool

waste). Remove the roof of the orbit first by doing the following:

allows for better visualisation of how objects intersect.

from the toolbar, select ‘add’ → ‘mesh’ → ‘cube’. Select the cube and press ‘n’ on the keyboard for object details (scale

10.

is above the optic canal. 6.

11.

dimensions of text. Switch to edit mode to edit the text. Switch back to object mode. In the right-hand vertical menu, click the ‘a’

tool (blue wrench icon) in the right-side vertical axis → click add

icon. Under ‘geometry’ change extrude to 2 mm.

click the dropper icon in the ‘object’ menu → select the cube to subtract. Then click the arrow in the top right of the Boolean

12.

Right click the text object, ‘convert to’ → mesh.

13.

Position the text appropriately on the model and ensure that it overlaps with the structural support. Use the Boolean modifier

modifier menu bar and select ‘apply’. That portion of the orbit

‘union’ to join the text to the model. Make sure to click ‘apply’.

will now be removed but the cube will remain, so it must be deleted. Select the cube, press ‘x’, press ‘delete’. Continue the above process of subtracting (via Boolean modifiers) to remove unwanted parts of the model. 8.

Add model/patient numbers by pressing ‘add’ → text. Increase

To subtract part of the orbit: select the orbit, click the modifier modifier → generate → Boolean. Select ‘difference’ and then

7.

Use Boolean difference modifiers to trim any overhanging parts of the object. Resize the supporting cube as necessary.

accordingly to subtract orbit roof). Place the cube in the appropriate spot to subtract the top part of the orbit, ensuring it

Position the orbit so that its edges are touching all aspects of

Add structural support to the model using Boolean modifiers. For example, a floor with two walls can be added for support. ‘Add’ → ‘mesh’ → ‘cube’, and scale the cube just larger than the orbit model dimensions. Change position of cube to 0 on all axes.

Delete the text mesh after it has been joined to the model. 14.

Alternatively, the Boolean difference tool can also be used to create indented text on the model.

15.

Use the Boolean union modifier to join the orbit to the support plate too. The blender file will appear as it does in step 14 when the original item that has been Boolean modified has not been removed after the union. Make sure to delete the outstanding objects after union.

AJOMS Volume 3 | Issue 2 · Nov 2026

| 97


16.

Once finalised, save the file.

17.

Export the file as a .stl file for importation into slicing software to prepare for printing.

Slicing 1.

Open slicing software Creality Print (Version 5.1.4.10249) (Figure 5). • Creality Print was used for compatibility with the 3D printer used for these printed models. • Other free, open-source software, such as Ultimaker Cure can be used.

2.

Select corresponding printer and plate type.

3.

Import the .stl file of the orbit and support structure created using Blender.

4.

Enable auto-supports and then select ‘slice plate’. Slicing will give you a breakdown of the print time, including total time and time for printing supports, etc. It will also give a material weight/ length/cost breakdown. Note that in the screenshot (Figure 5), the model is not sitting completely flat on the plate (due to not ensuring Boolean difference modifiers were used to cut the offsets from the model off the supporting cube properly).

5.

Once happy with the slicing, save the data. Click ‘export plate’ and save the file as a .gcode file.

6.

Transfer this .gcode file onto a USB, which will then be inserted into the 3D printer.

Printing 1.

Insert USB into printer (Creality Ender [Version 3]).

2.

Use loaded polylactic acid (PLA) filament. If not loaded, load PLA by pre-heating the nozzle to maximum temperature and inserting desired PLA filament into nozzle head.

3.

Commence printing, nozzle temperature will automatically set.

4.

Once printing is complete, remove from the print plate. Break off support structures with fingers or tools.

Figure 6. Isolated floor defect repaired with a prebent stock plate on 3D anatomical model. The 3D model has the fracture outlined on the orbital floor

Sterilisation 1.

Once bent, titanium mesh plates were sterilised.

2.

During the sterilisation process, it is best to have the plate stored in a protective casing to ensure the plate is not bent out of shape during sterilisation and handling.

Adjust titanium plate on model (Figure 6)

Limitations

1.

There are several limitations to the use of low-cost 3D printing in

A Synthes preformed orbital reconstruction plate was used. The cost of the plate varies depending on the arrangement between the hospital and supplier. At our institution, one plate costs $500. The plate is then modelled and bent to cover the orbital defect.

this workflow. Models printed using a home or office-based fused deposition modelling (FDM) printer are not sterilisable. Vat-based printers, which use photopolymer resin, are more appropriate if a sterile model is required (provided sterilisation and hospital protocols

2.

The plate is cut to shape, and any sharp edges are smoothed off.

can be adhered to). It is also prudent for models to undergo some

3.

The position of the plate is checked, and digital pressure is

form of quality assurance (eg, the model dimensions can be measured

applied anterior to where screws will be placed to ensure the

and compared with the patient’s CT scan to confirm there has not

plate does not hinge and lift off the posterior ledge.

been any major size distortions). Some hospitals may not allow for

4.

Efforts should be made to avoid repeated bending of the titanium plate as this may result in fatigue failure and predispose the plate to biomechanical complications.

5.

The planned plate position may be marked on the model to allow intraoperative verification against the presurgical plan. Reference measurements from the fixation holes to the infraorbital foramen may also aid in accurate and reproducible plate seating.

98 | AJOMS Volume 3 | Issue 2 · Nov 2026

the sterilisation of single-use stock plates as the first sterilisation process uses ethyl chloride and hospitals may have a policy against steam sterilisation for subsequent processing. High-volume surgeons whose current practice is to use stock plates may find little benefit from printing 3D models; however, this workflow provides a lowcost model that can be used for patient education and for surgical trainees. Another limitation to this method is the learning curve and time required to complete the workflow.


Future applications

of about $400. The cost for the setup of this workflow, including the

This low-cost, 3D printing workflow has other applications in oral and maxillofacial surgery and could be used for adapting reconstruction plates for mandible fractures or oncological defects, or as lowcost models used purely as an exercise in learning. In addition, this technique can be applied to other surgical procedures where the use of an anatomical model is useful as a learning adjunct or to adapt sterilisable plates. We plan to further validate this workflow in a prospective study looking at the operative time, surgeon preference, restoration of orbital volume and cost–benefit analysis.

3D printer, is less than the cost of a single third-party manufactured anatomical biomodel.

Author contributions Ruscoe Z: Conceptualisation, methodology, formal analysis, data curation, writing - original draft. Sklavos A: Conceptualisation, methodology, formal analysis, data curation, writing - original draft. Mian M: Data curation, writing - reviewing and editing. Carter M: Data curation, writing - reviewing and editing.

Conclusion

Conflicts of interest The authors declare no conflicts of interest.

The use of 3D anatomical models can aid the surgeon in posttraumatic orbital reconstruction. Here we have described the workflow for a low-cost, open access technique for surgeons to print

Funding

their own anatomical models. The total cost estimate for each case

The authors have no funding sources to declare.

with the low-cost open access workflow is $600, with a setup cost

References 1

2

3

listed on the Prostheses List. 3 March 2023. https://www. health.gov.au/sites/default/files/2024-07/prostheses-listpost-listing-review-consultants-report.pdf (accessed Jan 2025).

Nguyen E, Lockyer J, Erasmus J, Lim C. Improved outcomes of orbital reconstruction with intraoperative imaging and rapid prototyping. J Oral Maxillofac Surg 2019; 77(6): 1211-1217. Murray-Douglass A, Snoswell C, Winter C, Harris R. Three-dimensional (3D) printing for post-traumatic orbital reconstruction, a systematic review and meta-analysis. Br J Oral Maxillofac Surg 2022; 60(9): 1176-1183.

4

Australian Government. Department of Health and Aged Care. Prostheses List Post-Listing review – Consultants report. Review of surgical guides and biomodels currently

5

Mukherjee P, Clark J, Wallace G, et al. Discussion paper on proposed new regulatory changes on 3D technology: a surgical perspective. ANZ J Surg 2019; 89(1-2): 117121. Venchiarutti RL, Clark Am JR, Dusseldorp JR, et al. New regulatory changes in 3D printing: implementation in

surgery and research at the point of care. ANZ J Surg 2021; 91(11): 2249-2251. 6

Australian Government. Federal Register of Legislation. Therapeutic Goods (Medical Devices) Regulations 2002. Version F2025C00021 (C66). 14 December 2024.

7

Shah D, Naik L, Paunipagar B, et al. Setting up 3D printing services for orthopaedic applications: a stepby-step guide and an overview of 3DBioSphere. Indian J Orthop 2020; 54(Suppl 2): 217-227.

ANZAOMS27

ANNUAL SCIENTIFIC MEE TING 1 3 -1 5 M a y 2 0 2 7 / C r o w n P e r t h , W E S T E R N A U S T R A L I A

KEYNOTE SPEAKER Dr Stanley Y. C. Liu MD, DDS, FACS

KEY DATES Call for Abstracts Now Open! Registration Opens 16 November 2026 Call for Abstracts Closes 7 December 2026

RD EARLY BAITION REenGsI16SNTovRember 2026! Op

Join us in Perth for an inspiring and memorable Annual Scientific Meeting. The ANZAOMS 2027 program will feature an engaging mix of leading speakers, scientific sessions, and the latest insights in oral and maxillofacial surgery, providing valuable opportunities to learn, connect and share ideas. Set against the stunning backdrop of the Swan River and Indian Ocean, Perth offers world-class dining, vibrant culture and easy access to some of Western Australia’s most iconic destinations.

Final Program Released 22 February 2027 Early Bird Registration Closes 15 March 2027 ANZAOMS 2027 ASM 13-15 May 2027

www.anzaomsasm.com.au

AJOMS Volume 3 | Issue 2 · Nov 2026

| 99


SCIENTIFIC ARTICLE

The experiences of Australasian second-degree students pursuing oral and maxillofacial surgery specialisation Monk JHG (BDS, MBChB, FRACDS (GDP))1; Wockner RS (BDS, MBChB, MMedSc, MRACDS (PDS))2; Abu-Serriah M (BDS (Hons), MBChB, IQE (GDC), FDSRCPS (Glasg), MRCS (Glasg), FRCSGlasg (OMFS), MSc(MedSci) (Hons), MSc (Hons), PhD)1

Introduction

ABSTRACT

Oral and maxillofacial surgery (OMS) is a highly specialised field focused on the diagnosis, surgical management and adjunctive treatment of diseases, injuries and defects affecting the jaws and related structures.1 In certain jurisdictions, OMS training requires a dual qualification in medicine and dentistry, extending the overall pathway length and introducing significant academic, financial and social pressures.2 Although this dual-degree model is recognised internationally, the structure and sequencing of training can differ

Purpose: Dual qualification in medicine and dentistry is a prerequisite for oral and maxillofacial surgery (OMS) training in Australasia. This extended and costly pathway presents unique challenges, particularly for students pursuing a second degree. This study aimed to explore the motivations, barriers and experiences of second-degree students aspiring to enter OMS training in Australia and New Zealand.

considerably across countries, shaped by regulatory frameworks and

Methods: A cross-sectional, mixed-methods online survey

educational systems.3

was distributed between July and November 2024 to students

In Australia and New Zealand, candidates must complete both degrees before commencing OMS training, followed by a minimum of four years of supervised surgical education.1 The Royal Australasian College of Dental Surgeons (RACDS) sets training standards. It

undertaking a second degree in medicine or dentistry who intended to pursue OMS training. Quantitative data were analysed descriptively, and open-ended responses were thematically coded.

provides educational oversight, but does not routinely facilitate paid,

Results: Twenty-two participants responded, most of whom

pathway-aligned roles or structured mentorship for second-degree

were medical students. Motivations included interest in surgery

students. In contrast, other surgical colleges in Australasia (eg, the

and the OMS scope. Key challenges were financial strain,

Royal Australasian College of Surgeons) offer formal mentoring

difficulty gaining admission and limited formal mentorship. All

schemes.4

female respondents reported entry barriers. Many participants

Despite its intensity, OMS remains an attractive career option. Motivations often include early clinical exposure, the broad surgical

reported limited awareness of OMS among their peers and noted a lack of structured support, particularly in Australia.

scope of the specialty, and its reputation for long-term stability.5,6

Conclusions: Second-degree students face financial, structural

However, prospective trainees face substantial financial strain related

and equity-related barriers within the OMS training pathway.

to prolonged study, high tuition costs and gaps in paid employment,

Findings highlight opportunities for reform, including earlier

which may steer some towards more accessible specialties.7,8

OMS exposure in medical curricula, structured mentorship and

As mentioned, OMS training pathways vary globally, and some countries have introduced reforms such as integrated dual-degree routes or shortened programs to improve efficiency while preserving core competencies. However, these alternatives are not widely adopted in Australia or New Zealand.2,9,10

targeted financial support to improve equity, recruitment and retention across Australasia. These matters need to be formally addressed by the Royal Australasian College of Dental Surgeons Board of Studies in OMS and by the Australian and New Zealand Association of Oral and Maxillofacial Surgeons (ANZAOMS).

Critically, Bridgman and colleagues believed that Australia and New

and retention challenges in rural and regional areas.11 Ricciardo

Zealand, but particularly New Zealand, have been confronting an

and colleagues reported some improvement in workforce elasticity;

OMS workforce shortage and training bottleneck this decade, driven

however, the main concern is filling full-time positions rather than

by the increasing complexity of training, limited registrar positions

part-time positions. These constraints can pose risks to both the

1

University of Auckland, Faculty of Health Sciences, Auckland, New Zealand; 2 University of Otago, Faculty of Medicine, Dunedin, New Zealand.

Corresponding author: Jared Monk

✉ jmon130@aucklanduni.ac.nz | doi: 10.63717/2026.MS0085

100 | AJOMS Volume 3 | Issue 2 · Nov 2026

Keywords: surgery | career choice | health workforce | oral and maxillofacial surgery | medical education


sustainability and geographic equity of oral and maxillofacial surgical services and training positions in the region.12

Question

Answer type

Demographic characteristics

Although previous research has captured the experiences of

1. What is your current age?

Open-ended

second-degree OMS students in the United Kingdom (UK), limited

2. Please describe your gender.

Multiple choice

region-specific data exist for Australasia.5-10 In this context, where

(Male, Female, Non-Binary/ Other)

entry barriers, financial burdens and training limitations converge, understanding the lived experiences of second-degree students is essential. This study, therefore, aimed to explore the motivations,

3. Which country are you studying in?

challenges and perceptions of students undertaking a second

Educational and training background

degree (medicine or dentistry) in pursuit of an OMS specialisation in Australia and New Zealand. By capturing the perspectives of this underexamined cohort, we aim to inform reforms that improve recruitment, retention and workforce sustainability across the specialty.

Methods Ethics Anonymous data were collected from volunteer participants via public digital platforms. No identifiable personal or clinical data were obtained, and participant risk was minimal; accordingly, the study was deemed exempt from formal ethical review under institutional

Multiple choice (Australia, NZ)

4. Are you pursuing a second degree in medicine or dentistry?

Multiple choice

5. Do you currently hold any postgraduate qualifications?

Multiple choice

6. Did you have to sit an aptitude test to progress in this pathway?

Multiple choice

7. Was the aptitude test essential to pursuing your second degree?

Multiple choice

8. Which university are you currently studying at/or just graduated from?

Open-ended

(Medicine, Dentistry) (RACDS, MRCS, PG, Dip) (No, UCAT, GAMSAT, BMAT) (N/A, Yes, No)

Awareness and perceptions of the OMS training pathway 9. Why did you pursue a second degree to become an OMS?

Open-ended

10. How aware were you of the OMS training pathway before your second degree?

Likert scale (scored 1-5)

11. Are you aware of differences in OMS training between countries?

Likert scale (scored 1-5)

12. How do you perceive the length of OMS training in your country?

Multiple choice

13. Do you believe integrating medical and dental training is necessary? Why?

Mixed

14. How satisfied are you with your pathway to becoming an OMS?

Likert scale (scored 1-5)

Multiple choice

Survey development and data collection

15. How many years after your first degree did you begin your second degree?

A draft survey was developed in Google Forms and piloted with

Personal and professional challenges

six second-degree students to evaluate clarity, structure and item

16. Have you encountered any challenges unique to pursuing a second degree?

Open-ended

17. How do you manage the demands of your studies and personal life?

Open-ended

guidelines. Participants received a description of the study’s aims and implications, with implied consent established through voluntary completion.

Study design and participant recruitment This cross-sectional, mixed-methods survey was conducted from July to November 2024. The target population comprised students enrolled in a second degree in medicine or dentistry who intended to pursue an OMS specialisation in Australia and New Zealand. In the absence of a centralised registry, the population size could not be precisely determined but was estimated at 50 to 60 individuals based on known institutional entry positions and stakeholder consultation (personal communication, AN Goss, Emeritus Professor, Adelaide University, 8 June 2026). Convenience sampling was employed, with recruitment conducted across OMS trainee groups, professional networks, formal and informal mailing lists, and OMS-affiliated email lists to maximise reach and reduce selection bias.

relevance, with feedback informing subsequent revisions. The finalised instrument was deployed via SurveyMonkey on 21 July 2024 and remained open until 15 November 2024. Thirty items addressed six domains: demographic characteristics; educational and training background; OMS pathway awareness and perceptions; personal and professional challenges; financial considerations; and satisfaction and future outlook (Table 1). Quantitative responses were captured via multiple-choice and Likert scale items (scored 1–5), with awareness items dichotomised for analysis. Open-ended questions elicited qualitative data on motivations, experiences and barriers.

(Not at all aware → Extremely aware) (Not at all aware → Extremely aware) (Too long, Just right, Too short) (Yes/No + Open-ended explanation) (Very satisfied → Very dissatisfied) (1-9+ years)

Financial considerations 18. How do you manage the financial aspects of your second degree?

Multiple choice (Part-time employment, Loans, Self-funded) (Continues on page 102) Table 1. Survey questionnaire

AJOMS Volume 3 | Issue 2 · Nov 2026

| 101


(Continues from page 101)

Question

Answer type

19. Are you concerned about student debt, mortgages, or financial stability?

Yes/No + Open-ended (If yes, explain)

Satisfaction and future outlook

Group total (%)*

Gap between first and second degree (years)

Length of second degree (years)

1–2

3+

<3

4+

Country New Zealand

10 (45.5)

2 (20.0)

5 (50.0)

5 (71.4)

2 (28.6)

Australia

12 (54.5)

4 (33.3)

7 (58.3)

2 (20.0)

8 (80.0)

20. How optimistic are you about entering an OMS training programme?

Likert scale (scored 1-5)

Age (years)

(Very optimistic → Very unoptimistic)

< 30

12 (63.2)

4 (33.3)

6 (50.0)

4 (40.0)

6 (60.0)

30 +

7 (36.8)

2 (28.6)

4 (57.1)

2 (33.3)

4 (66.7)

21. Do you have any concerns about your future training?

Open-ended

Gender Male

15 (68.2)

5 (33.3)

7 (46.7)

4 (36.4)

7 (63.6)

22. What is the length of your second degree?

Multiple choice (1–6+ years)

Female

7 (31.8)

1 (14.3)

5 (71.4)

3 (50.0)

3 (50.0)

23. How well has your seconddegree prepared you for medical practice?

Multiple choice

Incomplete dataset, row percentages are calculated based on available data. *Column percentage, for group totals for demographic characteristics.

24. How aware are medical students of OMS?

Likert scale (scored 1-5)

25. How important is it for medical students to understand OMS?

Likert scale (scored 1-5)

+ N/A for dentistry pathway

(Not at all aware → Extremely aware) (Not at all important → Extremely important)

26. Have you registered your interest in OMS with a regional association?

Yes/No

27. Do you receive support from your OMS association?

Likert scale

+ Open-ended (Formal/ Informal) (None at all → A great deal)

28. How have you engaged with the specialty during your second degree?

Multiple choices

29. Do you engage with social media or online OMS resources?

Yes/No

30. What changes could your OMS association make to support you?

Open-ended

(select all that apply: Observer, Research, Journal club, On-call work) If yes, specify (Instagram, YouTube, etc.)

Abbreviations: NZ = New Zealand; RACDS = Royal Australasian College of Dental Surgeons; MRCS = Member of the Royal College of Surgeons; PG = Post Graduate Degree; Dip = Post Graduate Diploma; UCAT = University Clinical Aptitude Test; GAMSAT = Graduate Medical Schools Admission Test; BMAT = Biomedical Admissions Test; N/A = Not Assessed/Required; OMS = Oral Maxillofacial Surgery.

Table 1. Survey questionnaire

Table 2. Group totals and postgraduate timing (brackets contain valid row percentages unless otherwise specified)

Motivation for second degree

Pathway awareness

Requirement† Interest‡ Influence Not aware §

Aware

Country New Zealand

0 (0.0)

6 (75.0)

2 (25.0)

0 (0.0)

9 (100.0)

Australia

4 (44.4)

3 (33.3)

2 (22.2)

1 (9.1)

10 (90.9)

< 30

0 (0.0)

6 (66.7)

3 (33.3)

1 (9.1)

10 (90.9)

30 +

2 (40.0)

2 (40.0)

1 (20.0)

0 (0.0)

6 (100.0)

Male

3 (23.1)

8 (61.5)

2 (15.4)

0 (0.0)

14 (100.0)

Female

1 (25.0)

1 (25.0)

2 (50.0)

1 (16.7)

5 (83.3)

Age (years)

Gender

Incomplete dataset, row percentages are calculated based on available data. † Second-degree is a requirement for the oral and maxillofacial surgery training pathway for the Royal Australasian College of Dental Surgeons. ‡ Interest, in medicine, surgical specialty and/or career. § Influence, by prior experience, mentorship or community needs.

Table 3. Pathway motivation and understanding (brackets contain row percentages unless otherwise specified)

54.5%), with no statistically significant difference in age distribution between genders (χ²; P = 0.161). Survey completion to question twenty-nine was 72.7% (n = 16), reflecting a dropout rate of 27.3%.

Data analysis Quantitative data were analysed in SPSS (version 30, IBM Corp), with descriptive statistics used to characterise demographic and training variables, and chi-square tests applied for categorical comparisons (P < 0.05). Qualitative data were analysed thematically using an inductive, iterative approach; themes were identified through repeated reading and open coding, with independent dual-researcher review to ensure rigour and minimise bias.

Most respondents were enrolled in a second-degree medical program (n = 20, 90.9%) across six universities in Australia and New Zealand, with the majority holding additional qualifications (Diplomas/Masters/ Membership/Fellowship; n = 17, 77.3%). Formal aptitude testing (Graduate Medical Schools Admission Test [GAMSAT] or University Clinical Aptitude Test [UCAT]) before the second degree had not been undertaken by 40.9% of respondents (n = 9). Second-degree duration was ≥ 4 years in most cases (n = 10/17, 58.8%), with commencement ≥ 3 years following the first degree in 54.5% (n = 12). Table 2

Results

demonstrates that second-degree duration was consistently shorter

Twenty-two respondents were included (male, n = 15, 68.2%; female,

Motivations for pursuing OMS and pathway understanding are

n = 7, 31.8%). The majority were aged under 30 years (n = 12,

102 | AJOMS Volume 3 | Issue 2 · Nov 2026

among New Zealand respondents.

presented in Table 3. Surgical interest and the OMS lifestyle were


Pathway challenges

Challenge management

Admission† Personal‡ Academic§ Support¶ Personal^ Struggling# Country

with 59.1% (n = 13) undertaking part-time dental or OMS work to fund their ongoing studies. Career outlook data are presented in Table 5.

New Zealand

3 (60.0)

1 (20.0)

1 (20.0)

0 (0.0)

5 (83.3)

1 (16.7)

Australia

4 (50.0)

4 (50.0)

0 (0.0)

3 (30.0)

6 (60.0)

1 (10.0)

< 30

5 (71.4)

2 (28.6)

0 (0.0)

1 (10.0)

9 (90.0)*

0 (0.0)

availability and competitiveness were prominent.

30 +

2 (50.0)

1 (25.0)

1 (25.0)

2 (50.0)

1 (25.0)

1 (25.0)

Specialty engagement and pathway improvement

Age (years)

Optimism was consistently high among Australian and New Zealand participants despite recognised barriers, although concerns about post-training

recommendations are detailed in Table 6. Although

Gender Male

4 (40.0)

5 (50.0)

1 (10.0)

1 (9.1)

9 (81.8)

1 (9.1)

most respondents maintained formal or informal links

Female

3 (100.0)

0 (0.0)

0 (0.0)

2 (40.0)

2 (40.0)

1 (25.0)

with OMS organisations, Australian respondents reported more frequently that specialty support was

Incomplete dataset, row percentages are calculated based on available data. * P < 0.05 chi-squared test. † Gaining admission into the second degree. ‡ Personal challenges (financial, logistical, circumstantial). § Academic redundancy and relevance. ¶ Support systems and relationships. ^ Personal strategies (physical wellbeing, wellness activities, adaptation). # Struggling to balance or manage.

insufficient.

Discussion This study examined the experiences, motivations and challenges of second-degree students pursuing

Table 4. Pathway challenges and management (brackets contain row percentages unless otherwise specified).

OMS in Australia and New Zealand, highlighting the length and complexity of current training pathways. The exploratory design and small sample size (n = 22)

Career optimism

Future concerns

Optimistic

Neutral

Unoptimistic

Availability†

Personal‡

New Zealand

3 (42.9)

2 (28.6)

2 (28.6)

5 (100.0)

0 (0.0)

Australia

5 (50.0)

5 (50.0)

0 (0.0)

8 (88.9)

1 (11.1)

< 30

6 (69.2)

3 (23.1)

1 (7.7)

9 (100.0)

0 (0.0)

30 +

2 (33.3)

3 (37.5)

1 (16.7)

3 (75.0)

1 (25.0)

Country

Age (years)

preclude thematic saturation; findings are therefore indicative of common issues rather than definitive prevalence. Convenience sampling of online volunteers introduces inherent limitations in representativeness, and self-selection bias, reflected in the incomplete response rate, should be considered when interpreting results. To our knowledge, this is the first study in Australasia to document, at this level of detail, second-degree

Gender Male

5 (45.5)

5 (45.5)

1 (9.0)

9 (100.0)

0 (0.0)

Female

3 (50.0)

2 (33.3)

1 (16.7)

4 (80.0)

1 (20.0)

Incomplete dataset, row percentages are calculated based on available data. † Availability and competition for training positions. ‡ Personal concerns (family, age, relocation, other commitments).

OMS students’ perspectives on admissions testing, reliance on informal mentorship and perceptions of the training pathway. The integration of quantitative data with qualitative accounts extends the predominantly UK-based literature to an Australasian context and elucidates the emotional, social and financial

Table 5. Career optimism and concerns (brackets contain row percentages unless otherwise specified)

dimensions of structural barriers, factors rarely examined yet essential to workforce sustainability and the identification of meaningful reform targets.

prominent motivating factors, particularly among New Zealand

Surgical interest, particularly in trauma and head-and-neck

respondents, whereas Australian respondents more frequently cited

subspecialties, was the predominant reported motivation, most

formal training requirements. A majority regarded dual qualification

notably among New Zealand respondents, consistent with prior work

as beneficial to training preparation (essential, n = 2, 11.8%; helpful,

identifying procedural interest and formal qualification requirements

n = 10, 58.8%; unnecessary, n = 5, 29.4%), and 55.6% (n = 10/18)

as dual drivers.2,3,13 Over half of the respondents regarded the

considered the overall pathway length appropriate. Despite high

pathway length as appropriate, a finding that contrasts with Herbert

self-reported awareness of training requirements, awareness of

and colleagues, in which 30% of prospective trainees disengaged due

OMS among medical student peers was markedly low (not aware,

to training duration, and aligns with evidence that OMS duration is

n = 16/17, 94.1%).

not substantially greater than comparable surgical specialties.8,14,15

Barriers and coping strategies are outlined in Table 4. Second-

That 94% of respondents perceived OMS as unrecognised among

degree admission represented the principal barrier, as reported by

medical peers reflects UK findings of limited specialty representation

all female respondents at this part of the survey (n = 3/7). Coping

in medical curricula. Insufficient exposure at the undergraduate

strategies were predominantly personal, encompassing exercise, time

level risks compounding recruitment shortfalls in regions already

management and peer support. The financial burden was significant,

experiencing workforce deficits.16,17

AJOMS Volume 3 | Issue 2 · Nov 2026

| 103


Support access

Pathway recommendations

the need for formalised mentorship and proactive engagement with OMS associations to improve equity

A lot

Some

Very little Optimisation† Financial‡ Mentorship§

New Zealand 2 (33.3)

1 (16.7)

3 (50.0)

2 (40.0)

1 (20.0)

2 (40.0)

Australia

1 (10.0)

2 (20.0)

7 (70.0)

1 (25.0)

0 (0.0)

3 (75.0)

< 30

3 (30.0)

2 (20.0)

5 (50.0)

1 (20.0)

1 (20.0)

3 (60.0)

30 +

0 (0.0)

0 (0.0)

5 (100.0)

2 (50.0)

0 (0.0)

2 (50.0)

Male

3 (30.0)

2 (20.0)

5 (50.0)

2 (33.3)

1 (16.7)

3 (50.0)

lateral-entry framework permitting accelerated

Female

0 (0.0)

1 (16.7)

7 (83.3)

1 (33.3)

0 (0.0)

2 (66.7)

progression for experienced clinicians could improve

Country

Age (years)

Gender

and retention.18-20 Reform at the systems level merits consideration. Existing admissions structures require full seconddegree completion with limited recognition of prior learning, unnecessarily prolonging training and compounding financial burden, particularly where lateral entry is unavailable. A nationally coordinated

workforce efficiency while satisfying RACDS

Incomplete dataset, row percentages are calculated based on available data. † Streamlining the training pathway. ‡ Financial support and paid opportunities (ie, on-call roster). § Mentorship (including networking, research, and application support ).

requirements.1 Standardised admissions criteria modelled on the UK’s Multi-Specialty Recruitment Assessment (MSRA) would further promote equity and

Table 6. Support access and pathway recommendations (brackets contain row percentages unless otherwise specified)

cross-institutional consistency, reducing unnecessary barriers and aligning supply with regional workforce demand.21

Sustained pathway length and cost are likely contributors to ongoing candidate attrition, a pattern documented in earlier surveys.8-10 Although views on dual qualification were divided, most respondents regarded it as helpful rather than essential. Evidence supporting medical integration for clinical scope and privilege must be weighed against the respondent’s endorsement of accelerated or integrated alternatives.9,10 Pathway rigidity and inter-route variability between dental and medical entry streams may compound transition difficulties and constrain recruitment.16 Second-degree admission was the most commonly identified barrier and was reported by all female respondents, reflecting established gender disparities in surgical training access.18,19 Entry testing requirements also varied, as 40.9% of respondents had bypassed formal aptitude tests via graduate-entry routes. Formalising and expanding such pathways may offer a practical solution to

A structured mentorship program is recommended to address the identified support deficits, particularly among Australian respondents, women and mature-age trainees who are currently dependent on informal networks. Such a program could comprise dedicated OMS mentor pairings, regional ANZAOMS mentorship leads and scheduled engagement, reflecting the structure of the UK’s Mentoring and Support Programme.22 Concurrent engagement with RACDS and ANZAOMS to develop targeted financial support mechanisms, including specialty-specific scholarships, paid clinical assistantships and subsidies for association participation, would address the economic burden intrinsic to dual-degree training and advance a more inclusive workforce pipeline.

Conclusion This study offers a trainee-centred analysis of the structural and

reducing financial and time burdens.

personal challenges confronting second-degree OMS candidates in

Respondents reported considerable financial pressure, relying

barriers and gendered inequities collectively influence the experiences

on part-time employment, self-funding or loans across extended

and progression of this underexamined group. Notwithstanding

periods of reduced income. These cumulative stressors are plausibly

these challenges, respondents expressed sustained commitment to

associated with burnout, delayed progression and attrition.2,8

the specialty, underscoring both individual resilience and systemic

Qualitative accounts further delineated the personal and social costs

support deficits.

of training, encompassing relationship strain, diminished self-care, and social isolation, particularly among those aged over 30 years, reinforcing the need for structured pastoral support beyond technical

Australasia. Financial burden, inadequate mentorship, admission

In addition to reaffirming established structural constraints, the findings delineate the personal and social costs of dual-degree

and academic outcomes.

training and identify concrete reform priorities: formalised lateral-

Professional association engagement was limited, with respondents

mentorship programs aligned with those of comparable surgical

from both countries frequently reporting minimal support. Concerns

training bodies; earlier integration of OMS into medical and dental

regarding training post availability were prevalent. In 2017, 11

curricula; and targeted financial support, including specialty-specific

OMS training positions were available across Australasia, with

scholarships and paid clinical assistantships.

none in New Zealand; in 2025, this figure remained at ten, with two positions allocated to New Zealand. This limited and inequitable distribution of training opportunities reinforces structural barriers that disproportionately impact under-represented groups. The reliance on informal networks to navigate these challenges underscores

104 | AJOMS Volume 3 | Issue 2 · Nov 2026

entry and recognition of prior learning pathways; structured

Thematic consistency across institutions and regions strengthens confidence in these findings despite the limited sample size. The results provide timely, evidence-informed guidance for Australasian training and professional bodies, particularly RACDS and ANZAOMS,


in sustaining a specialty workforce that is accessible, equitable and fit

Funding

for purpose.

The authors declare no funding sources.

Data sharing

Author contributions Monk JH: Conceptualisation, methodology, formal analysis, writing – original draft. Wockner R: Formal analysis, writing – original draft. Abu-Serriah M: Conceptualisation, writing, reviewing and editing.

The data underlying this article are available for sharing upon reasonable request to the corresponding author.

Acknowledgements The authors thank the respondents who participated in this study.

Conflicts of interest The authors declared no potential conflicts of interest concerning this article’s research, authorship and publication.

References 1

Royal Australasian College of Dental Surgeons. Handbook for Accredited Education and Training in Oral and Maxillofacial Surgery. Sydney: RACDS; 2026.

2

Mannion C, Kanatas A. Role of the dental degree in the UK Oral and Maxillofacial training pathway: is there a future without it? Br J Oral Maxillofac Surg 2020; 58(10): 1222-1224.

3

Kumar S. Training pathways in Oral and Maxillofacial Surgery across the globe—A mini review. J Maxillofac Oral Surg 2017; 16: 269-276.

4

Royal Australasian College of Surgeons. Mentoring Resources. [Internet]. https://www.surgeons.org/Fellows/ for-educators-trainers/becoming-a-mentor/mentoringresources (accessed Sept 2025).

5

Minks W. Perceived impediments to the junior years of oral and maxillofacial training. Br J Oral Maxillofac Surg 2015; 53(10): e80.

6

Perwaiz I, Rehman U, Sarwar MS, Brennan PA. What are the concerns of second-degree medical students entering specialty OMFS training? Br J Oral Maxillofac Surg 2023; 61(2): 147-151.

7

8

Laraway D, Howson K. How has the new junior doctor contract changed opinions on oral and maxillofacial training among current and prospective trainees? Br J Oral Maxillofac Surg 2017; 55(10): e152. Herbert C, Kent S, Magennis P, Cleland J. What causes trainees to leave oral and maxillofacial surgery? A questionnaire survey. Br J Oral Maxillofac Surg 2017; 55(1): 37-40.

9

Bhargava D, Beena S, Pathak AD, Gurjar P. Assessment of perception on dual degree requirement among the residents of oral and maxillofacial surgery in India: A cross-sectional survey. J Maxillofac Oral Surg 2020; 1-6.

10 Jain D, Chakravarthy C, Patil RS, et al. Choice of Oral and Maxillofacial Surgery as a specialization and career path: An undergraduate perspective. J Maxillofac Oral Surg 2022; 24: 577-584. 11 Bridgman JB, Fulton G, Lou SM, et al. The New Zealand oral and maxillofacial surgeon workforce in 2017-18: characteristics, practice and prospects. N Z Med J 2020; 133(1513): 11-22. 12 Ricciardo P, Bobinskas A, Vujcich N, et al. Survey of Australasian oral and maxillofacial surgeons 2011--scope and workforce issues. Int J Oral Maxillofac Surg 2015; 44(12): 1569-1573. 13 Herford AS, Pulsipher DA, Sinn DP. Integration of the medical degree in oral and maxillofacial surgery: A 10-year follow-up. J Oral Maxillofac Surg 2001; 59(12): 1471-1476. 14 Cameron M, Westcott L. Maxillofacial training is no longer than other surgical specialties. Ann R Coll Surg Engl 2008; 90(2): 146-149. 15 Douglas J, Begley A, Magennis P. UK Oral and Maxillofacial Surgery trainees join the specialist list at a similar age to other surgical specialists. Br J Oral Maxillofac Surg 2020; 58(10): 1268-1272.

Surgery? A scoping review. Br J Oral Maxillofac Surg 2020; 58(10): 1229-1234. 17 Harris K, Jefferies C. A multi-site cross-sectional survey exploring medical undergraduate knowledge of Oral and Maxillofacial Surgery. J Maxillofac Oral Surg 2019; 18(4): 623-627. 18 Royal Australasian College of Surgeons. RACS gender equity goals: 40: 40: 20. Surgical News [Internet]. 2023; 24(3). https://www.surgeons.org/surgicalnews/ Articles/2023/Volume-24/Issue-3/RACS-gender-equitygoals (accessed Sept 2025). 19 Woo VM, Jensen ED, Candy KA. Women in oral and maxillofacial surgery: the Australasian experience. ANZ J Surg 2025; 95(4): 690-695. 20 Royal Australasian College of Dental Surgeons. Become an OMS Specialist: Past Offers. [Internet]. https://racds. org/become-an-oms-specialist/ (accessed Sept 2025). 21 British Medical Journal Careers. A Guide to the MultiSpecialty Recruitment Assessment (MSRA). BMJ Careers. [Internet]. https://www.bmj.com/careers/article/a-guideto-the-multi-specialty-recruitment-assessment-msra(accessed Sept 2025). 22 Magennis P, Begley A, McLean A, et al. The UK Mentoring and Support Programme (MSP) for those considering a career in Oral and Maxillofacial Surgery (OMFS). Br J Oral Maxillofac Surg 2021; 59(8): 935-940.

16 Soh T, Lim Z, Yip H. Does the UK undergraduate medical curriculum prepare students in Oral and Maxillofacial

ANZAOMS27 Join us in Perth for an inspiring and memorable Annual Scientific Meeting. The ANZAOMS 2027 program will feature an engaging mix of leading speakers, scientific sessions, and the latest insights in oral and maxillofacial surgery, providing valuable opportunities to learn, connect and share ideas. Set against the stunning backdrop of the Swan River and Indian Ocean, Perth offers world-class dining, vibrant culture and easy access to some of Western Australia’s most iconic destinations.

KEYNOTE SPEAKER Dr Stanley Y. C. Liu MD, DDS, FACS

ANNUAL SCIENTIFIC MEETING

KEY DATES

13-15 May 202 7 Cr own Per th, WES TERN AUS TR ALIA

RD EARLY BAITION REGs I16SNTovRember 2026! O p en

CALL FOR A B S Closing 7 TR ACT S D e c emb

er 2 0 2 6 !

www.anzaomsasm.com.au

AJOMS Volume 3 | Issue 2 · Nov 2026

| 105


SCIENTIFIC ARTICLE

Survey of oral and maxillofacial surgery trainees in Australia and New Zealand and comparison to United Kingdom trainees Karczub ASL (BHSc, BDSc, MD, MPH)1; Ricciardo PV (BDSc, MBBS, FRACDS(OMS))1; Swarbrick WJ (BSci, MID, MPH)1

Introduction

ABSTRACT

In Australia and New Zealand, training for Oral and Maxillofacial Surgery (OMS) has changed significantly over the last 40 years to become a well-established hospital-based training program of a high

Purpose: A survey of Australian and New Zealand Oral and Maxillofacial Surgery (OMS) trainees was undertaken in 2020.

standard, with each step carefully monitored and peer reviewed.1

Methods: The outcomes of this survey are discussed herein

Since 1994, training in OMS in Australia and New Zealand requires

and compared with findings of surveys undertaken of trainees

both a medical and dental degree with further specialised surgical

in the United Kingdom (UK). The 2020 survey looked at the

training for a minimum of four years. An exit fellowship examination

demographic profile, academic background, training experience

at the end of training is required.

and career intentions of OMS trainees in Australia and New

A survey of current OMS trainees in Australia and New Zealand was undertaken in 2020 to assess the background and motivating

Zealand. An invitation to complete a detailed questionnaire of 47 questions was sent to all oral and maxillofacial surgery trainees.

factors for pursuing a career in OMS. This survey looked at academic

Results: Findings from the 2020 survey were comparable to

qualifications, research, workload and exposure to scope of practice.

findings from surveyed trainees in the UK. In the Australasian

It also explored training and practice ambitions following attainment

survey, the age of trainees and duration of training were

of fellowship [FRACDS(OMS)].

comparable to other surgical specialties. OMS trainees reported

OMS training in the United Kingdom (UK) also requires dual degree qualification. OMS is well established as one of the ten UK surgical specialties. The UK training involves core surgical training and the Membership of the Royal College of Surgeons examination. Training is then five years with an exit fellowship examination.2 Despite perceptions that OMS training, with dual degrees prior, is longer than other surgical specialties, the average age of OMS trainees is comparable to other surgical specialties in Australia.3 This is comparable to the UK with data showing that oral and maxillofacial surgeons are a similar age to other trainee surgeons and that the 4

length of training is similar to other specialties. The aim of this article is to describe the demographics, training experience and career goals of OMS trainees in Australia and New Zealand and compare findings with published survey data of OMS trainees in the UK.

Methods

academic engagement. However, prolonged second-degree training and work–life balance challenges remain significant concerns and may impact recruitment and retention. Conclusion: Addressing training length, flexibility and gender equity will be important to ensure a sustainable and diverse future OMS workforce for Australasia.

defined as clinicians who had completed a medical and dental degree and who were actively enrolled in OMS training in 2020 at an OMS unit in Australia and New Zealand. The survey was a detailed questionnaire of 47 questions. There were 32 responses from trainees to the survey, with information de-identified for confidentiality.

Results Thirty-two out of 54 trainees (59%) responded to the survey,

An invitation to participate in the survey was forwarded to 54 current OMS trainees in Australia and New Zealand. Current trainees were

1

high levels of overall satisfaction with the specialty and strong

which was slightly lower than a prior Australian survey undertaken in 2000, with 66.7% of trainees responding.5 The regional and

Royal Perth Hospital, Perth, WA, Australia.

Corresponding author: Andrew Karczub

✉ akarczub@gmail.com | doi: 10.63717/2026.MS0080

106 | AJOMS Volume 3 | Issue 2 · Nov 2026

Keywords: oral and maxillofacial surgery | survey | training | gender | United Kingdom


has not published any papers. Five (16%) trainees have published one peer-reviewed paper and 22 (69%) have published 2–5 peerreviewed papers. Three trainees reported publishing 6–10 papers and one trainee has published 11–20 papers. Twenty (63%) of the trainees were successful in their first application to training. On second application, seven (22%) were successful and five (16%) were successful on their third attempt. Regarding location, 30 (94%) trainees were willing to accept a training position irrespective of location. When asked about trainee recruitment, 17 (53%) trainees felt there were issues with recruitment. Following further prompting, common themes were identified such as accepting trainees with more OMS experience, suggestions of minimum OMS unaccredited registrar work requirements and increased lateral entry programs or integration with second degrees. Figure 1. Distribution of respondents by first degree, showing the percentage who completed medicine compared with dentistry

Half of the trainees reported that they worked 50–60 hours per typical week, and six trainees report working 40–50 hours per week. Eight trainees reported working 60–70 hours and two trainees reported working 70 or more hours per week. Of all 32 surveyed trainees, 13

gender composition of the 54 invited trainees was not recorded, so representativeness of respondents related to the invited group cannot

(41%) reported feeling overworked.

be assessed; this is an acknowledged limitation of the study.

Most trainees (29; 91%) were satisfied with their decision to train in

Respondents were drawn from all Australian and New Zealand

decision. When asked about the duration of OMS surgical training,

training regions: seven (22%) from New South Wales, seven (22%)

24 (75%) reported that the training length was appropriate. Seven

from Queensland, one (3%) from South Australia, eight (25%) from

trainees reported that the training duration was too short whereas

Victoria, six (19%) from Western Australia and three (9%) from New

one respondent reported it as being too long. This contrasts with

Zealand. Following training, 22 (69%) trainees intended to work in

answers about the duration of study for the dentistry and medicine

Australia, three (9%) in New Zealand and seven (22%) were unsure

first degrees, with 23 (72%) trainees reporting duration as too long

where they intended to work.

and 9 (28%) describing it as appropriate. Finally, 23 (72%) trainees

OMS with the remaining trainees (9%) being unsatisfied with their

reported that they felt the number of trainees on the surgical program The mean age of trainees was 35 years, ranging from 31 to 40

to be appropriate, five (16%) trainees reported feeling that there was

years. Regarding trainee family circumstances, 29 (91%) trainees

an inadequate number of trainees and four (13%) trainees reported

had a partner and 13 (41%) had dependents. Respondents were

feeling that there were an excessive number of trainees.

predominantly male, with 30 (94%) males and two (6%) females. Ninety-four percent of trainees believed that OMS is a specialty of Figure 1 shows that 66% of trainees graduated in dentistry as

dentistry and medicine. Figure 3 shows the subspecialty area that

their first degree and 34% of trainees graduated from medicine as

the surveyed trainees would like greater exposure to during training.

their first degree. Thirty-four percent of trainees had completed an

Aesthetics, orthognathic and oncology were the most popular.

‘accelerated’ second degree in three years. There was 94% of trainees

Twenty-seven (84%) trainees indicated that they intended to pursue

that considered the OMS specialty as a specialty of both dentistry

post-training fellowships.

and medicine. Seven (22%) trainees completed a higher degree by research: six held a Master of Research or Master of Philosophy and one had completed a Doctor of Philosophy. An additional 16% (five respondents) were currently in the process of completing a research degree. Figure 2 shows the number of research papers published by the surveyed trainees. One trainee

Figure 2. Number of research papers published by surveyed trainees

AJOMS Volume 3 | Issue 2 · Nov 2026

| 107


a medicine degree is increasing over time in the UK.9 As of 2020, about 79% of UK OMS specialists and trainees obtained a dental degree first versus 21% who obtained a medicine degree first.2,8 Cumulative OMS training pathways vary internationally; in the UK, training (including both primary degrees) takes about 18 years.10 The length of training as well as the cost of a second degree were among the factors contributing to poor retention in the UK of those already in training and those intending to undertake a second degree and further specialisation in OMS.9 Abbreviation: TMJ = temporomandibular joint.

An important structural difference related to how

Figure 3. Subspecialty exposure desired by trainees during training. Respondents were only able to select one subspecialty

healthcare is delivered between these countries underlies these comparisons: specialist OMS practice in the UK sits predominantly within the public National Health Service,

Discussion This article shows that Australian and New Zealand OMS trainees are broadly satisfied with their training pathway, and that their demographic and academic profile closely mirrors that of UK trainees. Training length and female representation remain the specialty’s key challenges. The 2020 Australasian survey findings generally align with surveys undertaken of UK OMS trainees. In Australia and New Zealand, trainees are of a similar age to those in the UK, with the mean age of trainees being 35 years. Older trainees are more likely to have more commitments and dependents, a factor which increases complexity of training and trainee demands. This is consistent with survey respondents as over 91% of respondents had a partner and over 40% had dependents. In the UK, it was found that impact on personal life was a challenge for OMS trainees and negatively contributed to the retention of trainees in the specialty.6 It is encouraging to see that the vast majority (91%) of our surveyed trainees were satisfied with their choice to undertake OMS training. This was a common thread between Australasian and UK trainees. When compared with other surgical specialties, UK OMS trainees were the most satisfied with a rate of 83.7% compared with the lowest satisfaction (General Surgery).7 In the UK, 74.7% obtained a position in a specialist training program on the first application, 19.8% on the second and 4.4% after their third attempt.8 In comparison with the Australasian 2020 survey results (first attempt: 63%; second: 22%; third: 16%), first application success rates were higher in the UK than in Australasia. Regarding subspecialty exposure and further interest, UK trainees were most interested in facial trauma, oncology and orthognathic surgery.8 These were similar themes to answers from Australian and New Zealand OMS trainees. Most trainees (75%) felt that the training length (4 years) was an appropriate timeframe, yet some thought that the dual-degree training requirement of medicine and dentistry, while necessary, made the training period too long. In the UK, trainees echoed similar views.9 The number of OMS specialists and trainees that start with

108 | AJOMS Volume 3 | Issue 2 · Nov 2026

whereas in Australia and NZ, OMS is practised predominantly in the private sector with some public work.1,2 This distinction shapes trainee experience of workload, remuneration and career planning, and should be considered when comparing satisfaction, recruitment and retention data between the countries.1 The dual medical and dental degree required for OMS training in Australia and New Zealand confers full and unrestricted registration across both professions. The length of the dual-degree pathway, while a genuine burden on trainees, is a direct consequence of the breadth of registration it confers. Lateral entry programs for the second primary degree contribute to reducing training time. Although lateral entry has been in place in South Australia for decades, a greater effort to introduce lateral entry for other sites for the second degree may help address this challenge of training time. Published Australian workforce data show that among Australian surgical specialties, female OMS specialists comprise about 11.8% of the surgical workforce, ahead of cardiothoracic (6.6%) and orthopaedic surgery (5.2%).11 At trainee level, there continues to be an increase in the number of female trainees. This suggests the pipeline of women entering OMS training has improved substantially, even though this has not yet translated into equivalent representation at specialist level. A further survey will help to assess the number of females currently in training. Training commitment, challenges to work–life balance and family planning are likely to continue to contribute to attrition of trainees between commencement of training and attainment of specialist status.11 In the UK, female representation has increased to upwards of 24% of trainees due to greater OMS promotion to female dentists and doctors and enhanced support of women undertaking this specialty pathway.2 These strategies have encouraged candidates towards OMS who may otherwise consider adjacent specialties such as otolaryngology.12 Further recommendations to continue increasing representation include encouragement of female OMS surgeons to mentor female trainees and encouragement to serve in leadership positions.13,14 Addressing gender and family-related biases through culture and policy change with flexibility in training will remain important to retain high-quality female trainees and specialists.14


Conclusion

Author contributions

This article provides a snapshot of OMS trainees in Australia and New Zealand with comparison to UK trainees. Given the high standard

Ricciardo PV: Conceptualisation, methodology, data curation, writing reviewing and editing.

of the OMS training programs, routine collection of data such as

Swarbrick WJ: Writing - reviewing and editing.

Karczub ASL: Writing - original draft, writing - reviewing and editing.

trainee backgrounds, subspecialty exposure and trainee challenges is important to identify any current and future challenges to the OMS

Conflicts of interest

specialty. Issues such as training length and subspecialty scope are important factors to address in improving training satisfaction.

All authors of this article report no conflicts of interest. No artificial intelligence was used in this article.

Maxillofacial surgery is a unique specialty as it continues to bridge the

Funding

divide between dentistry and medicine in training and education. This

No funding sources.

survey showed that trainees believed that OMS is a specialty of both medicine and dentistry. The number of trainees who have undertaken medicine as a first degree has increased in Australasia and the UK, which demonstrates the interest and scope increase in the specialty over time. Oral and maxillofacial surgeons are well trained to provide

Data sharing The Australian and New Zealand Trainee Survey data underlying this article is available for sharing upon reasonable request to the corresponding author.

excellent care to the community. It is important to focus on addressing the challenges in the training pathway, such as length of training and flexibility to ensure that it continues to be a highly satisfying training program with a wide scope in the future.

References 1

2

3

4

Ricciardo P, Bobinskas A, Vujcich N, et al. Survey of Australasian oral and maxillofacial surgeons 2011--scope and workforce issues. Int J Oral Maxillofac Surg 2015; 44(12): 1569–1573. Magennis P, Begley A, Douglas J, et al. Changes in United Kingdom oral and maxillofacial surgical specialty trainees since 1995 – numbers, gender, first degrees, and nations of origin. Br J Oral Maxillofac Surg 2020; 58(10): 1325–1332. Medical Board of Australia. Medical training survey 2024 report. Royal Australasian College of Surgeons 2024. https://medicaltrainingsurvey.gov.au/ Download/2024/2024%20Medical%20Training%20 Survey%20-%20National%20Report.pdf Cameron M, Westcott L. Maxillofacial training is no longer than other surgical specialties. Ann R Coll Surg Engl 2008; 90(2): 146–149.

5

Szuster FSP, Nastri AL, Goss AN, et al. Survey of Australian and New Zealand oral and maxillofacial surgery trainees and recent specialists — education and experience. Int J Oral Maxillofac Surg 2000; 29(4): 305–308.

questionnaire survey. Br J Oral Maxillofac Surg 2017; 55(1): 37–40. 10 Kumar S. Training pathways in oral and maxillofacial surgery across the globe—A mini review. J Maxillofac Oral Surg 2017; 16(3): 269–276.

6

Olding J, Fan K. Debt experience and sources of funding in OMFS training: a survey of current and aspirant OMFS trainees. Br J Oral Maxillofac Surg 2022; 60(5): 645–649.

7

Sharp E, Clementi R. Oral and maxillofacial surgery in the United Kingdom is the most satisfying surgical speciality for trainees whilst being one of the least competitive. Br J Oral Maxillofac Surg 2020; 58(10): 1355–1356.

12 Newman L, Brown J, Kerawala C, et al. Our specialty. The future. Is the writing on the wall? Br J Oral Maxillofac Surg 2020; 58(10): 1219–1221.

8

Walker TWM, Tahim AS, Lau CK, et al. Academic background of oral and maxillofacial specialty trainees in the United Kingdom. Br Dent J 2013; 214(10): 515–518.

13 Burgos CM, Josephson A. Gender differences in the learning and teaching of surgery: a literature review. Int J Med Educ 2014; 5: 110–124.

9

Herbert C, Kent S, Magennis P, et al. What causes trainees to leave oral and maxillofacial surgery? A

14 Peel JK, Schlachta CM, Alkhamesi NA. A systematic review of the factors affecting choice of surgery as a career. Can J Surg 2018; 61(1): 58–67.

11 Woo VM, Jensen ED, Candy KA. Women in oral and maxillofacial surgery: the Australasian experience. ANZ J Surg 2025; 95(4): 690–695.

Lighter. Brighter. Clearer Exc Distr lusively ibute d by

For more details please contact your local Geistlich Product Specialist or call our customer service team on 1800 776 326.

AJOMS Volume 3 | Issue 2 · Nov 2026

| 109


CASE REPORT

Management of recurrent intraosseous dentinogenic ghost cell tumour: a case report Al Balushi L (BDS (Hons))1; Luo A (BBioMedSc, BDS)1; Bealing M (BOralH(DSc), GDipDent, MPH, MD)1; Connor N (BDS)1; Singh T (BDS, MBChB, MPhil, FRACDS (OMS))1

Introduction

ABSTRACT

Progressive mandibular swelling and facial asymmetry are

A dentinogenic ghost cell tumour (DGCT) is a benign,

common presentations in oral and maxillofacial surgery. These

odontogenic neoplasm characterised by ameloblastoma-like

findings are frequently attributed to odontogenic infections, cysts,

epithelium, ghost cells and areas of dysplastic dentine. It typically

tumours or fibro-osseous lesions. A rare but distinct entity within

presents as an asymptomatic swelling in the jaw and may

this spectrum is the dentinogenic ghost cell tumour (DGCT), a

demonstrate locally aggressive behaviour with a tendency for

benign yet locally aggressive mixed odontogenic neoplasm of both

recurrence.

epithelial and mesenchymal origin, occurring in both intraosseous (central) or extraosseous (peripheral) types. Histologically, a DGCT

In this case report, a DGCT was diagnosed in a 38-year-

is characterised by ameloblastoma-like epithelial islands, ghost

old male patient with a long-standing history of recurrent

cells and areas of dysplastic dentine. Clinically, it is more frequently

mandibular swelling. The patient initially underwent conservative

reported in males, typically presenting between the third and fifth

management including enucleation and decompression; however,

decades of life, with no significant predilection for the maxilla or

he failed to attend multiple follow-up appointments due to

mandible.1,2 However, given that fewer than 140 cases have been

complex social factors. The patient re-presented eight years

documented in the literature, current epidemiological patterns must

later with a large destructive lesion involving the left mandible.

be interpreted with caution.3

A segmental mandibulectomy and floor of mouth resection was performed, and mandibular continuity was restored using a

The recurrence of DGCT has been well described in the literature.

pre-bent titanium reconstruction plate adapted to a 3D-printed

Depending on clinical and radiological features, wide surgical excision

model.

is often recommended, particularly in recurrent or extensive cases.3 Although DGCTs are typically benign, rare cases of malignant

Management of DGCT remains variable in the literature and,

transformation have been reported, underscoring the importance of

to our knowledge, no cases of DGCT have been reported in

definitive diagnosis and long-term follow-up.4

Australasia. Although conservative options have been described, our experience supports early radical resection with clear

This article describes a case of recurrent intraosseous DGCT of

margins and structured follow-up to reduce recurrence and

the mandible in a medically complex patient with poor follow-up

improve long-term outcomes.

over a 13-year period. It highlights the diagnostic, surgical and reconstructive challenges in the management of intraosseous DGCT.

Clinical examination revealed expansion of the lower left buccal

Case description

sulcus with mobility of teeth 34–37 and a soft intraoral swelling with

A 38-year-old male patient was initially referred to Waikato

orthopantomogram (OPG) imaging demonstrated a large, well-

unremarkable overlying mucosa. Computed tomography (CT) and

Hospital’s Oral and Maxillofacial Surgery clinic in 2008 with a twoyear history of progressive swelling of the left cheek and jaw. He reported a recent sudden increase in swelling but denied airway compromise or systemic symptoms. His medical history included morbid obesity (body mass index > 60), obstructive sleep apnoea, eczema and a history of smoking. The patient resided in a rural town about two hours from Waikato Hospital and was unemployed. 1

defined unilocular radiolucency involving the left mandibular body, with inferior displacement of the inferior alveolar nerve and resorption of the roots of teeth 33–37. A diagnosis of a calcifying odontogenic cyst was made following incisional biopsy and aspiration. The lesion was later enucleated via an intraoral approach with preservation of the inferior alveolar and mental nerves, and extraction of teeth 35–38 was performed. The patient subsequently defaulted from follow-up.

Waikato Hospital, Te Whatu Ora, Hamilton, New Zealand.

Corresponding author: Thasvir Singh

✉ Thasvir.Singh@WaikatoDHB.Health.NZ | doi: 10.63717/2026.MS0067

110 | AJOMS Volume 3 | Issue 2 · Nov 2026

Keywords: odontogenic tumors | jaw neoplasms | mandibular reconstruction | bone plates | mandibular diseases/surgery


weeks before presentation. Clinical examination demonstrated a significant left buccal and submandibular mass, prompting inpatient admission for airway monitoring, further imaging and definitive treatment planning (Figure 2). Surgical reconstructive planning was complicated by the patient having poor vascular supply to his lower legs and his body habitus rendering any other bony microvascular free flap almost impossible. A virtual surgical plan was carried out for a segmental mandibulectomy Figure 1. Photomicrographs of the dentinogenic ghost cell tumour pathology stained with Hematoxylin and Eosin. (A) Area of focal ghost cells. (B) Area of stellate reticulum-like cells and palisading ameloblast-like cells. Images were captured at 20x magnification.

and a reconstruction with a 2.4 mm Synthes reconstruction plate pre-bent using an adjusted 3D biomodel following the contour of the unaffected mandible (Figure 3). Initially, placement of a patientspecific implant was planned, but due to potential delays and the urgency of treatment required, a biomodel with a pre-bent plate was

He re-presented to the emergency department eight years later in

used.

2016 with further mandibular expansion and resorption of teeth

The patient underwent a subtotal mandibulectomy, bilateral access

41–33. CT and OPG imaging demonstrated a large expansile mixed

neck dissection, and extraction of additional teeth. The defect was

soft tissue/fluid/gas density lesion centred left of the body of the

reconstructed using the pre-bent plate and primary closure of the

mandible, crossing mental symphysis, with local bone destruction and

defect was achieved (Figure 4).

root resorption. Additionally, soft tissue extension was seen beyond the cortex with associated enlarged local lymph nodes (Figure 1).

Final histopathology confirmed features consistent with a DGCT with areas of secondary aneurysmal bone cyst formation. The patient

A decompression tube was placed under local anaesthetic and new

recovered well post-operatively, with mild oral-phase dysphagia and

biopsies were taken and re-evaluated by oral pathology services at

dysarthria that resolved over time. At ten months after the surgery,

the University of Otago and the University of Sheffield, confirming a

there were no clinical or radiographic signs of recurrence, and the

diagnosis of intraosseous DGCT. Due to the lesion’s locally aggressive

patient was satisfied with his functional and aesthetic outcomes

behaviour and failure to respond to decompression, surgical resection

(Figure 5). Unfortunately, he was subsequently lost to follow-up again

was recommended; however, this treatment plan was not completed

and died due to an unrelated issue in 2025.

as the patient was further lost to follow-up due to complex social reasons.

Discussion

The patient then re-presented five years later in 2021 to the

Although a DGCT is classified as a benign odontogenic tumour, it

emergency department with a one-month history of progressive left submandibular swelling, which had markedly increased in size following the dislodgement of the decompression tube about six

exhibits locally aggressive behaviour characterised by progressive bony expansion, erosion and displacement or resorption of adjacent teeth roots.4 Intraosseous DGCTs are more frequently encountered than the peripheral variant and tend to demonstrate more aggressive infiltration, cortical perforation and recurrence.3,5 Clinically, these lesions have no defining pathognomonic features, and radiographically they often present as unilocular or multilocular radiolucencies with radiopaque foci, mimicking other odontogenic lesions.6,7 Additional non-defining features include root resorption as present in our case.7,8

Figure 2. Computed tomography scan in (A) axial and (B) coronal. Orthopantomogram scan in (C), showing a large expansile lesion with soft tissue, fluid and gaseous components involving the left mandible (2016).

Figure 3. (A) Extraoral photograph following re-presentation to emergency department with left submandibular swelling and intraoral photograph. (B) Same presentation in 2021.

AJOMS Volume 3 | Issue 2 · Nov 2026

| 111


Figure 4. Virtual surgical planning for resection and reconstruction with a pre-bent 2.4 mm reconstruction plate on an adjusted biomodel following the contour of the unaffected mandible.

Figure 6. Orthopantomogram scan series of treatment. (A) Presentation in 2016 with resorption in the tooth roots of 41–33. (B) Decompression tubing placed in situ. (C) Lesion four months following decompression therapy. (D) Re-presentation in 2021 with advanced growth of the lesion. (E) Post-operative imaging after resection and reconstruction.

infiltration. In our case, the evolving classification and the recurrence has informed the shift from initial conservative management including enucleation and decompression to definitive surgical resection once the tumour’s true biological behaviour became clear. The change in the WHO diagnostic criteria thus had direct implications for both our treatment planning and prognostic expectations. Although conservative management with long-term monitoring may Figure 5. Post-operative orthopantomogram scan of pre-bent plate in situ following surgery.

be considered an appropriate approach for a DGCT, it is important to recognise the practical limitations within our setting alongside no reported cases in Australasia to aid in directing our management.

The recurrence rate for intraosseous DGCTs has been reported as high as 30.3%, whereas the peripheral variant has a considerable lower rate of 1.9%.3 The discrepancy can be explained by the infiltrative growth pattern typical of intraosseous DGCT.9,10 Management strategies include conservative approaches (such as enucleation, curettage and decompression) or more radical approaches (including segmental or marginal resection). Reported recurrence rates after conservative management can reach 73%, compared with about 33% following radical resection with longterm follow-up.11 Due to the nature of DGCTs, several authors have

The Oral and Maxillofacial Surgery Department at Waikato Hospital services a large portion of New Zealand’s North Island, and many of our patients reside in geographically remote areas.17 As a result, access to regular follow-up care is often limited, and patient compliance can be challenging, as demonstrated in this case. Therefore, when managing a DGCT, patient-related factors such as geographic accessibility and reliability of follow-up should be weighed alongside clinical and histopathological findings. In certain cases, these considerations may support a more radical surgical approach, even in the absence of aggressive histological features.

recommended resection with an adequate safety margin, with reported cases of metastasis to the donor site used for reconstruction

Author contributions

following resection of DGCT.8,12 Regardless, DGCT should not be left untreated due to a malignant potential.4,13

Al Balushil L: Data collection, writing original draft, literature review, approved final manuscript.

When our patient first presented in 2008, the World Health

Luo A: Case identification, writing original draft, data collection, literature review, approved final manuscript.

Organization (WHO) had classified the DGCT (in 2005) as a solid variant of the calcifying odontogenic cyst, reflecting a more cystic

Bealing M: Writing original draft, literature review, approved final manuscript.

interpretation of its behaviour.14 However, in the 2017 and 2022

Connor N: Case identification and data collection, literature review.

editions, the WHO reclassified the DGCT as a distinct benign

Singh T: Case identification, provided oversight, expert guidance and final approval of the manuscript.

odontogenic tumour with locally aggressive potential.4,15,16 This redefinition recognised its neoplastic nature, differentiating it from cystic counterparts and emphasising its capacity for recurrence and

112 | AJOMS Volume 3 | Issue 2 · Nov 2026


Conflicts of interest

Patient consent

The authors declare that they have no conflicts of interest.

The patient provided written consent for publication.

Funding The authors declare no funding involved in this research.

References 1

Soluk-Tekkesin M, Wright JM. The World Health Organization classification of odontogenic lesions: A summary of the changes of the 2022 (5th) edition. Turk J Pathol 2022; 38(2): 168-184.

7

Konstantakis D, Kosyfaki P, Ebhardt H, et al. Intraosseous dentinogenic ghost cell tumor: a clinical report and literature update. J Cranio-Maxillofac Surg 2014; 42(7): e305-311.

13 Li BB, Gao Y. Ghost cell odontogenic carcinoma transformed from a dentinogenic ghost cell tumor of maxilla after multiple recurrences. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107(5): 691-695.

2

Yamatoji M, Igarashi M, Ishige S, et al. A peripheral dentinogenic ghost cell tumor: A case report. J Oral Maxillofac Surg Med Pathol 2017; 29(4): 337-340.

8

3

de Souza Vieira G, de Pinho Montovani P, Rozza-deMenezes RE, et al. Comparative analysis between dentinogenic ghost cell tumor and ghost cell odontogenic carcinoma: a systematic review. Head Neck Pathol 2021; 15(4): 1265-1283.

Park H-R, Min J-H, Huh K-H, et al. Distant metastasis of intraosseous dentinogenic ghost cell tumour to the donor site of a bone graft. Dentomaxillofac Radiol 2013; 42: 20120172.

9

Ledesma-Montes C, Gorlin RJ, Shear M, et al. International collaborative study on ghost cell odontogenic tumours: calcifying cystic odontogenic tumour, dentinogenic ghost cell tumour and ghost cell odontogenic carcinoma. J Oral Pathol Med 2008; 37(5): 302-308.

14 Praetorius F, Ledesma-Montes C. Calcifying odontogenic tumor and dentinogenic ghost cell tumor. In: Barnes L, Evenson JW, Reichart P, Sidransky D, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Lyon: WHO and IARC Press; 2005. p. 313–314.

4

El-Naggar AK, Chan JKC, Grandis JR, et al. World Health Organization Classification of Head and Neck Tumours (4th edition). France: WHO and International Agency for Research on Cancer; 2017. pp 226.

5

Bafna SS, Joy T, Tupkari JV, et al. Dentinogenic ghost cell tumor. J Oral Maxillofac Pathol 2016; 20(1): 163.

6

de Arruda JAA, Monteiro J, Abreu LG, et al. Calcifying odontogenic cyst, dentinogenic ghost cell tumor, and ghost cell odontogenic carcinoma: a systematic review. J Oral Pathol Med 2018; 47(8): 721-730.

10 Sun G, Huang X, Hu Q, Yang X, Tang E. The diagnosis and treatment of dentinogenic ghost cell tumor. Int J Oral Maxillofac Surg 2009; 38(11): 1179-1183.

15 Carlos R, Ledesma-Montes C. Dentinogenic ghost cell tumour. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. World Health Organization Classification of Tumors: Head and neck tumours (4th edition). Lyon: WHO and IARC; 2017. p. 226–227.

11 Buchner A, Akrish S, Vered M. Central dentinogenic ghost cell tumor: an update on a rare aggressive odontogenic tumor. J Oral Maxillofac Surg 2016; 74(2): 307-314.

16 World Health Organization. WHO Classification of Tumours: Head and neck tumours (5th edition, volume 9). Lyon (France): WHO and International Agency for Research on Cancer; 2022. https://publications.iarc.who. int/Book-And-Report-Series/Who-Classification-OfTumours/Head-And-Neck-Tumours-2024

12 Sun G, Huang X, Hu Q, et al. The diagnosis and treatment of dentinogenic ghost cell tumor. Int J Oral Maxillofac Surg 2009; 38(11): 1179-1183.

17 Hung TC, Singh T. Ameloblastoma: Demographic data and treatment outcomes from Waikato Hospital, New Zealand. N Z Dent J 2019; 115(3): 97–101.

SHIELD TECHNIQUE

-resorbable sutures

NOVAMAG® SHIELD

Unique Unique approach approach for for buccal buccal wall wall defects. defects. EASY EASY HANDLING HANDLING 3D 3D MECHANICAL MECHANICAL STABILITY STABILITY

Resorbable magnesium membrane

months post-op

OTH

Immediate IMMEDIATE IMPLANTATION IMMEDIATEimplantation IMPLANTATION

→ Reduced invasiveness¹ → Completely resorbable¹ → Mechanically strong 1,2 SHAPE → Easy application2

RIDGE PRESERVATION RIDGE PRESERVATION Ridge preservation Compromised Compromised Compromised buccal / palatal buccal buccal // palatal palatal wall wall wall

Create an instant buccal wall

EASY EASY APPLICATION APPLICATION

→ Place the NOVAMag® membrane → Place NOVAMag® membrane → between Place the the the NOVAMag® bone andmembrane periosteum between the between the bone bone and and periosteum periosteum (soft tissue) (soft (soft tissue) tissue)

PREDICTABLE PREDICTABLE OUTCOME OUTCOME

→ Supports new bone growth → Supports bone growth → Magnesium Supports new new bonemaintains growth → shield → Magnesium shield maintains → ridge Magnesium contourshield maintains ridge ridge contour contour

Scan the QR for more information

1

Straumann® n!ce® Zirconia

Clinical step by step video

Clinical step by 11 Straumann® Clinical stepTabanella by step step video video Dr. Giorgio (IT) Straumann® n!ce® n!ce® Zirconia Zirconia Scan QR Code Dr. Dr. Giorgio Giorgio Tabanella Tabanella (IT) (IT) for more information 1 Rider, P., Kačarević, Ž.P., Elad, A., Tadic, D., et al. (2022) ‘Biodegradable magnesium barrier membrane used for guided bone regeneration in dental surgery’, Bioactive Materials, 14, pp. 152–168. doi: 10.1016/J.BIOACTMAT.2021.11.018. 2 Blašković M,

490.945.indd 1 Butorac Prpić I, Aslan S, Gabrić D, Blašković D, Cvijanović Peloza O, Čandrlić M, Perić Kačarević Ž. Magnesium Membrane Shield Technique for Alveolar Ridge Preservation: Step-by-Step Representative Case Report of Buccal Bone Wall Dehiscence with28.11.24 17:17 490.945.indd 28.11.24 490.945.indd 1 1 28.11.24 17:17 17:17 Clinical and Histological Evaluations. Biomedicines. 2024 Nov 6;12(11):2537. doi: 10.3390/biomedicines 12112537. PMID: 39595103; PMCID: PMC11591876.

28.11.24 17:18

Straumann Pty Ltd/Straumann New Zealand Limited c/o 93 Cook Street, Port Melbourne VIC 3207, Australia AU Toll Free 1800 660 330 Email customerservice.au@straumann.com www.straumann.com.au © Institut Straumann AG, 2026. All rights reserved. Straumann® and/or other trademarks and logos from Straumann® mentioned herein are the trademarks or registered trademarks of Straumann Holding AG and/or its affiliates.

AJOMS Volume 3 | Issue 2 · Nov 2026

| 113


CORRECTION

Correction to Table 4 in: The establishment of the Australian & New Zealand Association of Oral & Maxillofacial Surgeons Temporomandibular Joint Replacement Registry – Regulations and Registry Development (Goss A, Burgess M, Moore L, Murdoch B, Mellowes B, Smith P. AJOMS 2026; 3(1): 43-50) Table 4 (Revised). Types of temporomandibular joint replacement devices available in Australia & New Zealand Make

Fossa components

Ramus components

Manufacture process

Surgical approach

Stryker

 Titanium 6Al-4V alloy  Ultra-high molecular

 Condyle - cobalt chrome

 CAD-CAM custom design  Computer controlled milled

 Preauricular incision for

TMJ

weight polyethylene (UHMWPE) fused to commercially pure titanium mesh backed fossa

Concepts

1

molybdenum

 Ramus - titanium  Minimum eight screws

prosthesis

 Designed for individual

patient’s specific anatomy

 American based company

 Minimum four fixation

fossa

 Submandibular incision for ramus component

 Allows concurrent osteotomy

screws

OrthoTin

 Titanium 6Al-4V alloy  UHMWPE insert with two

 Ramus and condyle Ti-

 CAD-CAM custom design  Computer controlled milled

 Minimum four screws

 Minimum five screws

 Designed for individual

locking tabs into the fossa

6Al-4v with multilayer C-TiN--C ceramic coating

prosthesis

patient’s specific anatomy

 American based company

 Preauricular incision for fossa

 Bearing fossa replaceable  Ramus component fitted endoscopically or by submandibular incision

 Allows concurrent osteotomy

 Titanium 6Al-4V alloy  UHMWPE fused to

Maxoniq Version 4 Arthrojaw

2

commercially pure titanium mesh fossa

 Ramus - titanium G4  Tear drop shape  Minimum six screws

 Minimum four screws

 CAD-CAM custom design  3D printed components  Designed for individual

patient’s specific anatomy

 Australian company

based at the University of Melbourne

KLS Martin IPS TMJR3

 Titanium 6Al-4V alloy  UHMWPE fused to fossa  Minimum four screws

 Ramus & condyle Ti-6Al-

4V with optional coronoid extension

 Minimum six screws

Biomet Stock TMJR

 All polyethylene fossa

- ArCom compressionmoulded UHMWPE

 No metal backing or

titanium mesh in stock device

 Minimum four screws  Available in three sizes (small, medium, large)

 Co-Cr-Mo (ASTM F1537)

or Ti-6Al-4V (A5TM F136). each with Ti-6Al4V plasma-spray coating (both options available for stock and custom)

fossa

 Bearing fossa replaceable  Submandibular incision for ramus component

 Allows concurrent osteotomy

 CAD-CAM custom design  3D printed components  Designed for individual

 Preauricular incision for

 European international

 Allows concurrent

 Fossa and ramus template

 Preauricular incision for

 American based company  Custom device not

 Submandibular incision for

patient’s specific anatomy company

Zimmer

 Preauricular incision for

provided for size selection

available in Oceania

 Minimum five screws  Available in three sizes

fossa

 Submandibular incision for ramus component osteotomy

fossa

ramus component

 Select best fit by template  Remove bone to improve fit

(small, medium, large)

Footnote: There have been major changes to the supply of TMJRR since this table was originally drafted in late 2025. 1 Stryker/TMJ Concepts have advised ANZAOMS that they are withdrawing from supply of TMJR this year. ANZAOMS is seeking ongoing device monitoring & supply of replacement parts (August 2026). 2

Maxoniq continues to exist as a company but supplied the last TMJR in December 2025.

3

KLS Martin released its TMJR to the international market in late 2024 and in Oceania in late 2025.

Potentially there is another European designed TMJR coming onto the Oceanic market. doi: 10.63717/2026.MS0088

114 | AJOMS Volume 3 | Issue 2 · Nov 2026


ANZAOMS27 A NNU A L S C IE N T IF IC ME E T ING

13-15 May 2027 – Crown Per th, WESTERN AUSTRALIA

Join us in Perth for an inspiring and memorable Annual Scientific Meeting. The ANZAOMS 2027 program will feature an engaging mix of leading speakers, scientific sessions, and the latest insights in oral and maxillofacial surgery, providing valuable opportunities to learn, connect and share ideas. Set against the stunning backdrop of the Swan River and Indian Ocean, Perth offers world-class dining, vibrant culture and easy access to some of Western Australia’s most iconic destinations.

KEY DATES

KEYNOTE SPEAKER Dr Stanley Y. C. Liu

Call for Abstracts Now Open!

MD, DDS, FACS

RD EARLY BAITION REenGsI16SNTovRember 2026! Op

CALL FOR ABS Closin TR ACT S

Registration Opens 16 November 2026 Call for Abstracts Closes 7 December 2026

g 7 Decem ber 2026 !

INTERNATIONAL INVITED SPEAKERS

Final Program Released 22 February 2027 Early Bird Registration Closes 15 March 2027 ANZAOMS 2027 ASM 13-15 May 2027

www.anzaomsasm.com.au

Dr Mark Green

Dr Phillippe Korn

Prof Alfred Lau

Dr Bonnie Padwa

Dr Cory Resnick

A/Prof Patricia Stoor

Further speakers to be announced!

AJOMS Volume 3 | Issue 2 · Nov 2026

| 115


Nov 2026 AJOMS Volume 3 | Issue 2

+61 2 8091 0535

ajoms@anzaoms.org

Level 13, 37 York Street, Sydney NSW 2000


Turn static files into dynamic content formats.

Create a flipbook
AJOMS Vol 3 Iss 2_Nov 2026_Final by anzaoms.org - Issuu